var title_f37_36_38464="Collagenase: Patient drug information";
var content_f37_36_38464=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Collagenase: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12931252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12931253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/53/6996?source=see_link\">",
"       Collagenase (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/6/31843?source=see_link\">",
"       Collagenase (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16760 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-C04F1AFADF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38464=[""].join("\n");
var outline_f37_36_38464=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/53/6996?source=related_link\">",
"      Collagenase (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/6/31843?source=related_link\">",
"      Collagenase (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_36_38465="Conduit leak A";
var content_f37_36_38465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78777%7EOBGYN%2F58479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78777%7EOBGYN%2F58479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leaking conduit at urethral anastomosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph showing conduit leak at urethral anastomosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Conduit leak at urethral anastomosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph showing percutaneous stent placed into conduit, which allowed drainage and subsequent healing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38465=[""].join("\n");
var outline_f37_36_38465=null;
var title_f37_36_38466="Rigid bronchoscopy equipment";
var content_f37_36_38466=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rigid bronchoscopy equipment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 501px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    From left to right:",
"    <br/>",
"    (A) Rigid biopsy forceps.",
"    <br/>",
"    (B) Rigid optical telescope for visualization.",
"    <br/>",
"    (C) Rigid bronchoscope.",
"    <br/>",
"    (D) Rigid tracheoscope with attachment for anesthesia port and side working channel. Note that the rigid tracheoscope is shorter for tracheal intervention compared with the longer rigid bronchoscope, which can be placed in or beyond the main stem bronchi.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38466=[""].join("\n");
var outline_f37_36_38466=null;
var title_f37_36_38467="Nail biopsy specimen orientation";
var content_f37_36_38467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal sectioning of a nail biopsy specimen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38467=[""].join("\n");
var outline_f37_36_38467=null;
var title_f37_36_38468="Traction alopecia hairline";
var content_f37_36_38468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Traction alopecia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC7ECCvAPfp0NXFGATngfpWc1ysQLOhwn3gkg3L9R6VBc6ylrHbSySQwQOGZ3fJ2DaSDx9K+hbSPFNxiAo3bhkdB1/LrUbyFbglyUiAHLJ0J569weBj1xXD3njkWV1LG4uPNXDtvtiGRCOM59RyPSuN8S+IbjWJjcRyMtkMFGY4Z+xO3POOoHHrUSqxiXGm2et3+vWVs6rLeWdvuAPzS/Of9njmuf1LxbbRuHileUklXuVx5RHBCxn1z6fma8XudUdGkWzbETvnc6jc/wDdLe49O1VkvblufPlOMkAMePp6demK554vokbRwz3bPev+Es0u6tJ7x7qOI7f75Rk6/IOMEk+vFYfiLxUJNPlEd0rWyoHEMh2yFgRhcqPnXH0H5V4+t44CBc5X+LOeMdPzqEl5SWbk4/ib86zeKdtEWsPrqekXXj+cx4KNbSEDBVtxx1Xc3JJz+XFZknjrUZb03QkMTGPytqYZNv8AdAbPB5J6npXEq/zc5GBk56Cgcrkcgcc8/jWcsRN9S1Qj1OvuPGMzQIi24ZipVyzEsy/X1AyB7E1op8QLtbdYElYxAncJE3F+MA8d+cDPHfIrz9+CFbIIHQf19KQkkn5hhs9ehpe3n3H7CHY7IeNL8PBIhdHjVY8ecxV1HO05ORnjnORVuL4h6x5DwM0Cq7ZQ7MhT64OenP55rgnbhkJDDOMgUoddnfrgtnt9KPbzD2MOx6JpXja5inKTKLwOQVlIbdDyMkKeMY4/CtlPHEAg3wOscKguISCyv7beCAWPIz3ryPcQDg46529xSlgpBG3JHNUsTJEvDxZ6dJ8S7qGVhasUjfiQIowTjHfp/wDWrOPj/UrdrcWFy6woilhJFk7x1XPp7jpXBbipHGe+Ae3vQshGRgEAdDzS+sTBYeB6rY/EnzLhpL6NYwULOwy4kkC/IT3yCSPQ981pav8AE2GZ4zCscSqquGwZXyOTyMAE5I5zxXjXmjk8Hnn16etK7fMCCNuOACffrVfWZWE8PG56R/wsSR4Mstw0ilW2EgKuD/CAMA+/6VPY/EueGZtylGYfLLK5cBhnOfRSPxry9TiINsbByM4609du8gcKOjMcknsOKSxM0P6vE9uf4jWEvnSRyPHcxqCoyrq3sOhxnqRzWnD8RbLUYVCl4CJBubAKnHUAZ9R6HNfPWXyS598+tAmIXOTzycDAFWsU+qIeFXQ+oZPFlrC0UBns7uWflGhlAGT3YH7v488VzNn4hu5jM2pSW7WwBmacIY26kKRyTyRwB+leGW11LbyiWKQ7lGB6fjVgajcyxx73YvGQRIXJZfbryM881SxNyHhmtj6g0vUEa3A5Me0P8kiuEX3I6c9jVuW7t0Vy0iiMY+ckbTnpzXzBB4ivBJmSXJ8wMzL8pyP6Vv2Xj6580S3hLlM7BEMZ9M/j6g1qsRBkPDyR72l3HJcTQ5AdcHaTyR9O1DvjIIIIryjSPHyzT2wkjCqqOZHUKpZipyWBOCMccYNdvo2rx6vZQyQXMWflVgJOQT6jP0yMZ/nW0ZxlszJwkt0b8jqW+XDE/wB3kijggMOhHWooGLrEWBR9xBUkEk9+nbI4FTlQHXg8nacCrIGAc0pwACTjJwPc0UjEj6UFikgdTTGbHI6HrQTjtmmsc4NArEe4EnFIGOaB1NMzg0DBzjGetQyfzqSTnFRMMH2pkjOnc/gKKX86KdwscdrV1HbmdYmt5HAMkrTYLZHbjnpzg1xGua9PG7Qnd5sW4Miyhl2kDDdME4OKwH8T6j5TKs2dxDFiq5LdznGSf/r5rEkkeR8lmZjxgnpXnVMSmrRO2GHa3LNzeCQZkaaRy2SzsTx6c+/eqzSI6oDxzg+mcdqbkbgdpbPJwece9NRjv4GecDHr7VyOTZ0pJArZBPVemegzTvmViMDjrzVi6he3MSSMxOzzGKkFSCe35EVVOGICKxOe3H6VLKH5YAJuO1ueoFNLFcjhcgj3NRkDaMgnk9uKU8AcHGccetK5VkSJy3G4lj9QBTEZh0LAZ4BoycHucc55zSysvmMwXZkjC54HtRcLIczHcQTkk85oOMsA2Mcg/pTWQqxJG7tlTkfnSkxtAoLP5pJIUdMepP8ASmmJrsSHKHYNpKZU+mD6+tRBT2JyT0xjP0pyy7T8rBFPVQDj3/CnSqF2FegXgMOnPPSi4rCFhlSx6/KT6Y70ofvhcgcA8fjUWCrkLxkYG3nFDtuweSFHVuT7ClcLE2QFYvIN3TH155pm0AknBOPwxTWwCCpAzgHj9KEYZDOiOAfusevtVBZksbZVQ5xgYHbP+TQgUqeMlsg88AetM4wSwHJ49D7UqZZiVQlSM++M0BYfvAWQLKcdDyRvx7VE7gDbyPxx+GKPvfKMFuvPb/61Pk3fMNnKqTjP6/qKAE3ZPbBGBzmnS5RikigkkDcT09uKawKsFZQNxyB0zn6UhOQOF+TjIGKAHMAd20Afyz9KAH80bVzk5C44pokbdy2GxnOO3pxUm0yRFWO2MEH5jgDPegQgYbi7Hg5xxilDYXhj1xwMZpu5ck5JHQgc80o/eYGXCE53Yzxn0FADgx3ehI4OOn1HetLTdVu7MRiFyIkJI/vKT/EO4PvWR0IPOOjHBGD+NSKd2cKhwDkt7dxVKTWwnFPc9R8H+O5WA/tC6kjmjBKsx3CQk854646DivQdN8R2t9MgeZQ7qpA3EEHqTgnPQ/lXzZvZUYjaGBBJ6n8KvWerXFvbiJZQqZBBOcoRyCp6jHPsa6aeKa0kc08MnsfUYuI2eJFdXMgJBVg3QZ7U9jkYIwR2z1rx7QPHEd5JAmoz7HVh8oUIucYLZAxnr1616bYajFLbq7ywuh4V1JJNd0JqaujllFxZpsRjg0z+KkDKyBlYFSMg9iKM4PNUIYWOTmm0rDGTTc8cUANY56VG/AzxTx92omIIIHWgQwuM9qKjdyGxRTsM+YIJEXAfDoeCgbGaRVDKu49OD7e9IBlCzDj2wM//AFqBhj2A6+1eFc9flJ4oo2YxtKsEgGQJMjcc/dyOmfU8U5I7h0nuASGtyod9wDKWO0cdT+FV3kYqELgoDuIU8c9vrUsKkXHkuRGSOS2MDjPX8OKQcoyVi+wjeVQFQOu0elNG5DhCRt5OKV2D8qX9l6Yz/WnRtGWKvGW6gBW2jOOtA0rDBj0YoOSM9Kav3QATknHYZp+/a2CGC7umfy/CkbaT225zgdDQMACMswOCOCKOWOSp5Pf+dIODxkA46880SYcqSdpbkk85oATfkAOfuk49s0oO7ggnHQVI0UmxiYXVR1yOBUagM2N2MgkZHUjtQJO4AnBXu3FS3CogiCncCocuAQcnqvPXB4zTMqVC8kHGSee/YVIZna2SBgxCuXQEgD5vve/pQMjGd5YDHPzc/rTFweATtOMn1p3ykYCjd03H/PWlXZjed20YJ9RxQADcwcqv3Rklew6fjQCuOBwT9COKbG4EhLDcT26flihgNrAMDg8ep9KAHMcNlACobjdzn6ihjwZA2WbjAzn8famHBYcgAngHqBTyAUjDMMHnHpQA4ybS4iBRWxlc5/CmNsIJUYHct/jSggH58kBRyv6ZpqkM2S2NxGeKBJWHIu1QVHzycDjp7/Wnoxj7BwM/KxH5/wD16dJtVgEC5QnOT1+hqEKGQK5G31Izz7UAyRC42sABgjaRx0/mae7lyVaVThifmPBz3/GmI6bVQhgVY5y38Pt6f/XpQQTsZS3YLmi5LVhJCxMm1QM9cnO3tinDKxMqupVcZ5wR7D6012jADKu5jltzccemP601MeYpQ475/u/WhAlceSWDSSK4G4buc5z65oZVX1zjIAIJX60qu7M/zhUkGPm7/X8qRGUzL5i5TjgtgAeoNO4MQ7DnGSxHboaSN+fvAHoBjg0fLG4YMAeoKtjr0+npSh8qehUjAXGf8ihCJI2WNwMlccFuTg10vhXxVcaJcRsRK9uOkSy7FHHLD3rl+WVSHOV4C45X6GgE+WoII+blv51cJuGxMoKSsz6a0HWrXVLO3aBxlohIwXI25/w9K0IpAWKoG2kBhlccV8z6XrN7pc6S2dxNC6NuQg5x6jB4II7V6z4X8dS3qxi62SvIREuNu5j1yVGMZ4GenFejSxCno9zhqUXA9AkbDKuPvA/p1ppGOlR27CYFz8pIACg8KDzj3Pqalf7xzXQZEbELgZ61BKWAbZt3443dM9s1KSS5J7fKBUb4Oc00K5Xc/N/hRTvl9KKoLny8QNpJOCDjac0gJJ+U84oPIUZxjI+tC8Zz+Gexr589oTO3ggevNPK+XvDp1GcZx9DSIBvA6c5P4UhAJJx1OSAKAHRyMjh0JVgc7h2NAGMkbcdMZ5HvTNxUEDvT33rIFfqB0649jQApJb5jyWOfrTQnH93HHNSFkK/dKuOMr936kUyJWdwiYYk4BHTJ+vSgBHc4YYB571PawCedI2kSEkZ3scDpnn8v1qEh1LKzZwxBXOcHPrT4j95R94qVOVyDz29KAGrKzgg/NlcKCT8nfipLmMZ3LKJUcBwM8gH19P8A61Rv8uOBleM7s5pIXkibch2lwUPup6j6UAAJBPHJ4JPpR1UknI9x3ppBycA4HWlBGc7cntQAHGBnn17VLt+QurZJP3m46c4x3NRYAAOR1xgc9qUdQOo6gHigBfm4OSCwI5HakwDyTgdOKXJY/ebOAF59O1KQOgByBkgc/jQAO4abejIvGOFwOPQe+KAjHe4L4UZJxj/PWmnLDAAI7ECn72+zupJwdoOO4B7/AI0AJKCFjb+FuABxnHelUM7HysH+LCjgcc1Im8RKrtuiBDcN9zPHT1prYCqVXaNxyS5+bnr7UACyDyJPMkySRtB5z6mo0XGASAScE46ZqWKe4YRp5zeV91RnigONwEiqAORg8pj+dArO4x1GWBJJ6e59OtKS6FiFAO35eOnH8qa4AK79oyAcg5/M/wBKXACkbef4R/XFANEjAGNWjAX1IOc5PYdu9NZQsIDDI5Ze5bnjP+elLHGFH38qXwQOWPGR7Ur7QuSUY9WyPy+ooHsQZwp2/wC7t/8Ar96crZYCQ45Byf1qaPckiZQsc4VQg6/j/KkSMAOpmQEruaPBGOT7YJoARAyybh2GQcZxx6VLAEcCJlTAP+tZSAuehJ/TpUUjAxhd7SNjAdSQO2OCM8c5q1YxowkAIbaqlWYHCjOCSPxz+FBLKzR4LjYweNTuRmHGD7f5NRqr/dY8devArUiQ3wtl8tUzMESVE2hy3HI/Lk+p61Qu4DaTsqtnacZxjnv/AIfWhMkGDoAFXjPDNzuPr/8ArrRtpmj2XduVgvdx+ZiADkYG0/wnrnPH0qjauEmjadd8SAgxgZ3Z65BP+FWY/LtLmaSObCKjCGQLuywweQfbIxVJ9UDVz1Pwv4+jXyLXWP3Txfu2lxy3AA49eld5aXQubVJjMBvHOF4Ht7189mVZ45PMjijnQCUqoIDIeowPTOfUc4rtfCHiW4RYrEzR+XxhG3FlYclh2ORzj0HrXfRxF9JHFVopao9SBwpbkjNMYkPt68Z9xUFuZZ03pIjIy/K6phX56+opQCSHU8Y5GckGu22py2HYNFMZiDwCR7GiqEfMQGRu7frTkQuOGXgZ57iosEkdeakVQxYA9+w5wK+fPcE6HoenUjrSH7nBwTTnKFnKlio6EjG760wkbiRQA8sz4Bwwz2H9aQ8Fhg/iaTrTgoOMuck80ANXqOdvbNAweDkEjFOzgKB25JHJJ/wokcNIWCBQTnaucL7CgBOkZxn/AAp3ykjcQqg4OOfxFCLvDASKFXkt2p8aoACkili2MbSOPWgCMKGQH5QSPX9eKQEKxAHzH37U7YqMwkdlIH8I3HNK4GA6uWx94FcEf4igBFUEkLuGPTnp1NIy4YjOcHikAJbB6njg050wTxwMdKAEBKkYwGHIx3pQmVLdic//AK6dGg2ghgDs3HdxnB6D1pgRywVVOTyD3oAQcnrz9KVicDlSenPX6ULncBnp0zShhJu3BQQQfTigBzBR8qtyM/N2Pp0qMgqBz17ntQSFGQuGXHIpw3MZHYO20bmPfryTQAqtkgjaCPfg/j2pV+RixwcH19PamOGJ/ecnPJ705QN2HQYI9ePbPtQA9X2HCuELDBOePoaWJirhmUDOVKgfzqNk+YAjG3r7Hrj3qcLtCMy5Qn94g6A9uex60ANMe2Mg4VlGSe/POKeYmIJIA24Bx1/3eanQeaUWeVVjGVO9wCo7c1csUtZDkxPJngZIxj1J/Me9AGR5ZIAcqc/MeeOKsWMAaVMrGN3G2QkAjt0689q276zSNEa3hjQeXuLbCRjIPX+RrMuWniQcxqckYRuAPTPTHepTBoR7cblhglmeZgMswByfQjqOcjOaoFS6lgFUk8KDgNV5ppN2Y3Ybl27wAOOnXrgjIqAqroVLkgHIwPlH+f6UwKz7ACV3EsSM9Me2Kt2o82MxO5T+E7EyMKMgkDknJqD7hdQfvDAG7G4Htz9M06JGDCVR8wyAehGP60Ba4+YPHKrfvVlPy7gSCzA4GR29qfbx+XmS4XzQHKyx7ypcjk4PXPvURaQkDfuUEkk/zqa3dJoo45lZFYn9+ASQwz8x9RjGR1pktEjJHNbmS1a48zIZUmK72z6MOpGOh9KpxkZ2ffTOQNxBz6n0qa4tns5lDKAyhWjeMllfuGUjqOnPX6U5HZrjcHhRnJUM2A6nrn6k0XEX9LkhheCe4tmMobcgX5QQD8zFu5wTx/8Aqq3Zyq104QGeGINNEpcI5HVlxweg9vYVkQRXM8bmCCUmIfPsXOB2JH8JHfFWhKlxcQiW6QOiY3kFifTJ6jHIzziqUrEtXVj0nRfFMUpIMhiVFVJJmx35+Xk+2a6K0v47srJajdGGALiRVAHcbev4141BvSNZbmEoVG7KRgbQc4bb0zn+Vdn4dTULyJbi5Qm1+V1jMmwlcEjnGCOvGM+lehRruWjOKtS5dUegG4U4KPlT0KozD86Kp2stwUYJHC+GwSs2Rn8qK7OY5+VnzmOVBHpTRzggkUrAgAemaUH5iRk+ma8E9oQsGYDJ6dD3pxwAcE53cD296Nu4NjLYGTmmgj5tox6d+PSgBQcsee+elJ2IIIIOCPSgjBxxn2pFBoAdkgEHoemPWgDJwASzcAUnY+gPNIQcbhnae/rQBIBheGyuelNYgbtowp4p8TeUd0gJUjJ9R6EUg+Q7ztPGc+hz6UANGAAcDA7VLEQEl+VDvTGWP3PmBz/+v1psuBICqKqkZKYzj9fxpitgMQeCOT0BFACY+TcCPr6fWpVZkA+bAPPAznNRj95woy3Xihz8xOMdMgUAPZQBtOWB6H+tDcfMxzxt56ikXOQHyynkKO5prMGO5xknngYoAXKgAJnfjHIpRgYBJAzjNBIwACepJ44oVthBOASOvXmgBZF2H5cHnA54IpVBVgSF47jng8flSRrhlyqHcP4u+Of6U4KPLJwSDz8vG31x9aAEkAclgIwcYYJkA47/AFpY1XdiSXagHoSee358VGSQvykY689fxqzaSEBmXOAuco3Kn1596BN2GxxO06R5GTjljgAcHr6c0BiJQyMCxbp1z7EU6STzYif3vmA7WbdnKY4B46g+nrSoMSABMcng+4HPNAx3UNJJuDEDaAPz4/GpPOeIAAsmVIOcMHGep96ibJ/1ff7x9Cf5irAiEijO5RnPLYP1I7UAXYrmWfZCNyRooVeckAcdDyfpUcpjkm4QNsJwGPyjng+mOP1qpL8sSecWY52qGfkgDkY96FkBK7kORnAJ+8PSpYE0dm0ilUCFgcbs9OvTHX8OMU9UcxFHYFfmIIYMDn1AFTRu7RgOwSMHCg8knpwD07c0OIxMzPMytgsfujg9AVqR6Fc2vnAGN8Zz16AAc/N0qGUKrspljctjBYZA9j/nvW+LBVJER2rINgG7JIH3jyanJ051ghgt4ZLgwk7wvDYz8pHY9TRcbVjCe2jW3TEMpdiGBbAH+778ZxVb7KpfkklmI27cg9wRng+natN/MiikcvtcqFUEDbtH9KotvkKNHLGfmLFDgL7Y9PpVJk8oW4kjge2uE3Q5L+Xn5ozkZZD2bHboeh5qZbONLmKCe5jELEFCF+WVSeqk/d5GCD0OQaeEimmZ7nfCwIJaNNwz6FfT1wc81E5EVk8SzpcKXyI/LIVCevJ55GOnoPSmIfezJb3YMUSwSRIEjKsVLZBBLDuD35qNTvX7PNwWO4ZXlfl5III44qCaJTsgB81xx5nJyOygeg55/KpdOhJvbeOTcVDE5HXaDycjtgdKaJN3SEt5TO4kLmeKPfvU7DlxwSOe3piuv0S2v7WJknkaSHErDchO7/aVumMHA9MVSskMF5MdSuFNpJKrKd67GXdkYwOmQpxx07EGr2l6nJb38iSoEt42YmNyxyT8uc54PU46YrooySkrmNaDlG6OugjigjVC0b8Ag5BGMDp/P8aKrpN5CLHEzFABjaykdO3oPaivVscFz5z2ldruD83IHqKkSJ2jMmxvLBALdgTnrUYwyDGMjORn0qS1MaTkXEbugPzor7S2AcDP1rwj2CNCd5IHO1u/bpSMhEjKcqQOexFWMTLApUnZLy21Rgt6EflxRdyK7nywApIJXvnAz17ZoArjnBHA7H0oP3selOIbco5wwyBjg0jFSzFAFH90HO32oAdu2ouY1K8gNnJz3/8A1U1ixChmYjPBP+FPQpsIOQ+PlPHb1pgbkEYbIwfagAX5DuXqpzwOadvbnPAJyff0zSAkZ25x3AP6Uu1Tu2n5SeCTzQA9idiCRY8leD3OO/1qJM7Tg4+tAUk4XnjNKF+QYU9c7h15oAMhiM4GAfxNLGNxwSAD1JGabIpVMNtUnoM9akJAXaq7AQCwLZyaAGctgdT6dOaVM4BAIdT1zkf/AK6Rjk8nJ9RSNlVOOnTNADmyxIGAM5AFIchfmx9RyRSYPoc98f0p4Qt1Xeieo/nQAko+bGQyrjHuKcEXGc/uycZ7/lTtxgkQqMsDnp+lNKFWKk/ebG33/wAmgAZVZ8D7pz81Js3Z2tknv0BFPVAvynIb242n2p8ALJtKFkDAlRwWPPT8KBNDyIzsKu27IwgGPyx70R5UyNKX389RnPpSFMuVR0fagYMo+Ung4/CnbgG3EqwDAsD3PuR3oGPUKrhQFA4bIIy2e319qGOJA8mHPO5sn5jjpTgTE5dBlTGCdy8jPp/jUSbTNukLNkfdByaAJJAxGIQ5cEkjOSB3PHpTo0Z4hI8oB529PXke55q0ti8SESReTnnYOHI47+hrdsrCKSUvG4jjwI4mI28+oz979KiTsUotmI+1TjCyHaAdrZAIHGMe9Q2cTtO4jzIMFZApzuXGcZPXmupuNI2uiEru8whWfKKFJ64xnHT3qGG1sraeUXEbZWTjZngDsP73WpUkW6Zc0iyeJEaUsVUDy2CqXjVTuGP8fSrcGnjfBOFhaYH52VDvwTyw/XvzUsStPHE0G4Q4P7xDtdB9cds+9SLZADBDXPALGQbnXHAww59Dj2qHNrc1UF0MHUdKiMzSQ4kddyssZ/1ajnJB46GqywRLAsZheISNg3HJypxgMn07it7UbdY5oVEjGRQMxqxyoHU5zzwelVBZHCjywViJ5ZeOncHtmhPuJ0zFv4JUulktxHhVAU8cr9PXqfWiCMNEjMV8t5Sk4XqU7fMenSrzx3NrJFHJPE2CQyMgZM5784I5ODkUkhDmaSDazMNrRAYQ/L90egPv6dau5k4voULjSjHIZYHRY/MaMgEFcnpk5Py4IyPx7VVt7FmV5AiRGMhSVLbhjjt0HqfStqz8iEL5cTpM3Lxq4fpnHB7dh/OmvaG5a3donhUJhkU7TyM/e75HBFNysLlvuSW0NmuniCFSAuQcDBznJJJ69uPT61rOF3qtyJDO6pJGVwcnkMTzjt+ftVRbXyoQ0aqm7hlU/ez/APqq5EnmAS4yqoFwT0UnqPpmkp6l+zNW11FreBY2leMdQqYxg8+nrmiqBSQkmJyg7gqBz+NFd0ca0kjleBi3e55Gu0rjk09QS5BXOSGz3/yaQDhfm2nOD3NSoyqwZ2baGwSvXGeormNBnQMVcKcH15PoPf6+lDK5bkFgcEZ/lUiq8sxWBXlIOQqryRn09elM3uR/DkHOc0AI5GN2UUngL6DPb0qZI4Z0jJlWHYrFt/ILZ/hHfPHHb3p6tcMm75ijDacqDge3uPWkMMiql07qcscAnkn1IFAFcJ8qs4C7+cA8nnHNN3EZwMj6A1Ou3zJBKAXY8HO0A9zjvxximOI0jwAokJ+8SeMH/PNAEe04bnBOOKChBYgfiBUsgEAUbB8wDbhggj2P9OtMEgQA7FOcg9eR3oAZtABHQ+vpTvnCheQOpz/npTgylmLAseuPUnihnLuowoJ4oAbhgWI5PHPr7UpTG3owJHbmhowJGRyQwyOf1HtT4tzBRjcSQF4xx6igCP5ABjuecikG07mYEgH1xTwikKS4C854/nTio8s4O7PII/z6UAQkDaeo5yPpU8Y+RwzopOGHONwzjA9cZzSK5idWjOHBDhgMMpzxTG3SHfhgCOf7o55wKBEkCnLkMPl4CsCVPNRl0Dh3XJP3lzgH29qeGEh2FdqjjaDwKd5K7OHAJGVBHD8+vbjJ/CgNkNBbcCHxjrz2/rTUVj8rJ75bt71YgMX2kMquQSdu4Y256EntjrVq2kEksQ3xwqmQ8ix7iwAY7zn7xGcduMelCFzGfLHtwqk7ccknqcZx9afFIyopQEHOMk9Kmjhkj82Ftg2cFWYEgjocduKnsonDP5O4sPmyq5yAMk5/rQUQiLC7jvIIwWUcJ9fb2qzbxZQP5CksrARkEFiPb0qQQTwjDxmJmBfLEkupGT7Yz/Or9lauzRnLJE7ZkDLjPGDg9hx1z3pN2BJtgsF1F5MtwrmGTgSA/wAPOc8k/wD6q29DuGt7iQzKV+YsA0O9fw+uentmqai1t7aN7i482SIsGgVwylCemev1xmtKEoWgFjGbgMfJBd9kZOeFOevp6is5XZrFmhYfv7XdJGZDLKB+93Ao2T19B04PFIbKW6uyLeDYidRIT+8bOOAOhA5xXR6ZbKkdtNfXCxoiE7U5Zgw/iHTHGATz1qhcNFJdKLUqwIw+1ujYIz/TPes0dCV9yxawRyxwwXgnCquBx948Dj19aivYopLaNrWaTYPmdkOWYDqeeg7Z9anW1j+zq0pG0OFCgFgpPfHc+p96haKa2MnzPJCWLBTtx1549PYGk3c05UVxp/2UH7PCzwhyx5G4E+vvTL4S3A3ggjHl4fkgYx06ZwKufa5Xt2t1eJi/KO8fPHVR78YzTbgTPt82EQbo9zlGBMh7EE9D1yKh6MpLm0OcW3hWVAqLbozAbsHC5wCxHtnP40lzbXFuzQpDtaLgEENx0yCODnr7c1YmsXS5mZ96R5Ge4JHc/UfyqOF7mC4hWBXbdKADu+TGeD7H/GtE9DFqzMtbMrMJEckZ24cYViR0DDjOCTz6Vq2Vg0+3LSoyAkKVwCQMAk9zjg/XNX3soid6OkLEZeFMAY6nGR1yeDTbZJopfKNszyxHYWVwFPGQcmlcFG2oksckJJUnfn72z7wPAA7fX3pJAFB5IV8YBGMelTkqyuS+0OcMBxt6c47elR7HQHcVk4wTnHt/SpvrYtRurlJzJuOQX9x3oqyUtl/1s0ak8geb2opknkZQogdMquepqXYrBOf3hPzfX+lMQs5DfKVHRSenpT5N7krGjgMAWyc5Hr/9aus4QiWWErKpZGDZjZWwcqeoPtxULOWcPI+5s5z1yfWnspR32sWA4XdwcfSohjt/KgC9bXTRxoWfO1uI8kEkjrn0qO4lDBQoVmBDEhcZNV3JzgAZ/KgsMLlcHuQaAHs6FV3KNwJPHfNJLgOEyTgAMuMYPp+FS2twYlkUxRSxyKRiQH5T2YEc5BqFwMDkljktxg/XJoAI4w6tyeowOn1/pSMAG6HI9frSnG3JUjtz0p8QQfM/UDp6f40AMzvbcTtXFPMYI4YMo6k8YqRVKofK3ABQC3FI6ElUDA88DFACTiQzsXUblxwOmacd5iaSRkVMjnqWznjjtxSxqoMuWxgDnHPJxxTWLQMrKx2svBA9eo+tACsFZ1DttOegH8v/AK9NfIcrwpbON3f6mgIS2RtQnPJznn/PSmMuDwdvbjo1ADcOMgAkZz04NWJIvLfmRCcneFB4PYikhZUKsg/eA8Bhx1z+fWr5je5P2iQSMXUjGwAZPHBzj060CKE0ZjggfALSg8jvg4/A0xlLcjbkDBYn/PFTFCdxSJ8KMFc5YYHI/wDr0+5hVZGSPaSuF2txjA/xJoGQKCpQRSMcnjninW8zWt1DcZGA3fuOjD8iRTFHz/cJb1x/Kp0GUUyyHHJZcjK4oAmeGJb6YkeZjPlksMFT0JPXOO1aQhVhBG8xjaQEYQBTzzuyeCvH9KY4s7e1RpWjndADFg8L8wLA45YEZGOxpJDDLIJisKNKfkgT7sYx1I79vrQS0X5ILiQGSORSIUAHmvxjHGD245x61Ol0Gt3js3LyMQGGQF4HJPuewFRW6fbZImVIWVF2+dKSgPPcdTz+X0rR/s0mKORJWhYD90UQKOCec9wfWs5PU2itChYRxtdxQxRI7nPzMAAT1xx6Z49fauj0UTm0UkJECSsc330V1PDdfXFZkcvmtaCeYG2t1aOPzBt8vPP8PJPGBmuqghk8go0CgE8zb+ADgY2nr6dOp4qWaQV2SIkn7uLYkqhFJIXcQBk/e9MmrGmTmB557Ygljs8oBc8fKB6Z7nPrT4oo4L3y02yOBgLnkcjHyipVt97rMjKtxGTFICwwCT0bA4PTj+tQzdK+xHM5uGMbWjbgNm9TsYHPcH5e31qRreWJhDPdB3dcGNoQuznjaec8dcVZxEZpIZ1aJycrvYbT2yh9R780rWEc/mhiWIAYBF/ducdTnnP0pXLjG7K7W32RJvImtxGnymRsbCy/3W67vboeapJHuQFWaVzkMCp3ZPIcdsdRirsUcEdybeVSjOMn5jhu+Qx4FVwGW4MaMxmjUtt2gMQT03denpUtXL2RTniQDc7ZUgqxxknP8PpWbgRvHLaR5ZiYy2RgrwMe4+taMkQuHZE3OuflGMgf7Q/p61NDIFUC7jAhwR5qqSueOvrnPI/Kml0IbuVxxAJRtKgsIwpwzYONuDznsajnjju4W8uWPeqE7gvy46g8d/bpWhc6TKbiR5pI0VlXC43Feg+93Jz15I71Fqul5nzAs5ZQFLMF456kg8557Y4pOPYlMomNpkMskgLPGC24dcHBxTp8xQBlCybztK7c7h2/X8qdbytcOpcwKrAmIog2l+cfQkccVYtJElt4nnXD5bJH3iPUZ/LFQ+5onpYpCS6A/wBGDLGecLhefpRVdVDFjEkkykn5kBIHtRTuSeSlzKqKVRR03KoBb3PrVqd1EWyNs7gMhcfKarMqLjY3yleSxBOe9IWz8oUAgAYH8Q967jzQkLB97N849e9Rru257Hp9auxW0W8mS4iC+WShUbgXxkKR1Hpn1qpuXaV2lPl4B657GgBpBABOc/rSjPmAuSc85xzSZw2D3JHNOKsAu5hn07igBpUElfut0H/66dGMuUZsY74J5pEYIwwq9+oyKlii3EZkQDbnPU8D0oAjBLYMYy2eMngGhlxgD+Hr9amaQBFwNsQyVH8WT3PuajDkp93aCMHmgCUfKh80b0IAwf4aQnDbl6KMKWTHP0/GhfKaUjOEOBtAPIxUiyffVF/h+YyHP5UAEbMFKsI3zjOeGGPQ/jSu2VGFJ8sFt3JGP/11CkrAAYGBk7McU47449ylWU4IPXP1oAjfcZsEYbP3ScUdWyR8oPPPAqQq8sixIC7gHbz17kj2poiDEbNv3STkkbvpQBJbxSeYrxL8wywBI5AHPX26evaprXznc+WSFbPXBJGOBz1/p1qKOOScHbGrNjlFHKgd+vahZDISu4L0w3J4IAz+dAmW4kYSRPcFEiDFyC45Oc4455IqGfy9zPuyzkkuP4j/AJz+VLaxRiUOQjCIEsJRw4ORjjnn17cUxITk4ySqhl3kZP4d6AWwG3ABIKoCOQW545JP40Rjc26VCwOcBDyTSjC70G5mIBwcbh+HekeJkYqmAsfJZjj/AD1oGNR2di0rlt7c5GG4rQtbVpA5VUI2eYFJwoJ4C59eM1HY27SrEdm/JLHJxwB/Wt+PMJjhYW/kbgQqjd5bk5z74/rSbsNK5Lp80MNvbN+7WUIUVm+Zunb6Dsakudnkxz+Yfti9WViPMQn+Ht+GO9Lp1xLJFK0kqxrCrMI2UfvR3OcHjsPatmz077TGJSEEsbglNoK4wBz25yMGsmax2Oes98mqxOivMuz5x/Eo3Dbx25/lXSwmeGcEvIsZkwsjxjeM9gx9Pzqzd6PBp08QWJIRIrIdo5PcjOenv27Uq2cFuYxHIrRyb0JlfMfGBnOTxz3oLimiQTz3lyiKCYWKAo75JJPzkYyevv0rejeCDYWRkaPcqx7gY0Yf3+5ycYqPSY5oYElbYoEflExRAgg9gTxkkZ9qlmt0866AiYbY03jZjZ6bvXHGeO9Jo2QizI8ohn8kOBtxESzDjGTjt1qeIvBp86s7bAhI3tiQNkDgdcD+IdMEGo4dhEl1uBhLFVGwZz6KcdB19amiEDxOViddqDEjHhQG+bcT3I9fWs5bG0CrI5MmxQwVshHPLOwxknjGBT1i86+jWcKYypwjAshOOMHsep4PpU0MAS6McsLGIEm3wwYqM8/r+dOuFdbo28EZljgBlEJUt7EZHIHf8KIphLYEsy7TJqMcytJhAv8AFtHQNwATnvwc/lSTRY1AOgi3yJmZUTyQ2B0Cngv6g4z7UpeRbaGR7kee7jq+5WiYYJY9mzjg5zjt1qOGBLm8ihMJRnbb5a4dfNJwzJk4II/h7E9SK0toZNmfJYFfMS2nKOw2s0zH5hxnt0zwfTr2qmvnQxx75x5kg2vGXZSGU4xnPoMZ+6RzWnrC3TyXCwNGQn7tkYEBexBB6k+nY1l3Nw4ihZLeSN7f920UuHIJUgEL9CefcDmkvMlsZeFpoIyFjilKu8rrgAn+6B0wP0zVC6upQrBixD4MrbBkcA5/UfpS3QSXaWkmmt0YINuSQM7e3GTzwf51ADOonWSFY1DcRBc7SSecg/XrUuKBS7D4rpIE8u3dGC8M4JwzevUe1FZtvMlurBpfLZ2LsMkZJ78UUBc85SNX+9tU5wC3TPof8fWkXJi2xhtwO4r68f54qUFmcswx/CAAMD/GmTIsci7WXD8Ha2SK6jhGmTCgkfMFHIPQg0t1cTXLvLcu887dXlbLceppjnexLkcABTjr9f8AGmpuRhIBjngnpmgBcOEDADaO4GQT7mmkHk5BxjdmpWHmyKudrsev8I9T9KawxlSFyH5Oc/5FAEYK+pzyTxTgfkwM7e+e9AUAkEg+hHTNI5AQhd4z1Vhx1oACf7wOfT1pfmJ6gg9ewP8A+qnKwL7tx3/wk+vvSSDLr8h565PegAJ2nruB7ZqWMgAE8dHAHAJ6YoBXygBgsDkg1HIxlyFU4JyAB3oAmLxhiw5fdgDHBB75pjBiCWPQbvl9fb1pUi2pksQW43Z7+mO1O5WBiI8kEDkYK4oAesJAZ5GZcc5POT6Uzy45JViMqxqWC7mPyj3+lIjHchJ3Dd0xxnPSpvJbeETy2OeEyMNnsPpQJuxXKE7QAArN12nHpUjEuqxoNo3ce5pUjkKYKsT91Qfl654p8cG5SjOAx4CLzhv/AK9AyzZxRuIFWOMyOTlmJJJyR6f/AK6p/OmSdu8rw+e/arkcqqA2xm8k/J25zkZ/GpIJv3vmMsRGR8mPk9BkY5JoASLTmW5xJKgP3nx1UZx34Jo8mKInDGRnJC7lzjn73406WRXUyElWbnLcBWB5OPXtTreQY3RlGYBpB8vr1GOw7Um7BYms7YXX2k3ILqIflwMspGMYHvmtWFzHpCebCfL+4ssaYBbHfPf/AArKjeeRlm8qTdEPvY25I7e+P1rTE6lk89/MJ4jULkyZwSSvTI7ZqW7lR0JY44f3aTyKEK+WxifJdB2AHcnoa34WthFiOGMq5WKFZGI9sn1K/wD665uytZJFka3iAEkiRZZQrIc5yD2z69q3ru0EkIZJnDxpsQKwHmLkbuOcEDOD37VJpHXU1Ha7MDmOZnmWcrIoxtYDqvoucn8RitXTtMV0jaRUjjD5MaNvAAPOR9PzNZdnDb/Z5vsyPK7qHMi8qMnqp6HH880warHCDJGJdiJgGEY2qSd3BznP1xUvU2Wh018TGsXnwj7OqkxRQZ3u6kZY56dRn0B71Tsbd7zzJyWSBslD5mEjY5yMnlj9axry/vLuXfJbPFJIdqlZC8kjEgZAJ+QYboM88Zq5a6e9mCsMBV0B3vcAFdwOBgdM4PTn603sNPUv3FzLaMyNEvmRx4JVjtQYx079Pw61SFyXtVk/fM7sWaLcVQt3Oc/Nxj863LJrW2ikklhCOoKmDb8zFhggD8Ov8qzri5MQMMiRpgFmVRvIGeVOT0HJ98VDRdzR0Yx+c5e3K3rxhFRmUKmRnjnHPXPT8avySNb3JOmvsuIxvDqNxmU/e9ACBkj1xWVpOy1KO4kltjkPtGCfR09R1Bx0q7dTvP5KWVsBDsZFWOfeSvVgCepHqeRg1Udh3sLaWsR04ySCMXCzbEZF/wBrDA9kPcZyOc8VpLC4mkE4XyMLHsVhnGSUJJyAyjJLDpjvmqEdwkQKyx3EkrkSfaoiQyqowwI/vZOCfQ4q3p0892sblTJbW7eWZNvzNjGFxxz8w9wPpTJK6eclssckc0dsX2rtUKrc5Vwp6N1/OsTWNMtYrY+YLgRySbkDNlt5PUn/AGccj2NdDfTWkNzcTxhJRG4fKszh1ycuR1zgn6Gsi5naWNY4wJGcB0YKAuzqOPUn65rMqyaOXv8AzVaaUmUSuA5Ho+Rg46HGCTjk/nWPLcHznRLhPnUFiDkg+5HXv+NarrcXM0jGIEM5YgvgheSTjsOoGKqyWhjlCrCmC5whyQDj+Q4pXRnyu5QaG5CR+UcRlcqDgYGTjrRWzarPLCvlQnC/Ic4PI+tFLmRfIeQAsZQM5JP+efWnS8DhQp4HynIA9vWoQ6DKgYB9fTtSAYwGBI9B/Kuw88mhRp7hUjjZjy2EX2Jxj8KYQzEO/KA/Njt3qW3Mm6MwK5kVicJ1z6jHerkt5FHGoW123KEhizfKGOMHGPbOOlAFa6mVptseV4VeAMA0PbvGpP7sOCQwJ53emOQfwqEyCSUtIdu4YZjz+XvUkjiSTFuJFVRwM9APp+NAEMylpW3qVJbJ3d880SDDHa3IbBI5GPbNPbcsYTGUQcE9cnBP4VCyFRlgcnpuGM0AKxCrlTkEn6j601QeMsp9Nx604gooLYCnnk80n8YGMd+aAFxg5IIHUelCswVeWOTuPpxTSckrgBTxgUcluvegCdJAjiUZL/eUkd89fr3pwLncAx3DBx1JHqabBHI7lUHz4LDv0GaI3YhpG3FudhHr60ATW0T79nBDH0C5HcZ9KlSKM7vLUFE+Ylzxt6dfXpyKrF9nzgrvPf6/zp8SmQABlD43FiMjHvQA+9kR9zoXOduPTOOcj196Ym4zB0QYzlRn04xn8afO65HluGZRk5BKlvU5qaCaRlkR0U+YuT22ns34UriTuOiYboY5XRUCY3BdvA7E/XvULygsXCeXg5IBO32wD+dSwwtsJDosaEje/Jc4qu9v5QBbLMq7ioyfl9aYyMnewyC8hOMnge/09avQSR4ffLtAY/6sD5uPTr+NQwwLKFYxssZ+QbhjdnnvUrwbYY8su5vukAEjnjkVMhmtAXW2XzbkEEEBfMyW5B3Y7jjrTvIFzD9oW7UEghlQHcTnH5n0/KqljCzxqZ3XcHxtHDA+3Yj17VpsHtrKKUNH54UBUc8ZPAPTqB+WakEOubeJY1aXzlZB8o3gKO5BJOTjoPxrU0y8lvbWK3SFoYXwrNx5jLksAp6heoP6Vl2EMV5dof8AWORsEksgEYYdunrz+IrRlgtrSWN/s0d/KmA2WKKMDJXnvnrjrSKV+h0ds8CmNZY5wm8/L94bQRkkfxD0A+tayaN5y3zSG1CFsvuUkowHCrt/kPWua0kLPNEWuv3gLuIwAUjHGI4wRlsk4P0NalnGths8udcsxA3u37sn7yoM/qaTZ0x8y7BZWOnyg3mx2XKMsZ5VscBec4OcZ7c1DH4hN2sltDZ4kZt5YvlljAxtIxxnHbNRXMcVxdosyLJKRlJGcnnqxyOpHAoltY9OhkMMREigHeO4boyHse3tSuU/I0J5Xnm3XCpbkqADtySenJPbPSi4jlup0tVjEe2RkjeJQGbaCSDnoeRVMTPHGJo5h9pdgpiZQTtxjGDxzj9c1egt5JTFIkrCAKUAXjeGY9DjK9x74FCBakSfapbhpJLyJJ40xGsg4Ct0A5+XJqxZ2Daa8PnGSMsdwZ2DHLDG7HTnkE1Zt7GC3uVXeY4HciVkXewUj5Rz0Hqa1rFBm2FwSwdfLE79CRzsyOAOM/jSTNOUrzk3F6wtppRKFUIShHmE9HOOO3POMe9ULYNZ2qiYYljCy+dGpTa3IDDGRgHjHtir2qXUtpbzSWxR7nyyOHyTGB90HsPYVy02qSeWQuW+0ARKn/LN2xnHq2cH6mncmWhtXt3HJp5FvCyxLGY3Cj5GycksT6kHj3qJ9QDLawGGR5biFnyZNnGThvoAMduAOK5nQbsXd8ls8pZBE4SGRiw81epIyBnBx7Ek10CCQQyWSz3KxCOXH3ZAqKOQP+BE89sZFDjZXIVS7sQztKwjaVY8gsJgDuK5PBx269KoiWBMFNoYHjg856nHr0q3LcGeV5PKRwRuLE4YAkbSQehJA9+aoXDSBf3e/LEsgkPQZ5x7ZGf0rCS6m6ZLDOIgyjygM5+/tycDPb1zRVf7xYk9yB8oPf3980VN0M8VQ5zuGSenvSru3KxB69R39hU0cYGxtpk3EjYDg5p6xMscjsG+RsMCOmen0+tegeUR+W/30K7eTu3AEDP6GhldgMlWycbuv696mEUMjlYwF75PIPpx/Wp41hEG8sWlO1XiwOMcnB/KgCkkTEgKpJyQAoJzjvU8CSShImVUiLlmLDoQD+NTpcF4GDYVAxO5Dgge3+e1VrmM72B2lyxLHPToe1ADYYy0UrqhkjjwWPbnhf1/lUMzbnIwME56ck/WrKyb4nidwgbaxDD7xGT/AF4qNXMfmZ2tvHKk5x6HI7igCEM0THaQp5BxQ/zBSF4Hb0pH3O0jscknLH1pUhZsHA/HvQAxT81SwY3MTjkEDnGKaeAcAMPr0py5K4yTnuKAJI3x+8V0jKDIIzkH+maXZvLBecjK5Hp1x7U8wyFSXwE5568gZp4gXyt7ZVc9z29vc0AV403SrgjeTgEnAHvVpoGMG4yrxhVj6lj9PSrFvCFtwfIOD+7BYkL7kjqT9KiRC24Ax4UZLMQvGPSpbASCOGNYmmyFY5ypUsAfb61bVI0U+cLhUZmASPjeMcc+mcVHABHEVwd5C5JGDt9cEe2c0rxpPMzhx5YJ3ttBweuOOPypILEZeJGbEa528FR0OOhHb3pm90LR7UQsBlh34zk1Iw3QgqVQJzuzhzmpIyhtnIWLdGd5LAcMfU9/WncBYo5J2AbbESC2RJgqD6j39KVIoolgEkmWCszmPDbPYjpzkVLP5U8awxopzyvl7vm7nrnP+NJHGotlQRSG5JCqqAEY9c9fzolYFfqTSXsKrGsEKRPE+EJH3eRnIxgg46Vagkn1O7LyyPHnIdywIGOy/wB0Y6kVUitJrmY+VE0SOykuyErn1A74q/G8tspiCArGwVJGjJUnjOwds+9LQofblSz/AGOMgQrhoQvysMHt2P15rekaWUp5nkrLsVFWOPcxAX07+uRVVILe4jctICxLck8k9h05PXmr1hbWvml0VpRCNwLy8qe+CcHp2qGzWMdB8LpIyBisbBwpVhtbvyAMfL9Ku6hcG3ijWOYpGsalWRQNwIPY9+tF3EuHk8kxqVWKFhgs3T5v16VWkt/Ki8y7leMhj5iEbd2B049jSauarQUXYQWUTSRxbJMrIODEuOcc9TnGK0bOGK/ty7CQ+UG8qZ1O0FT8xGOw6VTtbFMho2kO5CqRkeZuOeB/L1q5Z3JiWG3gjMgiGNgY9M45XsOposUWdPszqWJAATErS/OuGwF+YnOc9sDPHNaUbwi18+KIAyllmA5MYJ+6B2GeRWaY0lMly0ksgh5ki5Qud3YDoeePXkdqtXEcCTpuMrO4Bd84OOMLnHOMYx3zSemxUUTWNzHE7OZWwU2opQ5ZgQMnB9x68ZrQtJhDcyeReF4N6KxdSMOzYYgHoMZPP9azod0EPABwFI3fM2cYUdPTggfWpo5Soma2kzCFO2MtnewOcdOTnnPpUlbiTTrNFcpDBJJPKzI8khCqBux82emME8DvXN6nD5k07iRhLGwVUCn90wbICkccLjnir9/bTzSStH5pE+APIUrx6k9T15qglvPZ2siwxojAMSzyfLOucblH94Y6d8daaRnJ9ynbWotjdXEsOJH242SZZWb5gSepPHt75rb07UYrhVSzgEjO6mQEbTKzAjKAjjoPQe3emiJZJZrq2G/zoDbtEwG5QSM7vTpkdwKms7N7a4muTcr50RMYWM8uh43JnoQBgY9TTu7CUdboq3EaPMkzeUXDsXl24Lv/AHiBxj29qWaBo9qEOqyENGwO4hB6jsTz+FWZ2KCY3aJvR9xUnBJ64Ptz1rOvLyMzKPNZndF/hAwMYzx06YA5rGT0N7W3EklSLYrwvu2jgZG32ooMM7gFJJVAGCVA+Y9zzRWYanjJlONittjBLZznnpTN5bKsxHQfX/GkYneNuQwA4Hr60iB3LFVBJPUnJPtXotHlly2aG3O941lEZ3Yzjd7Z/pU5liFtkDMvmKCWHzMvLE46Y7VnwjawZlUYYfK2SG9almaNlIYOASSiq2VA9CevFCAlumgW4d41doySFYjlgf4sdjioYyoBbDGTPCeq98n1poDyAgEAlgF65X8KVflY+WTuIGNwpgOI2vldu8HdgnOKbMu923sjZYEjPH41G5fPzLhumfX1zSDBUiTCtjcvvQBIqooXcxZFbG0DGR9T/WpZ5ViM8UfMTnaAeffrUQfeDuUDnOeeOlP4lC7sZUEfMMD8+9ADGBZB8hHQYB6ntTow4A+7gDC4GM/X1NIG25DAFiAMnggjgYPt/SpVUvGAcENkDPTPrQA5iPJKKnzcZbknOeg/wq1BavdXG2IiNlJ3eYwx06D3pkUiIw2Z2rnbtXLN7n86miimlQQopwVKneMDcSOBzzUMCv8AcMYaZSYmIIHQcdeP6VorcQbQjIszqoAKJgAA8gE/zNQR20ks8cgCkkEFOVAHpntUzyhv3ahUgJIcNxk98kde/wDWkMWV5b2XD7EB+Y7iSMAHgDvj/wDVTo7C43CZ1jQOMklQ3y9jt/pS2AgUObgMoUY27+Wxz17/AOFSSXEHHySq83JwxeTOOgGcYPr29KQ0V2t5EjEpYbJU2qqpjtnjJx7Un9n3MuVSNRKCHJAwNuM4HbFbNjds13M0sBjcxgLE3CqB1YZ+namrPJNdLajAkYEuysAobuQB1P8AhT5mVyp6lSKymFuTcRtAifxjgMx7Y6n6irth9mllgYw/uWO1vlIwxB6k9uP1p0LsfMdw0kSy5PmKTJjt8v17Crcun/aIxKN0KBQGRU+Y7m5BGelTcfKPuAXmga03SS7RvZFbCkf3RjIHarFjazOVEkm+SZiuCM55PUD7x9j+NTrcWVraL5XmRqSu+V32YIOG4HLAYHX1p66pDGDFamUyk74mSH94ox2PYZ/GgtKwsM08QEQW1j2jA3oTg+g/nTYGlfZeTXf7/JTZtARTkcHjgY5z1qPUJYhaTCeVpDtO45Bbgc7jjHU9B+NLatPMscd0EiwQ8KkDMmehYj7ooKua5u9jqbotHEkrKMvnAOMHPU8jqamt3inuSbxHuBu2s5PAxyQR0z059TWEfMmvSZjbq7qSyyOcMOckds8EY9a0IkitLJoRO5hdCQ+CSOR0A6g8DOfWo3Ki7G5DHGkZVrjCfeBKhS3PGPTHH61DPdRxupZUZxjDN8x4PVfQ49Kx5NSlm8uEQOJG+VCFCt1559P50xhLKH8y6jaQvsKDCsMcBQcexzSZomjR1A+YjCSBTGrDa6MeMnIcHqff1qGO8eRzIVBiD4B8w7QAPu565wDVm6jhCi3ljaCQKo8084IIxwD9PzqC4mjaX7OtojagZfJ7hSoHLYzxnkY9qNhE1heTxKArpKCGZlRQ20Y6nPtn3qzFIuIyisGAB24JOccblGcdD74xWVMJY4l8weRGVyflA3KenA9RnmmW108jxLLLs2hthj+VuOg/pk8npSTvoD7nR31/5dqgTckEafZ1lJI3dCcHuMn/ADmqqWU97cPE0Uc13HmJIUyemWY4/iPQZ6DH1rIhmtzLJNKwVXkCKrIWKsCBn6HIH41sWbToElSVw5DeW6MCyNkjn36jjtRexcVzIuxxPCojgwEZikjsQQWwQce52k/hU+9o4/KiC+XEocHBXHY8ng9j9azbKfMAPCFfmWM5wjZ9Ogxgg59OKkEjXcpZ45Y93D7wc5JJwF/UmlzFqLSKmo7lHzHegfaVOOcHJJPeqc6lAsiRRjGSu4YJGR3H8615xDJacIszKCmMEjHXj6cAmqUojSZty5+7zuBC49fy6VEmO2o21SN4sy5dsnlDtH5UUMscwWR9yhh8oVu2e+B1oqLl8p4WAQA/3VPXauMU5k2MRb5IBHzkYySPSoyzHYoJI5faTkUvntGuFPBBycc4r0jxhrYEaEbi4GOfTtSKwYEYAboDTSwI3KWDdCc9aQg7sDGT6d6AJI2DNgYLNwMnjp19jUkcQMxzID/ebPAHrVdVBIxk/QVIoDEqFJBPJ7n15oAkcKYyu/OAcZ7mnOrb8Sp+8OGJcYznpn8KiLoFIQHd79vpUhK7VJlAkbggjcT/AJFADkUGMEfKVO3k8nPf3pr/ACyELtyenzdMfSpbeBpbtfIkdEOcNtLlfl54p0UUakLIFRVOwmIFuMckn29qAGW4dTvSFd6fMDLg+mOD+dSRxNcgBpTjJO5Vyvv9KtQW6zHAfEcbYRCPmbrz/jmrcTJA7NBGWjDb42JwqE925x3PHbikwK0FsWbaU2GPcx8wHpj7pJ6DjpViVJlhjnO6J5DkRBAB6cD0qJIZ7mQLJcOS53szH5QAfvMQefypkrvIqyALNM+S3yhCvP8AKpGWlhBtyX8zypEJ55wAeuO5J6D86SdZ5JZPtOPJgwjOeV6A8Ad6rySzzyttALlsfIANmBjgnoKfYRSzzlFSR3fIZUPC47+hPXrRYNweMzNCqI4Y5wkZK5J7Z6DpVni3gEE2wtkM7RyAnGPuDHc0jWaW0gS4uAkgA8wnLEr6cDjjHAq0bq0sHPkWUizRsCqsAVbPDHnoScVJS3LcUTzOr3FxIkaqNqwoCFQHIyT/AJzW1YRWNtBFJbILm5U7BFEQx5757devrXKXU8mouhNtMltu4UL949OSOvWpoJ57B0MfyleFVACSc9CB2I9eRU6mkWlsdBNdW9qZftSSyTnDYD9s9gBjjuSaqvfXMzqI4JQISW8ssPkB7n1HfNPt1SQsq20sMUrY/wBIk3AAHPJHbPrVzyyqJAGUw+SchujJnrn0HNMd2zItUl80+ZtkkIZyVQHcFHB6evNP+1WZLl/nMjfOR8xIzngjjr2qo5UyYiuZvLdGXcnUj09hzxTrS5jij8hvliVCgREH3e5IHP4+1Ji0NBI1uLNmsyX8shooyAqnu369/rVW51Cc3pVrl0+ZVcJGSSO647jpz0qO3AnuXW1jaMRDBKr32kdTwMk9B61JFI1sd1pIgJyXd+AR0JPfHt9afQOpbRIOJ/JlN1vJ3EdT2Kj8atobkkiOEyXBKxjM+M5HOAeh/SqpeSW0RoQ0v8RnwNhbpj3OePaq8spiuLNmcpIpClj8zEAYxn0/DrSbHY17eARK8U0WQPnEOOnYlSOufStq18qNZ3W2WFxleMllAGRgY5Prn1qjZHfKjRSqTwrM5Hy5YnA/zxWnb6nHPK7yyNFabmfYCDnHUnnJrNs2ikOntzJIPLdEjicKVK7vMP3sD0weOOOmelRfYVjuJ5HmAf7zNjaT3IB69TirCXsbzSuWjUhjgYOUAHJJ78Y6dTVG4uwp3QKWjdvnkz91D0BH58Vm7s1sjRMtuyxBQFkOWQkDCjAXIBqqbdY7trx2xAy7yGOWOeCfp0qvHslDkqxVcqOTll6j+gqXy3yuxnCbwpXA6YBJ9eBgUN2LSuEatBbTR7YwGYosrNtI6dCehPXipLZZoFEMcCRlxuy8nAyck8HOT059KgtozDMUkmLgZcxfdKnHcng9uavQtDPvuHVjMTkZyTgnjn+uPWp5ilEkASJVkR1XBydyZVxn09yev40rAwzBpSpRSzKEkxu5ABOexPb0pbfiRZQ57sGzkj3A7DHAqdjsAUiTcEwGUAADBz+HJFFx8otnbx3VzIGciCKBpWIXLBQcBQTxnOCcU7TLWM6dfrDcSrMEHmZUbZELe/Q81JpUcn24vBMLZ7dWkklZd7bAMHjkbfarV/Okti/lXsToT/qIbTyvMfORuPfA9eKVyWtTn7mOcsrWsatEygj27YoqVyEcjzZx0+6oI6UUjQ+fFYAg7ecdfSkwwG4kHP6U5YyWYZHy85Hf6UMm0pk5U8kAfoa9M8QTJ67VwRil8t2yyjgc/ShNqtyMgfdGM1YaTbOCqbFDDCjkDjnk0ARKsg+4CvG0nOBilYlQAdhBY/dJ+Yf4U0tnaB17E88U/bgbBknGTzjv/KgAiSJcNKGkQdFQjJOe/tVoqlxE8iIkGGynPBU9FA/rVdW8kBlYbweq89ajMrNEVbBB5HzdMUAbcd3BAqm2QPcvuDPIm1F4xwo9u9Et3G6zeRbmOE4SKM4AVgMsx9/pVWw8sLIDkyFD83QqPTB/i+lQSszNIc/vWwTu+8c9xjj0oAng1CeDzPIZMBSrFwM9eoHrTssd2CThflRmHyqDn+eeO9VMfum8zzNx6ADv3yKED7Qu4qFJzt55PbNJuwGpHOwkjPyt3Y+Wfmx0Gc8g1DEpu5WNuoRVUgkn7wzkYz+WKZFDJPHyHMbHG7bgN2OPXBrTP2ePZDKqy7WB3BRk54wo/D8Ki40UY7ZGjuGdimcKgBLF888flWzp9q8qLFDGYgB80rjv6AcDPv2qtDe3UyFgFJPyHcc8noSRzU0btaxhYrpW+XLDkDJPUegpNtmiSLf2WTTrWYIYpDIwIdlwSMfnjt+FI72/2JyhRi+3l13fMTxx+lZz3clzME3yKmSqsRgjIzkj0pY3ea8UHZJMMRxs54X/AGgOx4zzSsVdFx7qaOR0iiiJEgKyO+dpPf0x2q8Qu1ob+WMOzZWV/lXBHXjoRTIbeUxLFLCFjQbthIO4dSDxxn1PrxUJKLcr9liMitldhc9zwD7DFC0DoTw6wbGdoldkVVIyIyxC9ef896o3KQyhi0si7mCsh6Sj8PunJ6d6hu3l8xkVfLwSM/xdvXt1qaCMiQkltijcYfVARkgY68k9f5UydSe2hZHf7QGkSQYXH+rwBwM4xx74qUwm2gHlIpuZEZSoPls+e5x1HoQSOPeq0zTtbtBbpthlLZjzzuHTH0HNSx2p3RySjyrdk25ePBZTznP6bRSbSBJ7kDwyRTRpGLiIn5owuGxnoDz9T6itWIEvc3M7kRoiI7snGMEDOM4zyBnuKrWQu3iDR+UZF5CysfkAzgE9gBUVtqTWSF5D5xZTiGSP7/UZIHBHPX6UuYq1jet5jLEBHtcABt7LnOO4B+nT061Hb3kam5m2pksP3uzCgZxyfTriubkvbuQQ+RDMbVGHlqykhyTyXPQgfyrYkilWNfPFmjbMxeVyzNx8p9M8kEgDihx7jUzaRBOBJHHmMqZFkB34Hf5M5P8Ak1GZBcQozOkzD5VOwg59MA5+ue4rASC4DlmlLF0JDk8YyM9OnHWtG1R0kZpRv8qQkvG2whV579evBqbId5HRKJpYleVY8EFTJGBgcjOR2zjtUV5bJcQMsTo6o5fbG+0Dngkep9apSxyXckMs84QkKd82QVz3Kr1Pb361ZtoIYkjRl8qZzsV1b5iME8+wrPmOiCvuNsEcDaJPLnhAL5Ocr0yMexq60LZG5pRuH/fQ47AcdcVYg8x4tvDY/wBZIeCcc5H44pzGWOSR3uM7Tk8ccH/HrWTd2dCRDJbRRMp+dCF2ZDdMnp06dKdbB4g7A73U8ndx+g5+lWkiBCqvMfXnnJ68Y6CpoyQ26HgIWLY4X8un49aRRGgnj3mEuQykgscA/wB7APvj8jSFY5GXckSxjnZkuwz0yO/OT6VPbIH+R23ocFlClinr7n0pEIaTDq8Ry2f4Qcc9fT647CgbVjT0ixvY9l1b2sdzE4cbZJAgI9xUl7p7rYyNLptrbYAZ5I5ixA9hu71joqbmuIrdjJt+clsFiB+QzxU0cDjdy8mzDEFSwB7c+vbFBFncpuQgT51QkZICkUVoQRBlZmymWOBkdKKCj5qG1pHVtqkDuuDx2NK7oygjO4A5yBg+lIJQsR+T75IBz09qix24r0zxCVGC/wAJB6qR16UZIYHJIByoPP41HuUY2Enjg+/epI5Cj/Kowwxz6H60AOaYFMAYCnPHIA9DUbEFhldnGfrSquM8hlB6r0IpyReZuC4Qq3JboBigBqByGBztXnpzzU2YUAVYxJJu5LDI+mKn2RIrFCJAFO7Ix6DOD/OrEaSRxiUNEgH3cthx6jjuRQBVjZg26XcpGTH3HHpj0phjcRgcKgGGbPTPP1qzdTRtJkh0XaFGOw6ZPueelVYgTInlpuI5G4/pSAdGVdtrblDcYJJ69z61dghDhN6eWx6YIVNvTce+PWlghS3jIWTfC4+bsQf9n16UQbGIRk3REn7uOMehPSpbuM1rt7byZIIpmkkDgAnjeAOSPQd/8azdjNGI4T85XaQp/wAnn0qw1j56y3dvJK6w4ZpTGSoPoP73P4VuadYQSXBcRky8y+c/Kk46se5H90cCpuUotmEkkDw+SU3OTldv3sjrkegxnNXLXSxJhpZDGWJYq5JLADuB2z27VuPZ6b5jNC8klyiHOGAUkd2HTHNPWa2sbVDEltIGHzOM7oW7Dnjnr+FIpRtuYj6ba8by24ruTK4K8YI9/Xmpnge3RZLc+VGzkhCxyvTBJPOfr04rTcSz3BmlUPHDgAMwXIx+pzzWZKDbzebdTO6g4xnCsOc7T3PIxxUXZfKt0XyYbYlYzEzOmd7jex6ZJJ69auWbedCs1yEhiTLeWvyknpyfpWWl2kkzOWZ920DAKrtAyTipF1AyBY43jJc8ZG/b1/nxUSbNIpD7mOHcZRCIZ1bCs46YPc/y+tJaWMk8zm3VXL5LEthiSeoB6fQdaFlmlYtcbH4IVWBGc989uPwqcapPFaIjbbpHVQ0yjBQ+mfSmm3uDir3Jp5Yre58+SNJDMuSSuCD059D06VTa82JJbshlXeGYMD+ZPfn/ABrIkWScN5am3hEm8McvvI9Cf/1VZbT5TE773dmAAZXyD1zkjoen5VVrk37CtqESsISEZpWBeVWyp54/w+lVpYbprQyi3QOGaJ1dshRnkjPvxU40wJAgX/Xy/eXplOmM+h5z+Faa6Y1zIzSpuSMAK7Hdt29ceuPequluTyykYFjdzhUjtEVSU5dc+uMY/H9as2qPKAsgk2k8xsDgkjOWI9DzjpzW1No8MSlkcLDt4ETgb8jn3PQ56VqWVjBCojB3RnCEr82RjOR2Pb8c1EpJFRpu+pmafYP9pSGF7WLOA0jENt9cfWryWAkn+zxoxkRSN6tnDf3s46Dj8K0H03y2jS7RS0eSoZOrYOPp9KfYSm3kikhVo8jaYwpB77uOw4AqW3Y2UCCSO5SaOGVY0KAF5ZDkkt0bAxk+gq60Ty5VVDSZLbmGSoXH9KtPHbqgkMYIYbmGR06Z696WNQJA6x7lZcncwBJ64I+mOazbNYqxWtrfbIA8ZYKN27BwQe2B057VrQBVjVdkYUYZsnByO/0zUYdRAxxlJMMUjJ6+ufTpUqOrDyiRHGnzKwbO73/HJ4qDVLQbJEREAoZGx04O4eoHYc08sXLb2ZsupAAAGQMZBpTPGYm2qRxy235seufrzU8MWz5iCY8KpLLuJ9P/ANVBSQAFoyYCSSCFkjAX6An+L6io3UlGcbtrKA5ZgWIHUYPTnHOOcVLFIEV0hkRSRsOcDBAHUDoP8KdOy3C+ayhVcbdrL9/1GevPXJ/rSui7C2kDXTzGWR0ghVpJmHzMxAztAPfJHPbFaaWH2S0kZZZor1LdZpmT5EOTwuBzkZzmsvTnkSbzo5ltxGnmyuEz8g7e55A9Oa09UaSK3vvLvZ2KKtwyugy6lR/EO4zT6ESvexnJwCZLBp3b5mcZxn8Biis2cz7xhtq7RgAOePqCKKXMUfORBBO4Dp37UjAbsj05x60nXrjHvStwBjGD/nmvUPBEox+vc0E5OcYFOK4HzfnQA7J2grkrgMvP6fWnb9zFvu4IHp+FRuBwOMHn60HLckdKALQYupUBVUD5mYfzNQmTgAYJPGWXr/nimAknIJBJqdAfLYRgmTqT/dHf/IpAMjjLnABb+8R1q7b2jujMoOwE7ynYe9KsIjiVzIxlPSMLnr2qWAjygqCUBVycEHnPORjk4FJsBxDQxQROoKs27CkevbHI6VbtkUxCGVGidsgMq4Vh1O4+lV7OWO3vQwiWSNBgA45J+7kZx35rQh+Vz5LIYXBZlXJCkHk89/YdallxVzSsVt4oDIYkkeOTIiDnYQMHlT2zU+ranJJE6wlHJwQsfyorn+E9iAO3GKxZLpDeSoELswJ3hsknjknqB9KEMbxt8m3YC3lxscnn1qNbl3WxJA8BBmmmEpBJCMOPqQMZ/wAafJfGCUJbRbpAuJNynaehIA9vWqz2d1c71VoIhgFd4wzEj+H/ABPvSRRIH2O5bYcby5Kn6Y6jiq6C6m9bwh4oLhhMhwZJJWIfODxkVWuZYJ7klzmQOVDqoCrzwR24FVJZ7cQFojPEN3zu2doz6A8n0/WondVtQ0cTeWSWLRksFOMBST36mpsi7ksNr5moSxRIrNGPndicDp0PtWuEhs3SO3iVZGBLTv6n0Hb61jRzMs6sZVbPy+Zk5HtgfpU1y5ezmaWEsjAqqpnjnnkc5qGtVYpPRk1hKN9uXaRgrFt+zgjPAP4jGe9blxFbAuIYVEsoO95QABnryPoa5zTftc8DRSwSsrAIjxtg8ZPPPNat19rCDZCqQqmdm4BiO+e+fpQ9ClqroVDHHKrZ3x4ILA7gq9APTI6496nitZIm3EARMpKxBfmPoceveqNqjTwqreXHGZAmxQPk785/Gt1Vs43nEfnTlGLbA54XGSpP+FTzWLSutRZ0BDxzRy+Vn77AZLBe+Bkdec9fwqtFN5SuLAMrY3fex1746YpLi9ZGDIhJbO0fxYznJx0ArMRQhm85POhDeZtxkDA5X1/Kjfcq6jsa0TyrcLulKM3BAi4VSRk+pPrVtWjin82YGV1USOFB+ZuxPf0pEuBI8Je3kWUID5b5UIMdO+D371cjjcWiozJFPuQbSuCSTkfXipKQxn8wNBbTHzcsXI5ByBjJ9evarEaPFJvG6VnIUnOFUDnv2zUbJLcyAQzhYS2XdRkOQepA6cfzq+umwwxKI/vFRukMufmJ6+44ouNIgtwAFSQNNltqE/dPuB/jV20YM+1d0OAYuVwrckf5+tNEzsW8tSsu5SR6Y9KSUMZTmTc0gJBGSQc5zx+VS0VEvxAFWBSNQBsXaSAuBxj1HP6UcLsGzzCn/LRn+6fw61XR3R3XL/vOp46+vtkAD8KsMGYLEM7XwQqDtnJ5PQ9etQbRVx0Lm4Jk8yVZMAr0wD15FMZTCU85MyKcFiCxHPTPSnLwcbECsykKxB3HualLsUTc7SsvAVf4R6H1xxUtlpEUz5gA/dK/KjI+7znA/XNMtpVKPKOVJ4I5APqB27Uvmbo1LYI+6d3QnuOnXv8AhVWNljhSOOJETdgr0wCSc/XvUN2Kt2L2iXkt7qbxWckAZIzv8wkI6nqCPp2rYvRPc2cwgk0qHJRZXimPzAfcHI4A49q5/Qg9tctBa2cskcyOJI1Cjdnqc9jx1q5qVktjp08n9n3KxOVW4klmQsUznYm3jJPeri7oynuYrm/spHtw93GUOCu8jB/OiszUtQe+1C4uimzzX3BS5+UdAP0oqS0+6PD+QwU8D0pOmTTzuz7884zn1pCOncHp71654AAgNhs/hQBgkDIyMH3pOoyMmnKPl5OD1+uelIBQq7gQwUnOB6f/AFqlC8vk/Nz82OKltE25Z5Fjc4xuUc57+2OtWpFRkEccoluHbEjEDYR1wT+tLmAoMBtxIRjI6DmpWQFlMXKkA9+fwpdhWDGxgo53D+L8fTNXRbGC4WEvEHb5CquSU9SSP5VIEd5AITEZDI0xBeRSRgew9CKGjLyxpFHtlZjiJASQD19yT3q9b2UgyGEOUDEF3OMkdeasLZg3KmZo4X2qzOpJz/X8qTZai3qULaydYt8LKWPy54G3Jx6dTz9K0rbS7qRYi7zFnX5dnKlR3q3NaLAzs7KIBjO0kYYjAJH+etXo7tbdnEsUiLJ0cthivUkE8DgcHsKl6miiupBpmhqygzKkh3FR53yqoB/U5444qSPT7Z0O3Nu/nBNkRxkjsc/yBp66i8+JrW0jS3RDseWQ5IzxtXPbrVmzv1YQQzQRgQsdqnJOCOX2+pPSh7DSVys8SfZLhoA0APyIIl2iTJGQT2HeqQtIoyHjVZAcZyx3EDuB2rW2GaJzLCdxGSA+Cg6DOfu+471SkYRXUgiEaAcEE859qg0cUQJGrTQMQsgRjvCrkgAcn3FJHcW8l0sRw3y7sbeApOQvoPrRKQzATiQgdSzgBT6+n581dt1gkjSGGVIV2sxRRyq/zyT168UCM2W2N0+IU+zrgKrvzlT6Dtn3rc0/T5TGEtoXmjhI82RgQzY/ugf5NXrRIoYZJjMWYL1fGSSMDBHX+dMtpEFwqvK4TkxlQQZh12/7vPWobNYxRYttIjjLzJbySJICAsbEeWw5+6cDPBqcRW4jAMFwrqDKRuJBJGMn/CoZp45FbfMFQnIRnOQQeo9vwqWCQtGj3Fw6xyNuZS/MmTxkdai5pZLQRbGOWSN5Iy8O8BAoxhsZyfY0zVoITtjYQxxP8yoAMsfw6VI135hQxSKZGYkK2TxkdB+gp6RCRog0SxqpIO4ZyvbA9z60k+pTimZK6dDHGfMR1dB+9lcYynPcVoWdpZ2qguFkhCnBZupKnBP5g4HpTZCIwSWdEVyCvXe33fxHP6VattiyzSvEm3Db5JV+mMDtj29KdyLImii8ol2LBlGGO0be3K/mOO1NjIEnmXNuJGVGDfNwCSMnGcMSAAKkuPPeFfLDOyJt2g7SzHGdwPXPao1gKec0TSDzHyiYICkD7wH5/lVDZPpskzNIwijSN4wqqcAJyAcjsTj8cmrD3ajaiMdkiBNrrtC5U5JA6H2qvJGUmnaLMqSbVD53bueB74HOajNkXt4zcKSXJGQxBXgHOOnagNh1rqEMcQOwyxk/u2Vd289hg8jHr3rRgDvhjkI+0pCn8IB7+nHaqkUYuJAJMhXAWONV4wBw2B6mtG3kSNljG1HQ7mUMQuOmT+tSy4ibDsJCbSGOzzCMbcjP1qZ28uFo13vnKkZCqM/05pWLKgcIpJHB/wBrtmobmRvMzjdIrZ2Jx/wHP54rJs3igYKULsd6BRk/dXA6D1xSfaC2A6Ab2G0P1Y+w7AVJCRsA8sRjbwM8Z/qB61DcT7SySAB+OxGfc+lSWiG8OVMZRZc/KV3d8e/8qruZQ24FCD8pY/fLd+mfpUG3Mm+aIAJwhDbmbI547DtUXmSKr/vOCSQFx09z9KTVx3NTTr+O3nlS4EgilieEmPllDeg+o+tGoapbNpszytP9pkto4TA0TbUZDxJu6dPx5qDw9LI2oSyKVhPkPm4b/l34Hz8+nTHXmodVuruWykWTxHb3cbDH2dXYl+fcfjTijGbVzHADc+Yo9iTRTFXjhn/nRVcocx5HbwvKJBCP9WhkODjgdT/9amYGQSeev0qxY3ktpJK1sULSI0ZDDPH09arom4dVAAzjNeqeGGXKgjHHqakT7+1GUZIIOOc//rpjh94zgk4HpjipIyAQCAe5GOSfY+lJsCbfiBTmQSKdw5yGPrUrOXiWPLsv3gNvA/8Ar02ISztiEO2cD5AccH/GpZYMRuJJl2pkZwcsc98dKgZLBOy7XQCOTJ3SZwQAMYA7fhVlI45iN+/bktKR0AAz1/vHI/CoLQou3yywcD5WxuY+yipIhEzSI7sg37iu5vlzxyfrSY1uXIbcXDswiWSNNrkJkKFB5Jzjg84zzVmwjtxC1wsYlkxsjP3RnOc/UD+lTWypDbebPEHxlYhI+7dnpgE+tZxlF1eeZeSeWjZZkVs4x2zjC5PtUu5qXLy7SKVWSYJPgEsimRhx8oznk9eac0jSZRgWlJCleAMY7Z449TTbRra3RmXYrbTumzlUAP8ACPXOKZNfXDmdJIwdykAONgXHPQcj8PWmHqbexkVIVnd2yFiWZMqCDjcq46Dk/Wr/AJKI/LyTXHmF/Md9rN6k4GMEcY9a5e33Nc+ZG52bQRMW27QOoCk/KM/jitd7zZaqWlkkuHBUbACE9MccD1Jzms5XvoaRtbUljRsXVxfxxqu8SwxA/IoIwOO5+vU1mz30xm3GCN4/4ZSMNjIOfoPzqO1lZrq5kMjNNGQBNHllUY9Omee+BUkiWcQFxHFJcSZG4uzKE4/iz3JxQtw5m1oRx3W+SSdEG1xsAc43/NjJHbrVq0Mk0ht47c+W53FScEgHBw3v+VRlolSY3KebAxGEVWHzdcDHfvjPFasUlqyea6R+QhARmXDHHVcdvpRIasxy2ywOfIVvPK4UkA7Mdjj24zWw1qn2eOeVkLh8Hy3LDt146Dv61kpdN5kCwQgucsRHgBh2J7e1X4bttpcNKXRNghiTOB6/WsW2dEYokj09fMBmd2k2/wB0DBPIAGeBT7IfaIxJJN5Kg7V3j1PA9zxWbLIFjKrG7tKFIkYbcnGATmr1nhI8XYLSuxLIWBEIC5zn0qb3NEkWEDtOs8cWyLad7sdjKgPH9enrUN4QVRHVo4oBwA5YnAznj1OKuPPEUkCszh23bQM/IMc49MgVTnlaa4LiPY0qPEhjGSvXOR27049iZaECQRyQxrsCuSHOCMrgbj/KteMvNOyqEFwgQNCRnJJyc46Egg1l/ZpFkuGeNGAj2xhm+5lTuOAOox39altBPhgLbaqoGZmb7/HGfx/MVRN7GtdSIWme4YsWw8irnIAPAHf1NMUhpmM6nzuCrEjZgkYHHfkn8KdBM0hVFdE3K+5MBuQBtIPXHJ9xUzwL5CmXEgedU8wt1YE9R2xTKRFPNGbjcqDZFKI0AAXLAAbiP7vFMkee5kj4SWdflWTogIPbH40otCkKtjdNIwXcRn5c8Yz0HU/jVyJLuVMy7IkRsIAAQ/ODkeuelAyO1umUp9mWQtLkMz8Hp3B6c4/SrKoCFjdvMUk87du4DPf0zzmopo9isjyM0vRVjDD5u5PbPrmnRyxwRKhYHdhfMx2HUD3zxUSKgSmVU2JlcyJxle+en86knLQiJJIwGZiSBgHn0560zzVDRqAqoWz945VRzzUTSRcqrDA5BPqe4rE2RHtywYzeWD8v704U+g4qu5LSbkUuF7kE/QDNTzN5kQXOSM4UcAAdzVMgi3WNcsuCxLck5OaCivPcb/vgM2OBtyB+tVJZH8wllwSc5HSpWkZlZzGI1GRtPAHpnHfFU2+dhhT33A/ng0EtmvoVpdRf6ZGtlPE6snlXFyE3A8HIp2o2KxWMrjTNNgKgYkgvi7rz1C5Oayf7Kv7qJZbeyllVz99YyRnp1om0e+tbZ557W4it48bnKbQD9fT36VaRjJ63My5WZpMq/GOoANFRXSwJOyu8hcdcR4xRWnKZ8x5eFLMPvMWOB6mnoAuBght2OegFPjLDGWwmDyKGkd5SzBi38WRxn/CvQPKByHlDbQhzxtyRxUnlFWwoDEnO4ZAHt+PNORWjwy4QuOc8kDPSkcIclHGQScLxntioYF/7SAweNY4DgD5BwfzNIlsoQu6EcnADcHHr35JPPtVRYiZUDFSSfujkDjir7zM6JEU3FWDHyzyPXPb/ADikxinf5xeGFEAAVQwOBnt7nilRZo52MjBmhPl7Sqqc5/hH9ahYyKu5NpRW+USHO5s8kj2pJmYAqxQsFGwKvX1/nSKReZ32PPPdMJFYYy3zNnqF/D8KrK0zbjE2Cv3VU9ugAP8AF6YqqbhSq4dQP4kUdPoTUIuANwQA89xjiiw3I1lkmBSZsblUfO+Dnk/dApkV5BGW8kSFwdwYtlmbP6cViG4bay7jg8cdqXzuMdOM59aLdxc50Qa3uZrZTGZIifmT7vmN2GRwAKdLPGsxH2chydod5iVA7bgPTqO3rXPeaxYu27cRy561NbuHyGZ9xHTrntn3NLlDmOhsrhlUQk7ECncY1xvft068dwKurlmjlmhb7Opw0iZBfjt9B1JrPso5YwhURJGFCZGOQeM1pwRsZliUukSY3BV2rzxn1NQzaNy1a4fEryCOAljHGp3Rx5GNxPOSRge9X7eOziRmJdkRCWYr0Hc+i/Uc/Ss3JLCFTmIqTtV9pwP7wHT146mnvLKN8RCOAQdzMDnjIIHc8daiW5tTLpi89DKtxLHBGCELOMN+XoalsLeS2lTYsZuXyXAbIb1Ix7VVsnkkcSSJK7MmHM7YB56D25/GtVGuYYrlklTLjYpCD5OmBxwRWLNltcS2QMIditFGkmSBIG3jOAPm+7znrUkokENw8iBIiCTA+Mkk/MWIOTx26VWtpW+1NBB9lyrb5SVy24DgYHv07VDMTIxa0eGIEP5jDnn0LHr39BTSE5aGhG8c42WkaLC0a7mIwQF9O49ceuKuRLZpbFVRxJJKuzcThByTnuW6VkwI3lBzAIpVb9yzOME4HJ/A9K17VJonglWSOeRWMTSRtkpweMmrEtXqPFrIx81Edo0QbgzZckkgZBxxippYo40nVD5UQCpLbheXXOevrUfnJCkkbl1hRvmlb+8zdPp/jV26DSPOIkdLWQArJvwSDnGM+4oNCCSGJ5wYIwFaRkid2G5gP7uOn1oggN2YIiwhaRt5ZPmIAAPbjBP48VLdGAXbrbGRvIBxvOWYleTnpnjFMRkSS5cbMvHnfztHyk7Qvbr+lBKJFvEUp5Zk3yKo2k54CkfL6daiWKWdo2mBiHVYjyCB93HP684qw0/2fNyzb1iVSkjZIKjdkgD69KxI7tY2+z4M7KgJdyBtBIJxjg9R0oHe25qiFthePHyneNnJYnj/AD6UWkAG6UvlMYVd/AySTgjp+tFt5scG4n96oKLgdDgnkd+BjHapWSJIo9riZ0UbHHIyR6e5P4Vm3cuI6YzNcDyYFyWO8ltuPf8ACnZBdVymSPvrxnv0/Wmbv3bANG3O3I6qR07UlwxG8ttMZIBPUN9PSsjZEUwUzMGBcMcAc8+pPaoggRRHGoLLnGOwzk5q2jYQBguRnH+7VebITKx4HOARz70FGbdLvyeWxwoGAM1WmzHDISnyqCcZJJOK05E4VCvfsASf8Krt5ayMTtYgZHJ/ShGT3GaWnmzS+fJdC2ggedo4pCjOBj5R+J61vX9rZDTrgWqXrzRW0U6tLcMw8tiM4XuR71n6JAw1R3aWaFbaN5WMJDOwAwVAI6nP5Vo2Mklz4eurVZnDW6b8sBtaMnGwnqME5HatYmTXU457DLHy2RccNvUZJoq1O05k43JgfdyOKKdyfkePRjzGBCYwpBx0/wA4pm5QQFX7oGWA79qWGMkMCVBY89wKHwskiqOCepPTHpXcnY8oVQfMI2jcR93PH51Ku/lht2LyQO/tUES/KcqArAkgelSo7eWd2ME429MfWhjJFIA2IdwGW3Y7f4imiVUJC4PAPpUZcqGVgMZyPUcYH4VNZW73DiOD53Y4H1qW7Ak27Imkmj2DA39fmPI6fpSwwXsyhIEkG85BI2k/jXZaL4URmEk6hnxyQMDPsO1d1p/h+KOEhYtzEc7ux9655V0naJ2U8I2rydjx6DwxfSH5yqDHYZ/Cpl8JztGZHmAX6cmvb/7EjjOWACfTnPtUFwunWcbNMkflpnaOQDjp9an2smavDQW6PG4/CLuhO6UBQSxxxx/WmT+FJo9ypJyMYJHX6V61DqWlz3JQIoycj5gWc479uOalufsEvmrEWijdckS4LKfw749KPavuH1ePY8ZXw/N3dgoHUDOPWki0a4Us2HXacN2I+lem/Z4Gi3lUWTO1AM4YUqWUc0ijGBycd/z7U/bSSJ+rxex5/aWtxGDHlvKYDrxnvwanaCZpUG+WPDeX8y/6w/l1rujpsauqkbt5yB6D1NTf2dhVDnL4wCMhg2P8KlVblvD9jmrOxlWKRBGUBbd17epJ/nVo2Shw0i5YfeXqwxWtKGjjIYqXGAoySMemKZJalNuME5wxIySfx6c1HNc0UEinaKYwpUAN3bHJOc85/l2qyzlkwrfvUx8iZw1QsJAHG8ZU4CHvgetMSCVkIRcu47kBSPT8e1A9itrl4bX5XaMGQgOYwMHA+UfX396rR6hE0YZ32x5H3QCGz0UnuSf5YqWeykd5JcIhxhTIQpznge44z2pbOxMKbUkiQYIOUO3npjjJ9a1XLYwalctwObvanmtEWy6hlAAAHCc8Ek1PElxBH9qvo5IfPQEKR12nPGOM+3cVn3tk8tuLWKV2m3BlO04C8Ec9PX86r24nEv3nMSDZGN21gTkY+uP51a5bWIfMmdnBNuhZWt43Mj7kKtweeo9gP1qNrswIPnLqpAKAggEkHJz6de1YtmkqN5RMsWUCyM3ULuzgenOOe9Sz3BYmMxK2flMj8j7ozx7etZS1N4vuattIssKyXGwqZcxsP4mzx9D6/jVmObyopfIfdMHwztHtU/KeF9c5FYdnfDywItvkMQVUYwM8Hg07ULxWjFrjy4EzvkY5KnA4GOvAFEdyi3dzFGyY0LSEqgBPyqo3HA9efxpV+yvHC/m4Hykl0zuJOcMPywBWTdaoybVIWRVAKOvBIOMHHpt6j86SynlVbfchEu3gA+pz044x+WKu3UzctbHQQoy+Zkxyu/ynGVQdyDj161K6+TtEYEWAFYpxkYGQPfoKqzyLBciLziFUElU6E46ccH1+lSoZFEmzDF5M/vDnqf8A9dc8tzoh3J/MBQq6hMsWOw5JGM9PUcU4SBl5Kl15dhwG9PpyagSeOBHMqnDncqDk9QAoPueaTzk8jy1+bBC525OfUmpNUiSV5HgIWMAA46jDe9N04O8ReeJhI5K7AcYUd8fWlT5kkCFsHGI+QB7/AI1JGhCOVV/kO0gZ57460FWEkJbcwBYnsR3HHHtVV48uJFH7vGOTwfcVfdgrDBG3+HBOMUx0LuMHf14I9ew+nWmZtCWBhhu7eVbu4hlBLv5Sbih6Ae+Rn6Zq3qd5Hc2jRpezsVO9Y1sRErnPU49KTQ5VtbuSQXIhlaJkjmZuEZvu7vStOK51G3juEn1aN7mVkWFROJNrZGWbHRcZ61S2MpLU5ADzAGEcgJHO08E+tFaGrx276pdvaKv2dpCUwvGO+PbOaKnmaNFG54BJiNFKbcMS2M/570w9cu+G9MbiP/rUhVsZIwwxnBwDn+fFTNG8TeZyueASvtkA59q9I8IjHBdnLbRyB04p8qqCNikjggE84HXFN3ExLjnHTJ4X3pHLSMxXGcZII6j0oGT28L3M0ccRXJ5YAcD3r0LwhoW1SfK+ZuCccY/xrE8Jab5URklXLSgjpjHfH0r1jwpYLG0TyNxjJ57evvXLVm2+VHoYagkuZ7m94b8PRTRl5pI4ti7nZ2wCAOnuade3kFspCDcCCCwHeq2t6wsIIgdUhAyccfjiuQnurnVSWjISHrl+rD2rmlLojtStuXdV1/ykEcALy9MDt7VyGrre36l7yUgIPliX7oH9a6SKySHoAccFm6GqF+o2NtOWJ6e/9KiM9SpU21qcLc7oVPykHpkVe0a9v/mDTNKmMhZOf161el0s3MwDBiFweB3rXt9Aks0jeRC29eFJxj0zW/NdbHOqbvqQJPcKY5ZlKMwwpPUA9D6DOK17KY+VGdp8wEZI7+lStavcsIPMVwBlYjgMAf4sY6deeKjslVbh035CdM4HP41MlZXLhq3cuw3HmCRSBnvzyOadO5jlXa+QAQqk9DUuFjG4YOGydo6nuSKz7qQ4Kh1AYYwOce31rN67GthzCFgRJtcZwc989qeEVoycggfLz3/DuKprJtMZIZh0IyOferNswZXYHLbevt3P9Kd0LlYXEAMKoIiR8uQR09eDSiEIPLWN+WyQy5HsP/rVOBGFU7yUPzHPQA9ue9OKo6tzg7SN3IyOOfrTTE43Kd1BuYGT5scgAZ3c8/jiqYdfNzGygBwuH/hXv1rXnWRVcBfRvvZAOfT+tURNkL8rFgQ5JUZPoc+lVe5HLYgmZ2jKQbI0J2K44Lcen9axjcbJWkE6sI8hnHIU+xx9OlbLblYNKitvyGfAAH19PwrPupWDKQ8fBwFTjBx2FXGVzKaZWlvnkkZQ7yBRud3GUQ4Hcexpj3L3E4Zh85ffuU5AA6nHc4qG5kRkaML5l1ksxJ4dQegA79eazJpZy24tKxycqpCKPx61pFLoYybRorc+VfBUkfcQckcgjkjJ9fSla5EJBaZCm4Llec56kD0H51UZxABA24SMqlRj1U4OfXAqOdw0gVzBII8BNp4A45Pqc/nVWTJcmiWW9cxBt86g4B2JxgHIFaenSXMk8Z+40SZSNX5G7jkn8Tx0rLtysRVJUYJtZVVhgsw79fetexnS3nfyZl3Lzhhv5OeR3qZPQqGrudBatiFgUQKxPzKM4Oevv9amjwJN+0t/EhAztHH+c1nW8kk7nykdXIyzMBkAnpn+dWogVcgxrnHCge/Q+nFc8tzujsXSBEAkcsQAJ3KrZwfc+tWRGBlV+YDLMUPU+/tVWJkIYTBVReFOMcg1LDJiRVeTaAMkBTxnscfgalmq8iSRdpYs2M8k5PHsOOnFTjc7Ak7VYYLYIJ9/eobiVrdS8jbtg3YBIwvT8+9S2zq2XOSGwAXfJGB1A/xoQ7EnzbcB3CZORuDYpsC5jYjJ2YDAc4HXH609m3BcNkfKTxjcf8QBTLeWKcuYi21Dlst1ycZPqOKpEtFzRoUe9dgElby3aFH4VpB0Uj8yBVu5juX064fVofJyF8kvEI3MmfuDA5GOtZjo+1wqGTPIwuc++B6YNSW0bT2V49yHaS3hUxlmb+8ATz69KfkZOOtzNNl5rFvlznB+cLzRUipK2fIiDhThjkr83fjFFIux87LjcSM7gdy54/yamkXIKlNr9OucjHbsKhjxuHyhcHJJPtV+ICSA7rlNsa7gr/xDjoOmen4V6R4BXdPKBJ+UDB+bkH2qxZQtJeCJfl6bsjlR14+uaJ1GwuobgH7uduR29h3xW14WjE1xPcbcDgAscj1PNTOXLFs0pw55JHdeGLHzthlPKDHHfPrXXyyPHFtDgKvzYBxisHRYvKkjeLazqpGQcZH1pni68ew0mZ1YCR/3QIPOT3/LNcEnfQ9aCtqV4rlte1iSFcG3izlCcCRh7+ldBJAINqErwMDaAB+NYPwvkjRnDOcudu3YWLjGMcdq6zUoGtrhxJ/rM9QOP89qmfuwVjWl707sy54Qiguj9M7icgn1rHuFbrk7VJ5Jrq/srXEQWFSZHUDOf5dqbLpSomwqwlBwQOSBg56dayhFs1nIxdAt1kvVMikwE4Ixknvj8a6zxZP9r1AlYghj2oEXBA2jAAPpWNHC1uVMLbGIHJ/hOcj6cVfs9OubplQ/KBnLY4UdeTWrbUeVbmKSbuynBbTOkqxbwJFIKjkEDk5Hp/hXmMmtvZ+KRbqweJjskUDIz2Ir0Lx34nt9DtJbTTpkluJlCfIMA+/0B5zXlehWD3F950xLHJZm7lietXBaXkYVZPmtA9Be8iCBwOvJ6jJqg0yv8wcMGzyg6+1Vp0yrK+Tu4yOP/rD61oaVZMwXKhIwAAB2rNabHQ2x9vAxwWX5R1J6D6/4VciVAWyCQB93oMdq14bFAgyqMg4AwT7dP60+W0CqhUZLdM9APx60uUpMzdwLKOmAOApwPrSvkrjawUD+7k96tQCRFKoGXgnnBAPsKY4yc/KSwxlMDt0z07UrWYmUXYv5auTsH3QBx+FUCx3IGlZkHAA+8ozwMenWtVkHBIXLcBcZwB6H+lZssJjcsh+UH5flyeOoAqyGiuXVxIEYF8AcNgn2+v0qs+VicbRuwecjBP07nFTnlicglerBP8Kr3bLku6AFQGIC56dM5prczaIpJIYs7UyWU4KHpgds+9Y8+6J/OaTZcFCWXZ2+ntn+dXLqJJI+RtVmJAXO5/8A61RS2wLKsSo0jAksz4wD79enStk0jGacmVTZu8uTKse87mXaRsPTr6c0y2iaD53CBw2D5ZySAc8g/hir5WVtm5oR/AQRx25wPzoW0SJWYR7RIcq8ih+/b6dh1qlJmfJ2IGEUrQiQFwZS5I6P3OP174rQt7ZQgQbWZsbY1GMHPAz6Uw5QRpII9mC7hsZG7oPb19q0bcw7FlWJXY5G4LjH1/Os5Nm1OKL21FQqVAOCPn42jPf16VXuLfUGkUWmI7XILM7c7fXH9SasCQ85b5lXhvXA7/madHMACwcgn7zDoVz0zWbZvZPQsWM0iqyy+Uqk9A24n1yfy4q1EG3FVZBgDJAJwKoQohlzljgggEcfWryjYoA52nnHX6gVEjaCLEMjtyCQeuGIOQapXUkimIIVTcRksM5HcAdvxp8KiJ2mJVNq4Ue2TwB604S+YfMlO7qeuAB0xj60k7FlpZBIpyx2xnvwCc9B7VHYwrZmUWpMbSnexPJYf/qpwlULtPbqR3Pp9KBLEYdrHY7HjI6U+Zi5UacWr3dvAI7a8kWMZIAIByT16Zpkur3dxBJDNcyPGx+aNmBz6ZqWyudO+wTtPbl7pDu/1m3zV9BjuKo3N5ZSRyLb2Plu2MS/aC+3B646Gq5u5nyq+xEJDgYRZB/ew39KKr/bGiAWF5EHcIRjPeii6HY+fQ21sjJBHX/P4VKSCnDHJHOVwAaiViE+UAA9RmnLLw6sMqRyAetemfPE6zKgKleMfKqHq3qfwrsfA8IksWHUeacg/QVwoZiqrng89Ogrt/Adyn2S5iyN6PvAzk8j/wCtWdZXgdGGf7xHoOmQQRzl02s+cE8/KffPFYHxEuC1raxnk+cW49hz/Ot3TXklXpuxyCTjmuW+IK4+y8jh26fhXnx+NHqzVqbZd8C3D24HlEb89xx9K9GmaS5tVmljwxzhQOVXgDJ6HvXmHhCRlgBHqRn19q9L0doDZMTGZJGOVQ4C/h6mk3q4l00rKRY0yUIxDYxnp0z7f/qq/IkE8qsSI1yo5BLAnPX2AFZuQy7gxQkk7WPCjriqWoXxiVyMAjOamEmtDScL6my82nwogmxJtTooGGJGTk9fUflXK+KPFos4JLeyznAyi8ZIHU/nXPazrkskjpbHaSeWGCMntRomgT38ZuJI2aJVBEhBOcnGcj3z+VbK8tDnk1E5iO0ub++M90xd3Oc47f0xXa2OlR2lv5hxjGeema0IdOh04nzjD5rdQG4Xgjj17HFYuv67mPyrbDy4xvHIX/OKl3vYSioq5S1XUILMAMd0p6Rgcn/AVgWviSZbxPMufIznaAPlHsajS3l84s53zN95ieT/APWrC1eArOCwxn/PFbQhF6M56tScfeWx794ekF/ZkHORglUOen+c1avIyqO2ScA9Rk4z0H1riPg1qrSOlrdHmM7QxP3kPQ/ga9Xv7LG4hVwhxjkFj/8AqrJqzsdcJ8yucULiNy7fKxJyFHAB45q1IoKBQcZAIwee/BpLi0jgaQQjaoPUnB556enpTctgj+BFJGAB14/PrU3KsVL1QoUGQkn5ePlLcZ/DpWXPETEflUE8biOee/1rcuFY4O0gEkJhcA+v5VVliJZixLbmAIH60xNXOcCud0jsGbJVVjXywPwqtNH5LGMLnJxvJyDnjFbU8IaU8sqsuRx79Paq4iaTYXQjcpIjI75wM9uBTTM3Ey4IgrD/AEcs33VJblf8KFhkYMURQRksM5L+3P61aWEeY+xg6q+1NvB6YyadG6RvIJYo14Ow9SvoPer3ItYzYbeO3YuEYsQOVP5/lUM6GOYpJufdxskyAc9+O9Xnw5YKrt8xBx19Rmk+aKXMg3Lyu1myeRkHPpQTbuVE09LJnaZd0wUkurkg5/2fp+VWomG0FCWQHqWALHHTHrSLIkpMypLsxt+U/wBT70jeb5xRwWxHnKgALzzz+tD1RUdC2JA6cxFSp53NlunT0qRBFIyb/lKZw7EgGoDc7U+ZFk46AjLHuadGynykXDAdB1xxnJP9KgtMuwblAkYnPZj/AHhnP9KuQyPgcjf3bHI78VUzEANoc85G08j14+tODEt1J45DZ6+vWoZtEsCYqQePOx99uc+/15609JIlaMBiccEZHSoFcfLg/KMrg8HBFKzccf6we361Boi0sjtFhWBAGMA9Px/Kq8CCKaR2kZpW+6n8K+wHf603zPLUE9Tzil80LzJlyGOCvHB7+vSjYGbljb2Mumy3FxLdpNEcyQwRq3B4BGTyPWqd0mmiNhDPfPNx8skaqvPqQafGbO0023nvYppTOXVFRtiqqnHJPf2FMMVjeWdzc2MM0EtuoZxK/mK6ZxjPGDmrtoZ+ZWEzHPzJxxwtFU4uU/dRBkBwCM0VIzwxDuZQxIA9KXjpjIB4Peo/enKeOnSvXPnSRgG2lAcjg5PU+tbfh2T7NqAKyDDAqwAwc1ghiCM8j0PQ1YgldXjaEYZWzx6+lKSurFQk4yTR65o90THtU4wOoNZfjhC9nDMclRJ6Y6jrUGhXYEkbb/lkG7npj/GtTxLF9t0mY55CbgOvI6V5qXLM9u/PS0M/wqyrZnOMg856jPpXqHh9i1pJslC/JknaAdvtmvIvCc5Mci8k8dPz4/xr0nQbnfbmMnO4jnAzmiWkmOlK8EX7uXaSGLecBnLY5571zt2z3d3DbciaeQRA/wB3J61d1CfykYH5sEnPX8zXN2d6ZNXR2faFJAJ7e/8ALiopq8rmtaVo2G6pYCLU3jiDJEjYQPgsOn3sd+v9K6vT7lrPTlS3Me8cOoyCVbO4cH15o0nS2neW4cK0DIMnYBuBkAJXPYHBzx1qzrMMOngqLlZGUEBl56k4B9xW8rxTkjmhaTSOT1KYl9mDzwa5/wAwSy7UG1V7kdR6/nWxqMu2bAbJ2/MfT3rIt5SsuTjax5G3JUVnFaFVNzRWFdmVw25RjsPr+NZ2t6Y0nVecHtxXTW6JLZqNreaxycDgLg8/XjoarTwqAMlU3eg6nGcVSbWxDSe5n/D5DBqqjBUgAAjnHNfRUskKtAzKHR4wQx9R0zn0r55titlqEcyYCk4Yd8HpXqdlrqXFlEsrsSgwCDz0qJS1uzWlFcqSKniHMU8nln5+xIyDx19Ko2kqyQFJOgGSemfzo1u484mTIIbHQkY+tZ1tPkkNyB2/i/Os7mzj0NQkMm2P7gPQZNQ3EeMndkqeEyMH3OKUSFygUYU55z+VSyB/lw5yB1OCSfSrTuTYoTRqgy4AQnJJblz6Y+lZjkshAAVZGDYOcsucAew9vStS5gWVlJB4BOFOO/U1V2GB3jjYsp4duGK59umevFUZtambcAmQog2gtguD823ryB9MVWujksYgS7AL5Y5wcdf1q5cQw7wyv8i/OWBOG9sHnvUFwArGUREgAsgPB5OcY+tWtjJ7kdsVmhjLGQzOB2Iwc8/Tj1qG7gi34QyCRAVX8Of0pJJV2nau6X7rIBgsAf8A69ORWUKGXCnO4HBG329+lMQkCyecw81txYsBuyp45zxxx3qdkVTuO5VJPztzliByDSIx3gE+XvyORnv/AF44qdSAADuGVJAI+UEDsKlspIhljG7csGCORnrTVciVimUdT86sOBj/APXRJ8jE7vTG1uF/H+lR7W4wSxA79D7ZpAXYGK7gzhicEbl7mlbYhJ3Ak8E7uAfY1VQsIcqcnGVAyCfc06CYNtbLDH3T14z+lSzRSLqMSgAOT0wrccdj6U5MITjI+XcB/e7VVZvnRkyM9Rng/hTkPOfu7hnI4xUGiZNwCC3OOeOMfjSln2MwPVuvcYHSmq52dQSBwSOtQRyCRN8e4oM4OOfrzQU3Y6bSpngs0kl1OO1S5YmOKWLzUJBwWPXaM8fhUV/LqFzHqNveyCL7EqymGNAqShmAU8dRg5zWKNSZtMW2kihJRi0M2Tlcn5lHYg/pVmPV510drBo1nR08tZTw6ru3bfcZ7VSa2MmnuUhI4GFVCPXef6UVEmUUKnyqOg2dKKkq7PF0+8AO9PwMnLjgZB/HpUSjgZ+tSRKSxXacnr716586Phj3YJIXPPNaEEYULI5J52nA6fT/ABqlCrA9ASCcgnpitK3ttojZnwBnIY9cdKmVzSKRr6VMyhk6kHj29QK7GwLT2eDzxjHf8q4WN9pBTjjIwRwa6DRb91uA20FwMn2rkqwT1R6FCdlyszrdW0rXJrY7hGxwp9QeRXfeHp/3hzkMc4IPtjiuW8X2q3FvFdwYEkYBJHU8YP4ZqXwzqihonJAJGGU8jNZzV1c2py5XynTaxC4iPz7hjn1/EVzdtH5c6jHzE5PP5V2UsaXUOI8qo5POc+uT19a5a9Rracsy8dCeuPSpjoaTVz0C11FLayeeAEpIjI5VNy52jKbT0HTBHoO9czq981wHMmGds/xcjnI/nVWz1XfZvbO7NEMbcnlcHPy1HOIpJN2V8skgkDGeOPxyK0k+YziuR3IooTLlCDz8ue+cZpms6eLXTwseElX7+3v0wWP59K11uLe0tygaIz/eDBdwOO689xkc1h3l8hT5fmQcDJDE+maFHlQSbm7jY71o1ct8rAEjJ9Rj8qpT6mACNzKdo6HP/wCuqN5dZwR93+VZUzFiACSPaqSuZylY1m1UEkPnJ9+n0zWho/iFoHEUrYXoGznH1rkHt3Y5BPtSxxyqcuuQD0JpypprUiNWUHdHqyXS3CgmQnPOTyDQGaOXJYY78c/nXK6DJMADGTsHOOwFdNHOXQljwR0I5BrkmuV2PRhLmVzWhmR0HzAHH5DNTb2ZW42gkcgcZ/rWTaEeah69wcfpWrHMCFbO3HRhyKSBkmdynBLnkAcDBA4Oapzvsfc/BJLZ/wDretWhnYSzlzn7vT8BVS4XnYdzJgJyM+4/lVpktFJkYKFVVeVhzk42+/tUDJEw+ZdxQhtxfOR35q4UO84XaoPXPbrk9+1UTs2gBcgNw4ABOR1NUjJq2pTzFktD5YIzhiepxx261Cs+LclgASBnncQAMYI960Zoo0HktlyuWyvU8cfzqm6JvYhi7EjOOSRxmr5iLDILgpH5U3yMMM2TjI9v0pk8wTcfMOwH7uc59ae9ooUyICGzgE4J5H8u1V3DqirG8RI6jGMY9/X2pdRO6I2IZQAO3zZ4yPwp/myLEFGGYL0xk+3NUmt5Jn3SXGyLcTiPuSO//wBapYnaMBPmK4wD1IH1qpIlSvuXI5JGI+UlHYAfNj68elS5A2sMjB5Hv3qnG5k2LGMREEKeenfJqRsLtG8KuMbSeVIqDVOxdQtIf3uFGTgetSbsBSDk54BPHvUEbLldoLMeSdw9PSnMRsLDIccnPPb0qGjRbE5kCqqxn5s5HzcZ7VGxLKH2Bj65oULtBI5PJ4/WmRj97uO3PDEnqKOUDeso1sNKF0FhS48rzDIYw5XL7FVQeByCS30FNl2Xmkm6cK9ysZk8wRhGJRgroccN94EN9RUOnam0cfk3KuFGdk0QU4BOSpRuHXPPsabqV+s0AhgMsiuAGeXC5UHIVUXhVzye5NWZ63Mie6dJCoaQ44OzBA9qKaZvK+VYogvUdv5UUi7n/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hair loss on the anterior scalp is evident in this patient with traction alopecia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38468=[""].join("\n");
var outline_f37_36_38468=null;
var title_f37_36_38469="Role of surgery in multimodality therapy for small cell lung cancer";
var content_f37_36_38469=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of surgery in multimodality therapy for small cell lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/36/38469/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/36/38469/contributors\">",
"     Eric Valli&egrave;res, MD, FRCSC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/36/38469/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/36/38469/contributors\">",
"     Rogerio C Lilenbaum, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/36/38469/contributors\">",
"     Joseph S Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/36/38469/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/36/38469/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/36/38469/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small cell lung cancer (SCLC) is distinct from non-small cell carcinoma (NSCLC) both biologically and clinically. SCLC comprises approximately 15 percent of all lung cancers. It occurs almost exclusively in cigarette smokers; in one series, only 2 percent of 500 patients with SCLC did not have a smoking history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/1\">",
"     1",
"    </a>",
"    ]. SCLC is also the most common histologic subtype among uranium miners, probably due to exposure to radioactive radon, which is a byproduct of uranium decay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42552?source=see_link\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SCLC is distinguished from NSCLC by its rapid growth characteristics and the early development of widespread metastases. SCLC is highly responsive to chemotherapy, while there is a substantial historical experience documenting the futility of local-regional modalities alone. Prior to the introduction of systemic chemotherapy, median survivals for patients with limited disease (LD) and extensive disease (ED) were approximately 12 weeks and 5 weeks, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/3\">",
"     3",
"    </a>",
"    ]. Many studies have demonstrated that chemotherapy significantly improves survival when compared with surgery or radiation therapy (RT) alone, and combination chemotherapy is the mainstay of therapy for both LD and ED SCLC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=see_link&amp;anchor=H2#H2\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\", section on 'Benefit of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the combination of chemotherapy plus radiation improves survival in patients with limited stage disease, local recurrence rates in patients undergoing chemoradiotherapy are between 35 and 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/4\">",
"     4",
"    </a>",
"    ]. This high local failure rate has led to reconsideration of the role of surgery as an improved way to achieve local control.",
"   </p>",
"   <p>",
"    The role of surgery as a component of multimodality therapy in SCLC will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SURGERY AS THE PRIMARY MODALITY FOR SCLC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple observational series support the conclusion that surgery alone cannot be considered the primary treatment for LD SCLC.",
"   </p>",
"   <p>",
"    A trial conducted by the British Medical Research Council study in the 1960s randomly assigned 144 patients with apparently resectable SCLC to either surgical resection or RT. The study demonstrated an extremely poor survival for both treatment groups. The median, one, and five year survivals were 6.5 months, 21 percent, and 1 percent for those randomized to surgery and 10 months, 22 percent and 4 percent for those assigned to RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These outcomes are consistent with data from the Memorial-Sloan Kettering Cancer Center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/7\">",
"     7",
"    </a>",
"    ]. Among patients with SCLC seen between 1931 and 1971, only 7 percent had resectable tumors and only two patients survived for five years. Similar results were obtained in another report in which one 1 of 368 surgically treated patients with SCLC survived five years following resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/8\">",
"     8",
"    </a>",
"    ]. This contrasted with a 15 to 25 percent five-year survival for patients with NSCLC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SURGERY IN MULTIMODALITY TREATMENT FOR LD SCLC",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCLC is a highly malignant neoplasm that should always be presumed to be systemic, even when apparently localized. The issue is whether surgery might be beneficial as a component of combined modality therapy and if it has role how it should be integrated with chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42552?source=see_link\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542557076\">",
"    <span class=\"h2\">",
"     As initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of surgery as initial therapy arises most frequently in the context of patients with a solitary pulmonary nodule (SPN). In one series, 4 to 12 percent of lung cancers that presented as a SPN were SCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/9\">",
"     9",
"    </a>",
"    ]. In another report, 4 percent of patients with SCLC presented as a SPN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/10\">",
"     10",
"    </a>",
"    ]. Approximately two-thirds of SCLC that present as a SPN are the \"intermediate cell\" histologic subtype. This finding is in striking contrast to SCLC presenting with more widespread disease, in which approximately two-thirds are comprised of classic \"oat cell\" subtypes.",
"   </p>",
"   <p>",
"    The most extensive data suggesting a potential benefit from surgery in carefully selected patients with LD SCLC come from the International Association for the Study of Lung Cancer (IASLC) lung cancer study project [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/11\">",
"     11",
"    </a>",
"    ]. The IASLC database of over 8000 cases of SCLC included 349 cases (4 percent) in which the cancer was resected and staged pathologically. The five-year survival rates for patients with pathologic stage I, II, and III SCLC were 48, 39, and 15 percent, respectively. Similar results were seen in a Surveillance, Epidemiology and End Results (SEER) database study of 247 patients with stage I SCLC who underwent resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there are no prospective data addressing this issue, patients who are being considered for primary resection of a known SCLC should undergo extensive evaluation for mediastinal involvement and distant metastases. This evaluation should including CT-PET evaluation and brain imaging. Invasive staging of the mediastinum by endobronchial ultrasound (EBUS) or mediastinoscopy should be obtained even if there is no evidence of mediastinal involvement by imaging since there can be a significant discrepancy between clinical and pathological staging in SCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/11,13\">",
"     11,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective data cannot determine whether the encouraging trends in resectable SCLC reflect a beneficial effect of surgery or whether this is a surrogate marker for a reduced tumor burden among patients in whom resection is possible. Nevertheless, such data support continued investigation of the role of surgical resection followed by chemotherapy and possibly radiation in early stage SCLC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542556915\">",
"    <span class=\"h3\">",
"     Postoperative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data on the role of postoperative systemic chemotherapy in patients who have undergone resection of a SCLC SPN. While most patients who underwent surgical resection did receive postoperative chemotherapy, some did not and still achieved a prolonged disease-free survival. Nevertheless, most investigators treat patients who have undergone resection with adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also no data regarding the efficacy of adjuvant thoracic radiation in this setting. Postoperative RT has been advocated for patients with pathological N1 or N2 disease or in N0 patients where the surgical nodal evaluation was suboptimal. In patients treated by lobectomy in which the nodes are pathologically negative and where a good nodal evaluation was performed, the role of adjuvant radiation therapy is probably less important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9914?source=see_link\">",
"     \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data evaluating the role of prophylactic cranial irradiation (PCI) in these patients. Extrapolating on the experience in other patients with SCLC, PCI is reasonable in the context of a potentially curative regimen for such patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1830?source=see_link\">",
"     \"Prophylactic cranial irradiation for patients with small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     After induction chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential role of surgical resection following induction chemotherapy remains uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. One randomized trial suggested that this approach did not improve outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/17\">",
"     17",
"    </a>",
"    ], but more recent observational studies using contemporary chemotherapy regimens suggest that there may be a role for surgery in carefully selected populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized phase III trial conducted by the Lung Cancer Study Group in 340 patients with SCLC failed to provide any evidence for benefit from surgery following induction chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/17\">",
"     17",
"    </a>",
"    ]. All SCLC subsets with LD were eligible to participate. Patients received five cycles of chemotherapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ). All patients were restaged following induction therapy; those judged to be suitable for resection were randomly assigned to surgery followed by thoracic RT and PCI, or to an identical regimen of RT without surgery. The results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction chemotherapy resulted in a 66 percent response rate (28 percent complete and 38 percent partial).",
"     </li>",
"     <li>",
"      Following chemotherapy, 146 patients were randomized to surgery or no surgery. Resection was performed in 58 patients of the 70 patients assigned to surgery and in 54 tumor was completely resected.",
"     </li>",
"     <li>",
"      No statistically significant advantages in median or overall survival were observed among those randomly assigned to surgery. Actuarial two-year survival was 20 percent in both treatment arms.",
"     </li>",
"     <li>",
"      After induction chemotherapy, up to 15 percent of resected tumors contained elements of NSCLC histologically either as a component of a residual mixed SCLC-NSCLC lesion or as a pure NSCLC lesion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although this trial did not demonstrate any benefit from surgery, two subsequent phase II studies provide some evidence that a more aggressive approach to treatment may result in prolonged survival in a subset of patients with LD SCLC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study included 32 patients with clinical stages IB to IIIB SCLC who were to be considered for surgery following induction therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/18\">",
"       18",
"      </a>",
"      ]. Patients with IB or IIA disease received four cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      . Those with stage IIB, IIIA, or IIIB SCLC were given three cycles of cisplatin and etoposide followed by concurrent chemoradiotherapy. For both groups, 24 patients were taken to surgery after restaging to ensure a lack of mediastinal involvement; in 23, a complete (R0) resection of the primary tumor was carried out. In those with an R0 resection, 12 of 23 remained disease and event-free with follow-up ranging from 34 to 75 months.",
"     </li>",
"     <li>",
"      Another single institution experience included 75 patients treated over a 15-year period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38469/abstract/19\">",
"       19",
"      </a>",
"      ]. Patients with clinical stages I-IIIA were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      -containing induction chemotherapy. Following reevaluation, 46 patients were operated on and 35 underwent resection. Half of these 35 had had clinical radiological N2 disease at presentation. Only five of these resected patients experienced a local relapse, and the five- and ten-year tumor-free survival rates of the resected patients were 29 and 23 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/38/24162?source=see_link\">",
"       \"Patient information: Small cell lung cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/8/22659?source=see_link\">",
"       \"Patient information: Small cell lung cancer treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small cell lung cancer (SCLC) is distinguished from NSCLC by its rapid growth characteristics and the early development of widespread metastases. SCLC is highly responsive to chemotherapy, while there is a substantial historical experience documenting the futility of local-regional modalities alone.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery should",
"      <strong>",
"       not",
"      </strong>",
"      be considered standard therapy for the great majority of patients with SCLC. However, the evidence from nonrandomized studies supports the conclusion that resection in well-staged SCLC patients presenting with clinical stage I disease is a reasonable treatment option. This includes all patients with SCLC presenting as a solitary pulmonary nodule. Surgery might also be a reasonable consideration for some patients who present with stage II SCLC, although this approach is less well supported by the data. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Surgery as the primary modality for SCLC'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H542557076\">",
"       'As initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Postoperative chemotherapy and prophylactic cranial irradiation are probably indicated, based upon extrapolation from data in other patients treated for stage I and II disease. The role of postoperative RT to the chest is uncertain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=see_link\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1830?source=see_link\">",
"       \"Prophylactic cranial irradiation for patients with small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The role of postoperative radiation therapy to the chest is uncertain but should be considered in patients with incidental N2 disease at the time of surgery. (See",
"      <a class=\"local\" href=\"#H542556915\">",
"       'Postoperative therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery should not be performed in patients with LD who have stage IIIA or stage IIIB SCLC. Unfortunately, such patients represent the vast majority of those with limited SCLC. Surgery has no role in the management of patients with extensive SCLC. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=see_link\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ihde DC, Pass HI, Glatstein EJ. Small cell lung cancer. In: : Principles and Practice of Oncology, DeVita V, Hellman S, Rosenberg S (Eds), JB Lippincott, Philadelphia 1993. p.723.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/2\">",
"      Archer VE, Saccomanno G, Jones JH. Frequency of different histologic types of bronchogenic carcinoma as related to radiation exposure. Cancer 1974; 34:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/3\">",
"      Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973; 4:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/4\">",
"      Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/5\">",
"      Comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus. First report to the Medical Research Council by the working-party on the evaluation of different methods of therapy in carcinoma of the bronchus. Lancet 1966; 2:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/6\">",
"      Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet 1973; 2:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/7\">",
"      Martini N, Wittes RE, Hilaris BS, et al. Oat cell carcinoma of the lung. Clin Bull 1975; 5:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/8\">",
"      Mountain CF, Carr DT, Anderson WA. A system for the clinical staging of lung cancer. Am J Roentgenol Radium Ther Nucl Med 1974; 120:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/9\">",
"      Kreisman H, Wolkove N, Quoix E. Small cell lung cancer presenting as a solitary pulmonary nodule. Chest 1992; 101:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/10\">",
"      Quoix E, Fraser R, Wolkove N, et al. Small cell lung cancer presenting as a solitary pulmonary nodule. Cancer 1990; 66:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/11\">",
"      Valli&egrave;res E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/12\">",
"      Yu JB, Decker RH, Detterbeck FC, Wilson LD. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol 2010; 5:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/13\">",
"      Shepherd FA, Ginsberg RJ, Patterson GA, et al. A prospective study of adjuvant surgical resection after chemotherapy for limited small cell lung cancer. A University of Toronto Lung Oncology Group study. J Thorac Cardiovasc Surg 1989; 97:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/14\">",
"      Chandra V, Allen MS, Nichols FC 3rd, et al. The role of pulmonary resection in small cell lung cancer. Mayo Clin Proc 2006; 81:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/15\">",
"      Karrer K, Ulsperger E. Surgery for cure followed by chemotherapy in small cell carcinoma of the lung. For the ISC-Lung Cancer Study Group. Acta Oncol 1995; 34:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/16\">",
"      Tsuchiya R, Suzuki K, Ichinose Y, et al. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 2005; 129:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/17\">",
"      Lad T, Piantadosi S, Thomas P, et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994; 106:320S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/18\">",
"      Eberhardt W, Stamatis G, Stuschke M, et al. Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial. Br J Cancer 1999; 81:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38469/abstract/19\">",
"      Lewiski T, Zuawski M, Turski C, Pietraszek A. Small cell lung cancer I--III A: cytoreductive chemotherapy followed by resection with continuation of chemotherapy. Eur J Cardiothorac Surg 2001; 20:391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4601 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.80.101-C15F01F966-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38469=[""].join("\n");
var outline_f37_36_38469=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SURGERY AS THE PRIMARY MODALITY FOR SCLC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SURGERY IN MULTIMODALITY TREATMENT FOR LD SCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H542557076\">",
"      As initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H542556915\">",
"      - Postoperative therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      After induction chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9914?source=related_link\">",
"      Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/38/24162?source=related_link\">",
"      Patient information: Small cell lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/8/22659?source=related_link\">",
"      Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1830?source=related_link\">",
"      Prophylactic cranial irradiation for patients with small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_36_38470="Renal Bx - congenital NS of the Finnish type";
var content_f37_36_38470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Renal Bx - congenital NS of the Finnish type",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Renal biopsy from an infant with congenital nephrotic syndrome of the Finnish type due to mutations in the NPSH 1 gene that encodes nephrin, a transmembrane protein located at the slit diaphragm of the glomerular podocytes. Histologic changes include the characteristic findings of mild mesangial hypercellularity and increased mesangial matrix in the glomeruli, and irregular microcystic dilatation of proximal tubules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38470=[""].join("\n");
var outline_f37_36_38470=null;
var title_f37_36_38471="The pediatric physical examination: Chest and abdomen";
var content_f37_36_38471=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The pediatric physical examination: Chest and abdomen",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/36/38471/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/36/38471/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/36/38471/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/36/38471/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/36/38471/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/36/38471/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/36/38471/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the chest and abdomen in children will be reviewed here. Other aspects of the pediatric physical examination are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19943?source=see_link\">",
"       \"The pediatric physical examination: General principles and standard measurements\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11194?source=see_link\">",
"       \"The pediatric physical examination: HEENT\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34280?source=see_link\">",
"       \"The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10295?source=see_link\">",
"       \"The pediatric physical examination: The perineum\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHEST",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Chest wall",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest examination begins with careful observation and inspection of the chest wall. Normally, the chest is symmetrical and, in the infant or young child, almost round. The transverse diameter increases with age. When a persistently round, barrel-shaped chest is seen in an older child, the examiner should consider the possibility of an underlying chronic pulmonary disease, such as cystic fibrosis or chronic asthma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27351?source=see_link&amp;anchor=H4#H4\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\", section on 'Respiratory symptoms and signs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26010?source=see_link&amp;anchor=H25#H25\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The shoulders should be examined, especially in the newborn, for clavicular fractures and foreshortened or absent clavicles. The width of the ribs and length of the sternum should be noted.",
"   </p>",
"   <p>",
"    Nipple alignment and the distance between nipples should be noted. Accessory nipples along the milk line are a normal variant. A shield-like chest with widely spaced nipples can be found in patients with Turner syndrome. Widely spaced nipples also may occur in a number of other syndromes, including 9p deletion, fetal hydantoin syndrome, trisomy 8, and trisomy 18, among others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/37/3673?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of breast disorders in children and adolescents\", section on 'Accessory breast tissue'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33449?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An asymmetrical chest wall may occur because of scoliosis or an underlying cardiac disease that creates a precordial bulge. Poland syndrome, consisting of syndactyly and ipsilateral absence of the sternal head of the pectoralis major muscle, causes an asymmetrical chest wall with an inferiorly placed ipsilateral nipple [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=see_link&amp;anchor=H16#H16\">",
"     \"Diseases of the chest wall\", section on 'Poland syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A mild degree of pectus excavatum (funnel chest) or pectus carinatum (pigeon breast) is a common finding in an otherwise normal patient. Pectus excavatum frequently becomes accentuated with even mild degrees of airway obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18071?source=see_link&amp;anchor=H5#H5\">",
"     \"Pectus excavatum: Etiology and evaluation\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25207?source=see_link&amp;anchor=H7#H7\">",
"     \"Pectus carinatum\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inspiration normally results in expansion of the chest wall and depression of the diaphragm. In the patient with unilateral pneumonia, pneumothorax, atelectasis, or a foreign body lodged in one of the mainstem bronchi, inspiration can cause the diaphragm to rise and the chest wall to collapse on the involved side. Bilateral paradoxical breathing can be seen in patients with neuromuscular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Breasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast development staging is based upon standards established by Marshall and Tanner (",
"    <a class=\"graphic graphic_table graphicRef55329 \" href=\"mobipreview.htm?8/1/8220\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The range is from no evident breast tissue (stage 1) to complete adult development (stage 5) (",
"    <a class=\"graphic graphic_picture graphicRef72038 \" href=\"mobipreview.htm?10/43/10932\">",
"     picture 1",
"    </a>",
"    ). Infants of either sex often have transient breast tissue enlargement secondary to perinatal maternal estrogen stimulation; this enlargement may remain for several months before spontaneous regression occurs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42776?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of breast masses in children and adolescents\", section on 'Neonates and infants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a prospective study, palpable breast tissue was measured in 871 Caucasian children (443 boys and 428 girls) over 978 visits between birth and 27 months of age to provide preliminary information about normative values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/6\">",
"     6",
"    </a>",
"    ]. Palpable breast tissue in girls was larger and persisted longer than in boys. At &gt;10 months of age, 62 percent of girls and 45 percent of boys continued to have palpable breast tissue. At 18 months of age, the 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile for breast unit size was 2.88 cm",
"    <sup>",
"     2",
"    </sup>",
"    in girls and 1 cm",
"    <sup>",
"     2",
"    </sup>",
"    in boys. Breast unit size was calculated by 1) taking two measurements of the horizontal and vertical diameters of each breast (in cm); 2) multiplying the mean of the two horizontal measurements by the mean of the two vertical measurements for each breast to yield a breast unit value for each breast; and 3) averaging the right and left breast unit values. Additional studies in other populations are necessary before these threshold values should be used to make clinical decisions.",
"   </p>",
"   <p>",
"    Generally no discernible difference in the size and shape of the chest wall occurs between boys and girls younger than the age of 8 years.",
"   </p>",
"   <p>",
"    Both males and females may experience the development of a firm and often tender-to-touch unilateral or bilateral subareolar nodule sometime in early adolescence. In approximately 66 percent of normal boys, these nodules occur as part of the developmental pattern of adolescent male gynecomastia. They develop as a result of direct testicular secretion of estrogen and the peripheral conversion of prohormones to estrogen. These nodules decrease in size over one to two years, although residual nontender remnants may remain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42776?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of breast masses in children and adolescents\", section on 'Prepubertal and pubertal children'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Boys can also have true male gynecomastia; the cause is undetermined in most cases. Possible causes include drugs (eg, digitalis,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/24/38278?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/58/43943?source=see_link\">",
"     cimetidine",
"    </a>",
"    , phenothiazine, and antidepressants), herbal products (eg, lavender oil and tea tree oil), breast tumors, adrenal and gonadal lesions, gonadal dysgenesis, hyperthyroidism, Klinefelter syndrome, malnutrition, renal disease, and severe liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/8\">",
"     8",
"    </a>",
"    ]. Whereas gynecomastia is common in infancy and adolescence, prepubertal gynecomastia is extremely unusual and should be considered pathologic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/9/6294?source=see_link\">",
"     \"Epidemiology and pathogenesis of gynecomastia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27384?source=see_link\">",
"     \"Causes and evaluation of gynecomastia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, the mean age for the start of breast development in girls is between 8.5 and 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/9\">",
"     9",
"    </a>",
"    ]. The definition, etiology, and evaluation of precocious breast development are discussed separately. &nbsp;If the breasts fail to develop by middle to late adolescence, consideration should be given to the possibility of gonadal dysgenesis, adrenal hyperplasia, pituitary dysfunction, or significant malnutrition (anorexia nervosa) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19546?source=see_link\">",
"     \"Definition, etiology, and evaluation of precocious puberty\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22424?source=see_link\">",
"     \"Diagnosis and treatment of delayed puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment of breast tissue development and size is best determined with the patient in the supine position. While the breast area is being examined, the patient's head should be in the midline resting on the palm of the ipsilateral hand. The pattern for examination should be in concentric circles proceeding peripherally from the infraclavicular and axillary areas toward the areola. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/37/3673?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of breast disorders in children and adolescents\", section on 'Breast examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obese patients may have pseudoprecocious breast area enlargement, in which the areola is small, the nipple is flat, and the breast tissue is soft. This enlargement contrasts with normal breast development in which the areola is large, the nipple is raised, and the surrounding tissue is firm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lungs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observation of the patient's breathing pattern is foremost in examination of the lung. The rate, rhythm, and depth of breathing should be noted. A periodic sigh is normal in everyone. Shallow, rapid breathing can be seen with anatomical defects, pulmonary infection, pleuritic disease, and metabolic disorders. Slow breathing may occur as a result of central nervous system pathology, metabolic disease, and drug effect. Vigorous exercise, a state of anxiety, and metabolic acidosis may cause deep, rapid breathing. A prolonged expiratory phase occurs in patients with an acute exacerbation of reactive airway disease or true asthma. A sleeping infant may have brief periods of rapid breathing alternating with respiratory pauses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thorough auscultation of lung fields in children sometimes is difficult; successful examination frequently depends upon the age of the child. Fear of the examiner and discomfort from illness generally account for the patient's uncooperative behavior. Some of the anxiety may be alleviated if a caregiver holds the child. An experienced clinician, aware of the difficulty of auscultation of a noncompliant, often screaming child, concentrates on the inspiratory phase, as often little will be gained by trying to listen during the expiratory phase.",
"   </p>",
"   <p>",
"    An organized symmetrical approach to auscultation of the lung fields should be used. Sequential auscultatory examination proceeds from one side of the chest to the other, comparing breath sounds in anatomically similar areas. Either the bell or the diaphragm of the stethoscope may be used, depending upon the size of the child; the diaphragm is more appropriate for listening to the lungs of larger patients.",
"   </p>",
"   <p>",
"    The sounds produced by breathing may help localize a particular area of involvement or specific pathologic condition. Ordinarily, deep mouth breathing produces clear, soft breath sounds over the lungs. Atypical breath sounds in the form of rales, rhonchi, or wheezes are heard most often in patients with underlying pulmonary disease. Upper airway congestion in small children often produces coarse sounds that, when transmitted through the larger airways, may give the impression of an underlying lung abnormality. Frequently, coughing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vigorous crying will clear a congested upper airway, helping the clinician distinguish between upper and lower airway sounds.",
"   </p>",
"   <p>",
"    In small children, an inspiratory high-pitched stridulous sound with or without significant respiratory distress may be the result of narrowing at or near the larynx or anywhere along the trachea. This condition can be caused by a croup-like illness, anatomical defect, mass lesion, foreign body, or external obstruction. Patients in severe respiratory distress with stridor may have epiglottitis or croup. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=see_link&amp;anchor=H12#H12\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\", section on 'Presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43529?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features, evaluation, and diagnosis of croup\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When absent or decreased breath sounds are heard over a particular lung area, spoken words may sound muffled or the letter E may sound more like an A (egophany), especially in a child with a segmental or lobar consolidation. Fairly well-localized squeaky crackles during respiration may be caused by a pleural friction rub.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Heart",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     General appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician may evaluate the heart in older, cooperative patients at any time during the examination; it is best, however, to evaluate the heart in infants and younger children early in the examination. Before cardiac auscultation and palpation are initiated, the examining clinician should devote particular attention to the patient's general appearance. Central and peripheral color, nutritional status, respiratory rate and effort, presence of sweating, and chest contour should be noted. Jugular venous distention, peripheral edema, and evidence of hepatic engorgement suggest right ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation of the cardiovascular system should begin with the peripheral pulses. The pulsatile rate, regularity, and degree of fullness should be noted. Palpation can be useful in the diagnosis of valvular lesions, for assessment of ventricular function, and as a source of information about the patient's hemodynamic status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A rapid pulse may indicate heart failure, arrhythmia, an underlying respiratory problem, anxiety, or agitation. Bounding pulses suggest aortic insufficiency, patent ductus arteriosus (PDA), truncus arteriosus, or an arteriovenous malformation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/33/1559?source=see_link&amp;anchor=H4#H4\">",
"     \"Aortic regurgitation in children\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35656?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of patent ductus arteriosus\", section on 'Clinical manifestations'",
"    </a>",
"    .) An extremely slow pulse rate could mean heart block, a central nervous system problem, or a metabolic abnormality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33161?source=see_link\">",
"     \"Bradycardia in children\"",
"    </a>",
"    .) Simultaneous palpation of pulses in the upper extremities and then contralateral palpation of pulses in an upper and lower extremity should be done to help determine the presence of a filling defect in an aortic or peripheral artery (eg, coarctation of the aorta [COA]). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Palpation of the heart through the chest wall determines the apical impulse and the presence of a heave, tap, or thrill. Because the right ventricle remains dominant in the newborn, a palpable lift, better appreciated with the heel of the hand, is best felt in the area of the left lower sternal border. In a patient with left ventricular hypertrophy, a heave can be detected best with the palm and proximal surfaces of the fingers of the right hand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/12\">",
"     12",
"    </a>",
"    ]. A tap caused by pressure overload is felt near the apex as a well-localized sharp impulse.",
"   </p>",
"   <p>",
"    A thrill is a palpable loud murmur of grade IV to VI. Thrills associated with specific cardiac defects often are well localized.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thrill at the left upper sternal border usually is caused by pulmonary valve or pulmonary artery stenosis (PAS)",
"     </li>",
"     <li>",
"      A thrill at the right upper sternal border is caused by aortic stenosis (AS) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=see_link&amp;anchor=H5#H5\">",
"       \"Valvar aortic stenosis in children\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A thrill along the left lower sternal border generally is caused by a ventricular septal defect (VSD) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/19/8506?source=see_link&amp;anchor=H16#H16\">",
"       \"Pathophysiology and clinical features of isolated ventricular septal defects in infants and children\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A thrill at the suprasternal notch can be caused by a PDA, PAS, COA, or AS (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35656?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations and diagnosis of patent ductus arteriosus\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=see_link&amp;anchor=H5#H5\">",
"       \"Valvar aortic stenosis in children\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Auscultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auscultation of the heart can be achieved using either the bell or diaphragm of the stethoscope. The bell is designed for listening to low-frequency sounds and the diaphragm for high-frequency sounds. Thorough evaluation necessitates auscultation of all areas of the precordium, as well as the back, neck, and axillary areas. The process includes noting the rate and rhythm and listening for the normal first and second heart sounds. Close attention should be given to detecting ejection clicks, systolic and diastolic murmurs, pericardial friction rubs, extra heart sounds, and diastolic rumbles.",
"   </p>",
"   <p>",
"    Generally, the first heart sound is a singular sound caused by nearly simultaneous closure of the tricuspid and mitral valves and is best heard at the apex. Splitting of the first heart sound may be detectable in the presence of an Ebstein anomaly or a right bundle branch block pattern. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=see_link&amp;anchor=H3#H3\">",
"     \"Auscultation of heart sounds\", section on 'First heart sound (S1)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The second heart sound, best heard at the left upper sternal border, is caused by closure of the pulmonary and aortic valves and normally is split with inspiration, less so with expiration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=see_link&amp;anchor=H12#H12\">",
"     \"Auscultation of heart sounds\", section on 'Second heart sound (S2)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A third heart sound, although unusual, can be heard in normal children at the apex or along the lower left sternal border; it is attributed to the turbulence of rapid filling of the left ventricle. A dilated, noncompliant ventricle may create an abnormally loud third heart sound. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=see_link&amp;anchor=H24#H24\">",
"     \"Auscultation of heart sounds\", section on 'Third (S3) and fourth (S4) heart sounds'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rhythm of the first, second, and third heart sounds together should produce a beat similar to the sound of the three syllables in the word Ken-tuc-ky. An abnormal fourth sound, present in patients with decreased ventricular compliance, when heard in sequence with the first and second heart sounds creates a beat similar to the three syllables in the word Ten-nes-see. The rapid beat of the first, second, third,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fourth sounds, common in heart failure, sounds like the rhythm of a horse's gallop.",
"   </p>",
"   <p>",
"    Murmurs are characterized by the intensity and quality of the sound they create, when they occur and where they occur in the cardiac cycle, and whether they are transmitted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .) The intensity of murmurs is graded on a scale of I to VI.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade I murmurs are nearly inaudible",
"     </li>",
"     <li>",
"      Grade II murmurs are faint but can be identified immediately",
"     </li>",
"     <li>",
"      Grade III murmurs are loud but have no palpable thrill",
"     </li>",
"     <li>",
"      Grade IV murmurs are loud and associated with a palpable thrill",
"     </li>",
"     <li>",
"      Grade V murmurs can be heard when the stethoscope is barely touching the chest wall",
"     </li>",
"     <li>",
"      Grade VI murmurs are audible when the stethoscope is not touching the chest wall",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High-pitched, blowing murmurs are heard with mitral regurgitation (MR) and VSD. Harsh murmurs are heard in patients with AS or PAS. Murmurs described as having a vibratory or humming sound are generally innocent and of no significance.",
"   </p>",
"   <p>",
"    Most murmurs occur during systole and are either ejection or regurgitant murmurs. Those heard along the left upper sternal border may be caused by AS or PAS, pulmonary branch stenosis (PBS), tetralogy of Fallot (TOF), COA, or other defects (generally minor). Those heard along the right upper sternal border may be the result of supravalvular, valvular, or subvalvular AS. Murmurs heard along the lower left sternal border may be caused by VSD, tricuspid regurgitation (TR), TOF, idiopathic hypertrophic subaortic stenosis (IHSS), or an innocent Still's murmur. Murmurs at the apex can be found in patients with MR, mitral valve prolapse, AS, IHSS, or an innocent murmur. Regurgitant murmurs are heard in patients who have VSD, MR, or TR.",
"   </p>",
"   <p>",
"    Murmurs heard during diastole may occur in early, middle, or late diastole. Those heard in early diastole are caused by aortic or pulmonary valve incompetence. Those heard in middle diastole occur secondary to anatomic stenosis of the mitral or tricuspid valve and generally are preceded by a loud third heart sound. Those heard in late diastole are caused by vigorous atrial contraction, resulting in a rapid injection of blood into the ventricle.",
"   </p>",
"   <p>",
"    A continuous murmur is one that begins in systole and lasts throughout most of diastole. Continuous murmurs can be heard in patients with PDA, COA, or a venous hum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many children will at some time have an innocent or functional murmur with no anatomical abnormality (eg, the common but transient functional murmur best heard over the left precordium in patients with increased cardiac output secondary to high fever). An innocent grade I to III murmur noted in early infancy is the result of peripheral pulmonary branch stenosis, best heard at the base of the heart and bilaterally in each axilla and over the back. The continuous murmur of a venous hum occurs in the early years of childhood, is most readily audible over the upper thoracic and jugular areas with the patient in an upright position, and disappears when gentle pressure is applied to the jugular vein or when the patient's head is turned fully to the opposite shoulder. A Still's murmur is heard best along the lower left sternal border or apex, occurs in middle systole, has an intensity no greater than grade III, and has a vibratory or musical quality. It is best heard with the patient in the supine position and decreases in intensity with the patient in a sitting or standing position or when the patient is&nbsp;performing a Valsalva maneuver. The innocent pulmonary ejection murmur, detected most often in adolescents, is heard best in middle systole in the second left intercostal space; it has a harsh quality and an intensity no greater than grade III [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ABDOMEN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visualization of a child's abdomen for contour, symmetry, pulsations, peristalsis, peripheral vascular irregularities, and skin markings is performed best in good light with the patient supine and the examiner positioned at the patient's right side. Although often seen after a patient has eaten, abdominal distention noted at other times may indicate abnormal gas-filled loops of bowel, a ruptured viscus, fecal retention, mass lesion, or ascites. A scaphoid abdomen can occur in a patient with upper gastrointestinal obstruction or as a result of starvation. Peristaltic waves may be seen on occasion, but vascular pulsations generally are not visualized. The presence of hyperpigmented or hypopigmented skin lesions can be normal. Usually, vascular lesions other than hemangiomata are not present.",
"   </p>",
"   <p>",
"    Abdominal wall protrusions are common. Umbilical hernias frequently are present in the infant, toddler, and younger child, particularly in black children. Most umbilical hernias are uncomplicated, require no surgery, and resolve spontaneously. Diastasis recti and small epigastric hernias, if not readily visible, can be elicited by having the patient raise his or her head off the examining table while lying supine or by having the child tense the abdominal muscles; these hernias do not require surgical correction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Auscultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal auscultation often is difficult and unrewarding in the active, uncooperative child, but may be of significant benefit in the child experiencing abdominal discomfort. Active bowel sounds often are heard in patients with gastroenteritis and usually are decreased or absent in patients with appendicitis or intestinal obstruction. Stenosis involving the aorta or iliac, femoral, or renal arteries may give rise to an audible abdominal bruit.",
"   </p>",
"   <p>",
"    Some examiners have employed an auscultatory technique to determine the inferior margin(s) of the liver",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spleen by listening with a stethoscope over the patient's abdomen while gently scratching the abdominal skin surface with a blunt instrument. Starting in the ipsilateral lower abdominal quadrant of the organ being examined and advancing superiorly, the examiner is able to identify the lower border of the liver or spleen when a change in sound from tympany to dullness is heard.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Percussion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percussion helps detect mass lesions and organ size and often can identify local areas of pain. Solid or fluid-filled structures, such as a urine-filled bladder, produce a dull sound to percussion; gas-filled loops of bowel produce tympany.",
"   </p>",
"   <p>",
"    Percussion can be used to help make the diagnosis when a distended abdomen is thought to be the result of ascites. The patient should be supine, and percussion should begin peripherally. At first dullness will be noted. As percussion advances centrally, the air-filled loops of intestine, forced to the midline by ascitic fluid, will emit a tympanitic sound. When the patient turns to one side or the other, the locations of tympany and dullness shift as the fluid moves into dependent areas. A fluid wave can be produced when the examiner strikes one flank area with the tips of the fingers of one hand and detects gentle pressure with the other hand on the opposite flank [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/15\">",
"     15",
"    </a>",
"    ]. This finding is better demonstrated by employing the aid of an assistant who at the same time has placed the ulnar surfaces of both fully extended hands pointing toward one another along the midline of the abdomen.",
"   </p>",
"   <p>",
"    The overall accuracy of the physical examination for the detection of clinically nonobvious ascites was only 58 percent in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38471/abstract/16\">",
"     16",
"    </a>",
"    ]. The most useful physical finding was flank dullness; if this was not evident (in the hands of an experienced examiner) the probability of ascites being present was less than 10 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation is extremely beneficial for determining liver, kidney, and spleen size and for detecting abdominal masses. An examiner's warm hands and initial gentle, soft touch may go a long way in gaining the cooperation of the patient for deeper, more thorough palpation. The often-ticklish younger child may require a calm, reassuring touch, and no initial hand movement by the examiner. After a few moments, these children are instructed to take a deep breath and then exhale slowly while the examiner applies firm steady pressure to the abdomen. A fairly complete examination can be achieved by repeating the procedure in all four quadrants.",
"   </p>",
"   <p>",
"    The softer and less tense the abdominal musculature, the more easily organs and mass lesions can be felt. For the obese child, a two-hand technique with the fingers of one hand applying pressure on top of the fingers of the other hand may be required. When peritonitis is suspected, rebound tenderness may be elicited by pressing firmly and slowly on the abdomen and then quickly releasing pressure. Subsequent wincing by the patient or other audible or visual signs of pain confirms the examiner's impression.",
"   </p>",
"   <p>",
"    Abdominal organs are relatively easy to palpate in children because in general, the abdominal wall is thin. The examiner should stand on the patient's right side when attempting to feel the liver, placing the fingers of the right hand over the right middle to lower quadrant in a somewhat oblique position. Palpation should progress in a superior direction until the lower edge of the liver is detected. Alternatively, with the left hand under the right flank applying minimal pressure, the examiner can place gentle, cephalad-directed pressure on the liver until the edge of the liver is felt with the right hand. A similar maneuver in the left upper quadrant and posterior flank helps determine the inferior margin of the spleen.",
"   </p>",
"   <p>",
"    The kidneys can be palpated in much the same way as the liver and spleen. Renal tenderness is determined easily in a cooperative child with pyelonephritis through percussion of the flank areas. A firm striking blow with the ulnar surface of the closed fist to the flank area will elicit discomfort in the patient with renal infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H379026962\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examination of the chest wall includes observation of the shape, symmetry, alignment and distance between the nipples, and movement with inspiration and exhalation. Chest wall abnormalities may provide clues to underlying pulmonary, genetic, cardiac, or neuromuscular disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Chest wall'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination of the breasts includes assessment of pubertal stage (",
"      <a class=\"graphic graphic_picture graphicRef72038 \" href=\"mobipreview.htm?10/43/10932\">",
"       picture 1",
"      </a>",
"      ) in girls and assessment for gynecomastia in boys. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Breasts'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27384?source=see_link&amp;anchor=H2#H2\">",
"       \"Causes and evaluation of gynecomastia\", section on 'Causes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Examination of the lungs includes observation of breathing pattern and auscultation of the lung fields. Abnormalities detected during the lung examination may provide clues to anatomic defects, upper airway obstruction, pulmonary disease, and metabolic disorders. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Lungs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination of the heart includes observation (general appearance; central and peripheral color; nutritional status; respiratory rate and effort; sweating; chest contour; venous distention; edema), palpation (of the pulses and of the heart through the chest wall), and auscultation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Heart'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination of the abdomen includes inspection (contour, symmetry, pulsations, peristalsis, peripheral vascular irregularities, skin markings), auscultation (bowel sounds, bruits), and percussion and palpation (to detect mass lesions and assess organ size and localized pain). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Abdomen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Appendix I: Pattern of malformation differential diagnosis by anomalies. In: Smith's Recognizable patterns of Human Malformation, 6th, Elsevier Saunders, Philadelphia 2006. p.900.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38471/abstract/2\">",
"      Lord MJ, Laurenzano KR, Hartmann RW Jr. Poland's syndrome. Clin Pediatr (Phila) 1990; 29:606.",
"     </a>",
"    </li>",
"    <li>",
"     Barness LA. Manual of Pediatric Physical Diagnosis, 6th ed, Mosby, St. Louis 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38471/abstract/4\">",
"      Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969; 44:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38471/abstract/5\">",
"      Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970; 45:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38471/abstract/6\">",
"      Jayasinghe Y, Cha R, Horn-Ommen J, et al. Establishment of normative data for the amount of breast tissue present in healthy children up to two years of age. J Pediatr Adolesc Gynecol 2010; 23:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38471/abstract/7\">",
"      Kulin HE, M&uuml;ller J. The biological aspects of puberty. Pediatr Rev 1996; 17:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38471/abstract/8\">",
"      Braunstein GD. Diagnosis and treatment of gynecomastia. Hosp Pract (Off Ed) 1993; 28:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38471/abstract/9\">",
"      Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics 1997; 99:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38471/abstract/10\">",
"      Copeland KC. Variations in normal sexual development. Pediatr Rev 1986; 8:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38471/abstract/11\">",
"      Rigatto H. Control of ventilation in the newborn. Annu Rev Physiol 1984; 46:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38471/abstract/12\">",
"      Parrino TA. Hands on the heart: palpation of the cardiovascular system. Hosp Pract (Off Ed) 1989; 24:103.",
"     </a>",
"    </li>",
"    <li>",
"     Lehrer S. Understanding Pediatric Heart Sounds, WB Saunders, Philadelphia 1992.",
"    </li>",
"    <li>",
"     Perloff JK. The Clinical Recognition of Congenital Heart Disease, 3rd ed, WB Saunders, Philadelphia 1987.",
"    </li>",
"    <li>",
"     AH Robins Co. Physical examination of the abdomen [GI series], Robins, Richmond, VA 1974.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38471/abstract/16\">",
"      Cattau EL Jr, Benjamin SB, Knuff TE, Castell DO. The accuracy of the physical examination in the diagnosis of suspected ascites. JAMA 1982; 247:1164.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2860 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38471=[""].join("\n");
var outline_f37_36_38471=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H379026962\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHEST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Chest wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Breasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lungs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Heart",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - General appearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Palpation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Auscultation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ABDOMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Auscultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Percussion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Palpation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H379026962\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2860\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2860|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/43/10932\" title=\"picture 1\">",
"      Sexual maturity rating of breast development in girls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2860|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/1/8220\" title=\"table 1\">",
"      Sexual maturity rating of secondary sexual characteristics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/33/1559?source=related_link\">",
"      Aortic regurgitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33161?source=related_link\">",
"      Bradycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27384?source=related_link\">",
"      Causes and evaluation of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26010?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43529?source=related_link\">",
"      Clinical features, evaluation, and diagnosis of croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35656?source=related_link\">",
"      Clinical manifestations and diagnosis of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22424?source=related_link\">",
"      Diagnosis and treatment of delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/9/6294?source=related_link\">",
"      Epidemiology and pathogenesis of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/37/3673?source=related_link\">",
"      Overview of breast disorders in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42776?source=related_link\">",
"      Overview of breast masses in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/19/8506?source=related_link\">",
"      Pathophysiology and clinical features of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25207?source=related_link\">",
"      Pectus carinatum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18071?source=related_link\">",
"      Pectus excavatum: Etiology and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34280?source=related_link\">",
"      The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19943?source=related_link\">",
"      The pediatric physical examination: General principles and standard measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11194?source=related_link\">",
"      The pediatric physical examination: HEENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10295?source=related_link\">",
"      The pediatric physical examination: The perineum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=related_link\">",
"      Valvar aortic stenosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_36_38472="Imipenem and cilastatin: Drug information";
var content_f37_36_38472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Imipenem and cilastatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/30/7652?source=see_link\">",
"    see \"Imipenem and cilastatin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/39/11896?source=see_link\">",
"    see \"Imipenem and cilastatin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F182065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Primaxin&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F182066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Imipenem and Cilastatin for Injection;",
"     </li>",
"     <li>",
"      Primaxin&reg; I.V. Infusion;",
"     </li>",
"     <li>",
"      RAN&trade;-Imipenem-Cilastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F182088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Carbapenem",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F182068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses based on",
"     <b>",
"      imipenem",
"     </b>",
"     content.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     Weight &ge;70 kg: 250-1000 mg every 6-8 hours; maximum: 4 g/day.",
"     <b>",
"      Note:",
"     </b>",
"     For adults weighing &lt;70 kg, refer to Dosing Adjustment in Renal Impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Indication-specific dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      <i>",
"       Burkholderia pseudomallei",
"      </i>",
"     </b>",
"     <b>",
"      (melioidosis) (unlabeled use):",
"     </b>",
"     I.V.: Initial: 20 mg/kg every 8 hours for at least 10 days (White, 2003)",
"     <b>",
"      or",
"     </b>",
"     25 mg/kg (up to 1 g) every 6 hours for at least 10 days (Currie, 2003); continue parenteral therapy until clinical improvement then switch to oral therapy if tolerated and/or appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Intra-abdominal infections:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild infection: 250-500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe infection: 500 mg every 6 hours",
"     <b>",
"      or",
"     </b>",
"     1 g every 8 hours for 4-7 days (provided source controlled).",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended for mild-to-moderate, community-acquired intra-abdominal infections due to risk of toxicity and the development of resistant organisms (Solomkin, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Liver abscess (unlabeled use):",
"     </b>",
"     I.V.: 500 mg every 6 hours for 4-6 weeks (Ulug, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Moderate infections:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Fully-susceptible organisms:",
"     </i>",
"     500 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Moderately-susceptible organisms:",
"     </i>",
"     500 mg every 6 hours or 1 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Neutropenic fever (unlabeled use):",
"     </b>",
"     I.V.: 500 mg every 6 hours (Paul, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Pseudomonas",
"      </i>",
"     </b>",
"     <b>",
"      infections:",
"     </b>",
"     I.V.: 500 mg every 6 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Higher doses may be required based on organism sensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe infections:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Fully-susceptible organisms:",
"     </i>",
"     500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Moderately-susceptible organisms:",
"     </i>",
"     1 g every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum daily dose should not exceed 50 mg/kg or 4 g/day, whichever is lower",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary tract infection, uncomplicated:",
"     </b>",
"     I.V.: 250 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary tract infection, complicated:",
"     </b>",
"     I.V.: 500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mild infections:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Rarely a suitable option in mild infections; normally reserved for moderate-severe cases:  I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Fully-susceptible organisms:",
"     </i>",
"     250 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Moderately-susceptible organisms:",
"     </i>",
"     500 mg every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F182081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/39/11896?source=see_link\">",
"      see \"Imipenem and cilastatin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage based on",
"     <b>",
"      imipenem",
"     </b>",
"     content:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Non-CNS infections:",
"     </b>",
"     I.V.: Children: &gt;3 months: 15-25 mg/kg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum dosage: Susceptible infections: 2 g/day; moderately-susceptible organisms: 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Burkholderia pseudomallei",
"      </i>",
"     </b>",
"     (melioidosis) (unlabeled use): I.V.: Initial: 20 mg/kg every 8 hours for at least 10 days (White, 2003)",
"     <b>",
"      or",
"     </b>",
"     25 mg/kg (up to 1 g) every 6 hours for at least 10 days (Currie, 2003); continue parenteral therapy until clinical improvement, then switch to oral therapy if tolerated and/or appropriate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cystic fibrosis:",
"     </b>",
"     I.V.: Infants, Children, and Adolescents: Up to 100 mg/kg/day divided every 6 hours; maximum dose: 4 g daily has been used.",
"     <b>",
"      Note:",
"     </b>",
"     Efficacy in exacerbations may be limited due to rapid development of resistance (Zobell, 2013).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F182069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F182070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;5 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     should not receive imipenem/cilastatin unless hemodialysis is instituted within 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients weighing &lt;30 kg with impaired renal function should not receive imipenem/cilastatin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reduced I.V. dosage regimen based on creatinine clearance and/or body weight: See table.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Use the dosing recommendation for patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     6-20 mL/minute; administer dose after dialysis session and every 12 hours thereafter",
"     <b>",
"      or",
"     </b>",
"     250-500 mg every 12 hours (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis (unlabeled dosing): Dose as for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     6-20 mL/minute (Somani, 1988)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVH: Loading dose of 1 g followed by either 250 mg every 6 hours",
"     <b>",
"      or",
"     </b>",
"     500 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVHD: Loading dose of 1 g followed by either 250 mg every 6 hours",
"     <b>",
"      or",
"     </b>",
"     500 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVHDF: Loading dose of 1 g followed by either 250 mg every 6 hours",
"     <b>",
"      or",
"     </b>",
"     500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Data suggest that 500 mg every 8-12 hours may provide sufficient time above MIC to cover organisms with MIC values &le;2 mg/L; however, a higher dose of 500 mg every 6 hours is recommended for resistant organisms (particularly",
"     <i>",
"      Pseudomonas",
"     </i>",
"     spp) with MIC &ge;4 mg/L or deep-seated infections (Fish, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Reduced I.V. dosage regimen based on creatinine clearance and/or body weight:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"     See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Imipenem and Cilastatin Dosage in Renal Impairment",
"     </caption>",
"     <col align=\"left\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         Reduced I.V. Dosage Regimen Based on",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Creatinine Clearance (mL/minute/1.73 m",
"         <sup>",
"          2",
"         </sup>",
"         ) and/or Body Weight &lt;70 kg",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"left\">",
"       </th>",
"       <th align=\"center\" colspan=\"5\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Body Weight (kg)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"left\">",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          &ge;70",
"         </b>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          60",
"         </b>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          50",
"         </b>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          40",
"         </b>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          30",
"         </b>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Total daily dose for normal renal function: 1 g/day",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         &ge;71",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         41-70",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         21-40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         6-20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Total daily dose for normal renal function: 1.5 g/day",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         &ge;71",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q6h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         41-70",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         21-40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         6-20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Total daily dose for normal renal function: 2 g/day",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         &ge;71",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         41-70",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q6h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         21-40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         6-20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Total daily dose for normal renal function: 3 g/day",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         &ge;71",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         750 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         41-70",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         21-40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         6-20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Total daily dose for normal renal function: 4 g/day",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         &ge;71",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         750 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         41-70",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         750 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         750 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         21-40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         6-20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"     Reduced I.V. dosage regimen based on creatinine clearance (mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ) and body weight &ge;70 kg  (",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer labeling recommends further proportionate dose reductions for patients &lt;70 kg, but does not provide specific dosing recommendations):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Mild renal impairment",
"     </i>",
"     (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-70 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fully-susceptible organisms: Maximum dosage: 500 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Less susceptible organisms (primarily some",
"     <i>",
"      Pseudomonas",
"     </i>",
"     strains): Maximum dosage: 500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Moderate renal impairment",
"     </i>",
"     (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     21-30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fully-susceptible organisms: Maximum dosage: 500 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Less susceptible organisms (primarily some",
"     <i>",
"      Pseudomonas",
"     </i>",
"     strains): Maximum dosage: 500 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Severe renal impairment",
"     </i>",
"     (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     0-20 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fully-susceptible organisms: Maximum dosage: 250 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Less susceptible organisms (primarily some",
"     <i>",
"      Pseudomonas",
"     </i>",
"     strains): Maximum dosage: 500 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     6-20 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     should receive 250 mg every 12 hours or 3.5 mg/kg (whichever is lower) every 12 hours for most pathogens; seizure risk may increase with higher dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5432719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Hepatic dysfunction may further impair cilastatin clearance in patients receiving chronic renal replacement therapy; consider decreasing the dosing frequency.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F182043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: Imipenem 250 mg and cilastatin 250 mg; imipenem 500 mg and cilastatin 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primaxin&reg; I.V.: Imipenem 250 mg and cilastatin 250 mg [contains sodium 18.8 mg (0.8 mEq)]; imipenem 500 mg and cilastatin 500 mg [contains sodium 37.5 mg (1.6 mEq)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F182027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F182047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.V.: Do not administer I.V. push. Infuse doses &le;500 mg over 20-30 minutes; infuse doses &ge;750 mg over 40-60 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F182093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     W, mannitol 2.5%, mannitol 5%, mannitol 10%, NS, TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amifostine, anidulafungin, aztreonam, caspofungin, cefepime, cisatracurium, diltiazem, docetaxel, famotidine, fludarabine, foscarnet, granisetron, insulin (regular), linezolid, melphalan, methotrexate, ondansetron, propofol, remifentanil, tacrolimus, teniposide, thiotepa, tigecycline, vasopressin, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amiodarone, amphotericin B cholesteryl sulfate complex, azithromycin, drotrecogin alfa, etoposide phosphate, fluconazole, gemcitabine, lorazepam, meperidine, midazolam, milrinone, sargramostim, sodium bicarbonate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Filgrastim, gallium nitrate, idarubicin, telavancin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F182046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of lower respiratory tract, urinary tract, intra-abdominal, gynecologic, bone and joint, skin and skin structure, endocarditis (caused by",
"     <i>",
"      Staphylococcus  aureus",
"     </i>",
"     ) and polymicrobic infections as well as bacterial septicemia. Antibacterial activity includes gram-positive bacteria (methicillin-sensitive",
"     <i>",
"      S. aureus",
"     </i>",
"     and",
"     <i>",
"      Streptococcus",
"     </i>",
"     spp), resistant gram-negative bacilli (including extended spectrum beta-lactamase-producing",
"     <i>",
"      Escherichia coli",
"     </i>",
"     and",
"     <i>",
"      Klebsiella",
"     </i>",
"     spp,",
"     <i>",
"      Enterobacter",
"     </i>",
"     spp, and",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     ), and anaerobes.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F4628298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic abscess; neutropenic fever; melioidosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F182095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Imipenem may be confused with ertapenem, meropenem",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Primaxin&reg; may be confused with Premarin&reg;, Primacor&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F182086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (infants 2%; adults &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Seizure (infants 6%; adults &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (&le;1%, children 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (1% to 2%), diarrhea (children 3% to 4%; adults 1% to 2%), vomiting (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Oliguria/anuria (infants 2%; adults &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Phlebitis/thrombophlebitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, abnormal urinalysis, acute renal failure, alkaline phosphatase increased, anaphylaxis, anemia, angioneurotic edema, asthenia, bilirubin increased, bone marrow depression, BUN/creatinine increased, candidiasis, confusion, cyanosis, dizziness, drug fever, dyspnea, encephalopathy, eosinophilia, erythema multiforme, fever, flushing, gastroenteritis, glossitis, hallucinations, hearing loss, hematocrit decreased, hemoglobin decreased, hemolytic anemia, hemorrhagic colitis, hepatitis (including fulminant onset), hepatic failure, hyperchloremia, hyperhidrosis, hyperkalemia, hypersensitivity, hyperventilation, hyponatremia, hypotension, jaundice, lactate dehydrogenase increased, leukocytosis, leukopenia, myoclonus, neutropenia (including agranulocytosis), palpitation, pancytopenia, paresthesia, pharyngeal pain, polyarthralgia, polyuria, positive Coombs' test, prothrombin time increased, pruritus vulvae, pseudomembranous colitis, psychic disturbances, rash, resistant",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     , somnolence, Stevens-Johnson syndrome, thoracic spine pain, thrombocythemia, thrombocytopenia, tinnitus, tongue papillar hypertrophy, toxic epidermal necrolysis, transaminases increased, tremor, urticaria, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F182050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to imipenem/cilastatin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F182031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, have been reported (some without a history of previous allergic reactions to beta-lactams).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Carbapenems have been associated with CNS adverse effects, including confusional states and seizures (myoclonic); use caution with CNS disorders (eg, brain lesions and history of seizures) and adjust dose in renal impairment to avoid drug accumulation, which may increase seizure risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with moderate-to-severe renal dysfunction. Increased seizure risk and thrombocytopenia have been reported in patients with significant renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Valproic acid and derivatives: Carbapenems, including imipenem, may decrease the serum concentration of divalproex sodium/valproic acid increasing the risk of breakthrough seizures. Concurrent use of carbapenem antibiotics with divalproex sodium/valproic acid is generally not recommended. Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional antiseizure medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Lower doses (based upon renal function) are often required in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not recommended in pediatric CNS infections due to seizure potential.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F182036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May enhance the neurotoxic effect of Imipenem. Imipenem may increase the serum concentration of CycloSPORINE (Systemic). Imipenem may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Carbapenems may decrease the serum concentration of Divalproex.  Management: Concurrent use of carbapenem antibiotics with divalproex is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Imipenem. May increase risk of seizures.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Imipenem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Carbapenems may decrease the serum concentration of Valproic Acid.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F182039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F182052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events have not been observed in animal reproduction studies. Due to pregnancy induced physiologic changes, some pharmacokinetic parameters of imipenem/cilastatin may be altered. Pregnant women have a larger volume of distribution resulting in lower serum peak levels than for the same dose in nonpregnant women. Clearance is also increased.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F182076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3878676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Imipenem is excreted in human milk. The low concentrations and low oral bioavailability suggest minimal exposure risk to the infant. The manufacturer recommends that caution be exercised when administering imipenem/cilastatin to nursing women. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F182053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Imipenem-Cilastatin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (1): $7.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $14.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Primaxin IV Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250-250 mg (1): $20.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-500 mg (1): $39.18",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F182041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic renal, hepatic, and hematologic function tests; monitor for signs of anaphylaxis during first dose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F182054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anipen (PH);",
"     </li>",
"     <li>",
"      Arzobema (MX);",
"     </li>",
"     <li>",
"      Bacqure (TH);",
"     </li>",
"     <li>",
"      Cilapenem (KP, TH);",
"     </li>",
"     <li>",
"      Elastyn (ID);",
"     </li>",
"     <li>",
"      Imenam (TW);",
"     </li>",
"     <li>",
"      Iminen (MX);",
"     </li>",
"     <li>",
"      Pelascap (ID);",
"     </li>",
"     <li>",
"      Pelastin IV (ID);",
"     </li>",
"     <li>",
"      Penam (PH);",
"     </li>",
"     <li>",
"      Plastin (PH);",
"     </li>",
"     <li>",
"      Prepenem (HK, KP, TH);",
"     </li>",
"     <li>",
"      Primaxin (AU, GB, GR, NZ);",
"     </li>",
"     <li>",
"      Primaxin IV (BB, BM, BS, BZ, GY, JM, SR, TT);",
"     </li>",
"     <li>",
"      Supernem (TW);",
"     </li>",
"     <li>",
"      Tenacid (IT);",
"     </li>",
"     <li>",
"      Tienam (BD, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DK, EE, EG, ES, FI, FR, GT, HK, HN, ID, IE, IL, IN, IT, JP, MT, MX, MY, NI, NL, NO, PA, PE, PH, PK, PT, RU, SE, SG, SK, SV, TH, TR, TW);",
"     </li>",
"     <li>",
"      Tiesilan (CO, EC);",
"     </li>",
"     <li>",
"      Timipen (ID);",
"     </li>",
"     <li>",
"      Tipem (KP);",
"     </li>",
"     <li>",
"      Zienam (AR, AT, DE, PY, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F182030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. Cilastatin prevents renal metabolism of imipenem by competitive inhibition of dehydropeptidase along the brush border of the renal tubules.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F182049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Rapidly and widely to most tissues and fluids including sputum, pleural fluid, peritoneal fluid, interstitial fluid, bile, aqueous humor, and bone; highest concentrations in pleural fluid, interstitial fluid, and peritoneal fluid; low concentrations in CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Imipenem: 20%; cilastatin: 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Imipenem is metabolized in the kidney by dehydropeptidase I; cilastatin prevents imipenem metabolism by this enzyme; cilastatin is partially metabolized renally",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: Both drugs: 60 minutes; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Both drugs: Urine (~70% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ahonkhai VI, Cyhan GM, Wilson SE, et al, &ldquo;Imipenem-Cilastatin in Pediatric Patients: An Overview of Safety and Efficacy in Studies Conducted in the United States,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1989, 8(11):740-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/2687787/pubmed\" id=\"2687787\" target=\"_blank\">",
"        2687787",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society and Infectious Diseases Society of America, &ldquo;Guidelines for the Management of Adults With Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2005, 171(4):388-416.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/15699079/pubmed\" id=\"15699079\" target=\"_blank\">",
"        15699079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Balfour JA, Bryson HM, and Brogden RN, &ldquo;Imipenem/Cilastatin: An Update of Its Antibacterial Activity, Pharmacokinetics, and Therapeutic Efficacy in the Treatment of Serious Infections,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1996, 51(1):99-136.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/8741235/pubmed\" id=\"8741235\" target=\"_blank\">",
"        8741235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bomback T, Sesin GP, and Mucciardi N, &ldquo;Possible Imipenem/Cilastatin-Induced Aplastic Anemia,&rdquo;",
"      <i>",
"       Pharm Therapeut",
"      </i>",
"      , 1995, 20(5):293-302.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chung AM, Reed MD, and Blumer JL, &ldquo;Antibiotics and Breast-Feeding: A Critical Review of the Literature,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2002, 4(12):817-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/12431134/pubmed\" id=\"12431134\" target=\"_blank\">",
"        12431134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Currie BJ, \"Melioidosis: An Important Cause of Pneumonia in Residents of and Travellers Returned from Endemic Regions,\"",
"      <i>",
"       Eur Respir J",
"      </i>",
"      , 2003, 22(3):542-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/14516149/pubmed\" id=\"14516149\" target=\"_blank\">",
"        14516149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Finch RG, Craddock C, Kelly J, et al, &ldquo;Pharmacokinetic Studies of Imipenem/Cilastatin in Elderly Patients,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1986, 18(Suppl E):103-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fish DN, Teitelbaum I, and Abraham E, \"Pharmacokinetics and Pharmacodynamics of Imipenem During Continuous Renal Replacement Therapy in Critically Ill Patients,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2005, 49(6):2421-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/15917542/pubmed\" id=\"15917542\" target=\"_blank\">",
"        15917542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leo RJ and Ballow CH, &ldquo;Seizure Activity Associated With Imipenem Use: Clinical Case Reports and Review of the Literature,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1991, 25(4):351-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/1926901/pubmed\" id=\"1926901\" target=\"_blank\">",
"        1926901",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Norrby SR, &ldquo;Carbapenems,&rdquo;",
"      <i>",
"       Med Clin North Am",
"      </i>",
"      , 1995, 79(4):745-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/7791421/pubmed\" id=\"7791421\" target=\"_blank\">",
"        7791421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Donovan CA, White ML, Cheung A, et al, &ldquo;Seizure Incidence With Imipenem Use at VA Hospital,&rdquo;",
"      <i>",
"       Hosp Formul",
"      </i>",
"      , 1995, 30:172-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Overturf GD, &ldquo;Use of Imipenem-Cilastatin in Pediatrics,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1989, 8(11):792-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/2687788/pubmed\" id=\"2687788\" target=\"_blank\">",
"        2687788",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paul M, Yahav D, Fraser A, et al, &ldquo;Empirical Antibiotic Monotherapy for Febrile Neutropenia: Systematic Review and Meta-Analysis of Randomized Controlled Trials,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2006, 57(2):176-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/16344285/pubmed\" id=\"16344285\" target=\"_blank\">",
"        16344285",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Somani P, Freimer EH, Gross ML, et al, &ldquo;Pharmacokinetics of Imipenem-Cilastatin in Patients With Renal Insufficiency Undergoing Continuous Ambulatory Peritoneal Dialysis,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1988, 32(4):530-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/3377464/pubmed\" id=\"3377464\" target=\"_blank\">",
"        3377464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tegeder I, Bremer F, Oelkers R, et al, &ldquo;Pharmacokinetics of Imipenem-Cilastatin in Critically Ill Patients Undergoing continuous Veno-Venous Hemofiltration,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1997, 41(12):2640-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/9420033/pubmed\" id=\"9420033\" target=\"_blank\">",
"        9420033",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Toon S, Hopkins KJ, Garstang FM, et al, &ldquo;Pharmacokinetics of Imipenem and Cilastatin After Their Simultaneous Administration to the Elderly,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1987, 23(2):143-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/3470047/pubmed\" id=\"3470047\" target=\"_blank\">",
"        3470047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ulug M, Gedik E, Girgin S, et al, &ldquo;Pyogenic Liver Abscess Caused By Community-Acquired Multidrug Resistance",
"      <i>",
"       Pseudomonas aeruginosa",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Braz J Infect Dis",
"      </i>",
"      , 2010, 14(3):218.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/20835502/pubmed\" id=\"20835502\" target=\"_blank\">",
"        20835502",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White NJ, &ldquo;Melioidosis,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9370):1715-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/12767750/pubmed\" id=\"12767750\" target=\"_blank\">",
"        12767750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wong VK, Wright HT Jr, Ross LA, et al, &ldquo;Imipenem/Cilastatin Treatment of Bacterial Meningitis in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1991, 10(2):122-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/2062603/pubmed\" id=\"2062603\" target=\"_blank\">",
"        2062603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoshikawa TT, &ldquo;Antimicrobial Therapy for the Elderly Patient,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1990, 38(12):1353-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/2254575/pubmed\" id=\"2254575\" target=\"_blank\">",
"        2254575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhanel GG, Ketter N, Rubinstein E, et al, &ldquo;Overview of Seizure-Inducing Potential of Doripenem,&rdquo;",
"      <i>",
"       Drug Safety",
"      </i>",
"      , 2009, 32(9):709-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/19670912/pubmed\" id=\"19670912\" target=\"_blank\">",
"        19670912",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhanel GG, Wiebe R, Dilay L, et al, &ldquo;Comparative Review of the Carbapenems,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2007, 67(7):1027-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/17488146/pubmed\" id=\"17488146\" target=\"_blank\">",
"        17488146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zobell JT, Young DC, Waters CD, et al, &ldquo;Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations,&rdquo;",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 2013, 48(2):107-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/36/38472/abstract-text/22949297/pubmed\" id=\"22949297\" target=\"_blank\">",
"        22949297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8553 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38472=[""].join("\n");
var outline_f37_36_38472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182065\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182066\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182088\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182068\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182081\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182069\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182070\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5432719\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182043\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182027\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182047\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182093\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182046\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4628298\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182095\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182086\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182050\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182031\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299512\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182036\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182039\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182052\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182076\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3878676\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182053\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323195\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182041\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182054\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182030\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182049\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8553\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8553|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/30/7652?source=related_link\">",
"      Imipenem and cilastatin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/39/11896?source=related_link\">",
"      Imipenem and cilastatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_36_38473="Community-acquired pneumonia in adults: Risk stratification and the decision to admit";
var content_f37_36_38473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Community-acquired pneumonia in adults: Risk stratification and the decision to admit",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/36/38473/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/36/38473/contributors\">",
"     Donald M Yealy, MD, FACEP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/36/38473/contributors\">",
"     Michael J Fine, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/36/38473/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/36/38473/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/36/38473/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/36/38473/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/36/38473/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired pneumonia (CAP) is a common and potentially serious illness. It is associated with considerable morbidity and mortality, particularly in elderly patients and those with significant comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1801?source=see_link\">",
"     \"Prognosis of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hospital admission rates in the United States for adults with CAP vary by a factor of three and are often not directly related to local disease severity, suggesting that clinicians use inconsistent criteria when making the initial decision about the appropriate site of care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. In addition, clinicians often overestimate patient risk of short-term mortality, even among low-risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/7\">",
"     7",
"    </a>",
"    ]. A likely consequence of these overestimates is unnecessary admissions; low-risk patients with a physician-estimated risk of death in excess of 5 percent were over six times more likely to be hospitalized after adjusting for other potential confounders of hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical prediction rules and practice guidelines to determine the initial site of treatment for CAP and avoid unnecessary hospitalizations will be reviewed here.",
"   </p>",
"   <p>",
"    A variety of other important issues related to CAP are discussed separately. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnostic approach to patients with CAP. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment recommendations for CAP in patients requiring hospitalization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment recommendations for CAP in ambulatory patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The evidence for efficacy of different antibiotic medications in the empiric treatment of CAP and issues related to drug resistance. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=see_link\">",
"       \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The epidemiology and microbiology of CAP. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31514?source=see_link\">",
"       \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumonia in special populations, such as aspiration pneumonia and immunocompromised patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link\">",
"       \"Aspiration pneumonia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21273?source=see_link\">",
"       \"Pulmonary infections in immunocompromised patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PREDICTION RULES FOR SEVERITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since 1987, at least 16 studies have been conducted to identify independent predictors of adverse medical outcomes for the purpose of objectively assessing the severity of illness for patients presenting with CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/8-23\">",
"     8-23",
"    </a>",
"    ]. Each of these prediction rules for prognosis should satisfy rigorous quality standards for validity before widespread application to clinical decision making. We will review the quality of these prediction rules for application in emergency department and ambulatory care settings using the evaluation standard described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of the prediction rules satisfied three of eight criteria for quality:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The outcome of interest was defined",
"     </li>",
"     <li>",
"      The predictor variables were defined",
"     </li>",
"     <li>",
"      Appropriate mathematical modeling techniques were used",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results for the remaining six criteria were mixed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relevant outcomes used &mdash; All of the studies used mortality as an outcome. However, only five prediction rules were developed using both mortal and relevant nonmortal outcomes (eg, admission to an intensive care unit [ICU] for inpatients or subsequent hospitalization for outpatients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/9,11,14,19,23\">",
"       9,11,14,19,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Relevant predictors used &mdash; Eight rules limited clinical predictors to those relevant to physicians evaluating patients at the time of presentation in emergency departments, clinics, or primary care offices [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/9-11,19,22,23\">",
"       9-11,19,22,23",
"      </a>",
"      ]. The other nine included predictors rarely used to assess severity of illness in these settings (eg, serum albumin concentration or liver function tests) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/8,12-18,20,21\">",
"       8,12-18,20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Relevant patient cohort characteristics &mdash; Only two of the 16 rules were derived in patient cohorts representative of the broad mix of lowest to highest risk adult patients with CAP, including those treated as outpatients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/9,13\">",
"       9,13",
"      </a>",
"      ]. Validation cohorts in the other 14 studies were restricted to inpatients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/8,10,12,15-22\">",
"       8,10,12,15-22",
"      </a>",
"      ] or excluded outpatients with \"an obvious reason for admission\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/11,14\">",
"       11,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Appropriate study sites and design used &mdash; In general, clinical prediction rules developed using a prospective, multicenter study design have greater validity than those using retrospective or single study site designs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/24\">",
"       24",
"      </a>",
"      ]. Only three pneumonia prediction rules used a prospective, multicenter design [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/9,13,22\">",
"       9,13,22",
"      </a>",
"      ]; two of these studies also included representative patient populations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/9,13\">",
"       9,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Accuracy of the rule determined &mdash; The accuracy of clinical prediction rules is best determined in a group of patients other than the cohort used to derive it [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/24\">",
"       24",
"      </a>",
"      ]. Three prediction rules were validated using a new cohort of inpatients and outpatients in combination with mortal and nonmortal outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/9,11,21\">",
"       9,11,21",
"      </a>",
"      ]. While one reported a 2 percent risk of mortality or a complicated hospital course in low risk patients defined by the prediction rule, the validation set only included 71 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/11\">",
"       11",
"      </a>",
"      ]. The prediction rule itself in this study was derived using a retrospective cohort of just 141 patients.",
"      <br/>",
"      <br/>",
"      In contrast, the PSI was validated in a separate validation group and used a large multicenter cohort of 2287 inpatients and outpatients enrolled at five clinical sites. This rule stratified patients into five risk classes; the risk of 30-day mortality from all causes in the three lowest risk groups ranged from 0.1 percent to 0.9 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/9\">",
"       9",
"      </a>",
"      ]. In addition, increasing risk class was associated with an increased risk of subsequent hospitalization for outpatients and intensive care unit (ICU) admission and longer length of stay for inpatients.",
"     </li>",
"     <li>",
"      Effects of rule tested &mdash; For prediction rules to be considered legitimate decision aids, their safety and effectiveness should be prospectively demonstrated in actual clinical practice settings prior to widespread implementation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/24\">",
"       24",
"      </a>",
"      ]. The PSI rule was the only prognostic rule shown to safely reduce the proportion of low risk patients hospitalized for care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/25-27\">",
"       25-27",
"      </a>",
"      ] or to identify low risk patients for whom outpatient therapy is as safe as traditional inpatient treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, 15 prediction rules satisfied five or fewer standards for quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/8,10,12-21\">",
"     8,10,12-21",
"    </a>",
"    ]; one satisfied six standards, although the criterion for determination of accuracy was weakened by the use of just 71 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/11\">",
"     11",
"    </a>",
"    ]. The PSI rule fully satisfied seven quality standards for prediction rules and was the only rule shown to be safe and effective in actual clinical practice (eighth standard).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pneumonia Severity Index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Pneumonia Severity Index (PSI) clinical prediction rule meets the highest quality standards for both prediction rules and decision aids. The PSI is the only decision aid for risk stratification of patients with CAP that has had its effectiveness and safety for guiding the initial site of treatment demonstrated in randomized trials and other interventional studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PSI rule was derived and validated as part of the Pneumonia Patient Outcomes Research Team (PORT) prospective cohort study for the purpose of identifying patients with CAP at low risk for mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/9\">",
"     9",
"    </a>",
"    ]. The derivation cohort consisted of 14,199 adults with an ICD-9-CM principal diagnosis of pneumonia in the MedisGroups Comparative Hospital Database.",
"   </p>",
"   <p>",
"    Two independent populations were used for external validation. It was first validated using 38,039 adult inpatients with an ICD-9-CM principal diagnosis of pneumonia in a statewide 1991 MedisGroups database and again in the 2287 adult outpatients and inpatients (referred to above) prospectively enrolled from five medical institutions that participated in the Pneumonia PORT prospective cohort study.",
"   </p>",
"   <p>",
"    The PSI stratified adults with radiographic evidence of pneumonia into five classes for risk of death from all causes within 30 days of presentation. Predictor variables were based upon the medical history, physical examination, and selected laboratory and radiographic findings readily available at the time of patient presentation. In contrast to previous prediction rules, the PSI is applied in two steps that parallel decision-making processes the physician usually follows during a patient encounter. Step 1 of the rule identifies patients in the lowest risk class (risk class I) based upon the absence of 11 demographic, comorbid conditions, and physical examination findings.",
"   </p>",
"   <p>",
"    These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &gt;50 years",
"     </li>",
"     <li>",
"      The presence of coexisting conditions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Neoplastic disease",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Cerebrovascular disease",
"     </li>",
"     <li>",
"      Renal disease",
"     </li>",
"     <li>",
"      Liver disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of physical examination abnormalities:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Altered mental status",
"     </li>",
"     <li>",
"      Pulse",
"      <span class=\"nowrap\">",
"       &ge;125/minute",
"      </span>",
"     </li>",
"     <li>",
"      Respiratory rate",
"      <span class=\"nowrap\">",
"       &ge;30/minute",
"      </span>",
"     </li>",
"     <li>",
"      Systolic blood pressure &lt;90 mm Hg",
"     </li>",
"     <li>",
"      Temperature &lt;35&deg;C or &ge;40&deg;C",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If one or more Step 1 risk factors are present, the evaluation of illness severity proceeds to Step 2 (",
"    <a class=\"graphic graphic_table graphicRef81747 \" href=\"mobipreview.htm?37/13/38108\">",
"     table 1",
"    </a>",
"    ). This second step stratifies the remaining patients into risk classes II, III, IV, or V based upon the total amount of points assigned to each risk factor. A total point score is computed by adding the patient age in years (years minus 10 for females) and the points for each applicable risk factor. Total scores of 70 or under correspond to class II, 71 to 90 to class III, 91 to 130 to class IV, and over 130 to class V (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?43/42/44705?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Results",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PSI was validated by comparing risk class-specific mortality rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/9\">",
"     9",
"    </a>",
"    ]. All cause 30-day mortality in risk classes I and II was low (ranging from 0.1 to 0.4 percent in class I and from 0.6 to 0.7 percent in class II); only four (0.3 percent) deaths in the three lowest risk classes were attributable to pneumonia. In contrast, 30-day mortality in risk class V was 27 percent (",
"    <a class=\"graphic graphic_table graphicRef59537 \" href=\"mobipreview.htm?13/7/13435\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the initial validation study, increasing risk class was also associated with a higher rate of subsequent hospitalization among those initially treated as outpatients and an increased risk of ICU admission and longer length of stay for inpatients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/9\">",
"     9",
"    </a>",
"    ]. None of the 62 outpatients in risk classes I, II, or III who were subsequently hospitalized died, and only one was admitted to the ICU.",
"   </p>",
"   <p>",
"    However, a low risk of mortality is not the only factor to be considered in a decision to admit as illustrated in a prospective observational study in Canada, which examined the natural history of CAP in 586 risk class I and II patients who were hospitalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/29\">",
"     29",
"    </a>",
"    ]. Multivariate analysis identified the following findings as associated with admission:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Female sex",
"     </li>",
"     <li>",
"      Presentation at a specific inner city hospital",
"     </li>",
"     <li>",
"      Diminished premorbid functional status",
"     </li>",
"     <li>",
"      Comorbidities (eg, chronic obstructive pulmonary disease [COPD], asthma, heart disease, inflammatory bowel disease)",
"     </li>",
"     <li>",
"      Active substance abuse",
"     </li>",
"     <li>",
"      Psychiatric illness",
"     </li>",
"     <li>",
"      Respiratory rate &ge;28",
"      <span class=\"nowrap\">",
"       breaths/min",
"      </span>",
"     </li>",
"     <li>",
"      Symptoms of shaking chills, shortness of breath, nausea, or diarrhea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complications were reported in 111 (19 percent) of the low risk patients, with the most frequent complications not related to the underlying CAP including the need for urinary catheter insertion (8.5 percent). However, respiratory failure treated by mechanical ventilation occurred in 14 (2.4 percent) and empyema in eight (1.4 percent) patients. Five patients (0.9 percent) died.",
"   </p>",
"   <p>",
"    The study is limited as an application of the PSI rule because the authors did not follow all of the original PSI recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/9\">",
"     9",
"    </a>",
"    ]. In particular, the failure to use the non-hypoxemic recommendation (25 percent of their low-risk patients admitted had this condition) and the inclusion of many patients enrolled who met clear PSI exclusions (eg, alcoholism, psychiatric illness, homeless) invalidates the study as a measure of the application of the PSI. These data, however, confirm that death is rare in low risk patients, and the PSI should be integrated into decision making rather than replace it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Potential admission strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of the rule was initially estimated using projections from the Pneumonia PORT cohort and two admission strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/9\">",
"     9",
"    </a>",
"    ]. The first strategy proposed outpatient therapy for risk class I or II patients, brief observation or outpatient therapy for risk class III patients, and traditional inpatient care for patients in risk classes IV and V. This admission guideline would have reduced the rate of traditional inpatient admissions by 31 percent and recommended brief observation for another 19 percent. Among inpatients that would have been recommended for outpatient care under this approach, less than 1 percent died and 4.3 percent were admitted to an ICU.",
"   </p>",
"   <p>",
"    An additional margin of safety could be provided by an amended strategy of traditional inpatient therapy for all risk class I, II, and III patients with hypoxemia. The latter approach would still have reduced traditional inpatient care by 26 percent; another 13 percent of inpatients would have been admitted for a brief observational stay. Under this second strategy, mortality among inpatients recommended for outpatient therapy was still less than 1 percent, but the proportion admitted to an ICU was reduced to 1.6 percent. Either admission strategy would have recommended inpatient therapy for five of the six Pneumonia PORT patients who died following an initial course of outpatient therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PSI rule may oversimplify how physicians interpret some predictor variables. As an example, systolic blood pressures below 90 mmHg are considered abnormal, regardless of the actual value. While a systolic blood pressure of 40 mmHg probably has a markedly different implication than one of 85 mmHg, the same points would be assigned to both measures.",
"   </p>",
"   <p>",
"    A more practical limitation to routine use of this rule may be its perceived complexity. Clinicians may consider calculating a score based upon 19 variables, placing patients into risk classes, and selecting an appropriate site for therapy to be too time-consuming while seeing patients in a busy office practice or emergency department. This task could be streamlined through the use of a simple one-page algorithm that includes a standardized checklist with point scores adjacent to the variables in step 2. Integration of the rule into a computerized system that automatically reminds physicians of the rule, computes a point score, and displays the recommended patient disposition could ease this task considerably. PSI risk calculators are accessible on the internet (",
"    <a class=\"external\" href=\"file://pda.ahrq.gov/clinic/psi/psicalc.asp\">",
"     file://pda.ahrq.gov/clinic/psi/psicalc.asp",
"    </a>",
"    ) and may be incorporated into medical software for physicians' personal digital assistants (PDAs).",
"   </p>",
"   <p>",
"    Some basic clinical principles also can be gleaned from the rule that may be easy for physicians to recall during a patient encounter. As an example, candidates for outpatient therapy (risk class I and II) can be identified based upon the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No abnormal predictive findings in women &le;80 years and men &le;70 years",
"     </li>",
"     <li>",
"      A lone abnormal predictive finding in women &le;50 years old and men &le;40",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prediction rule is intended to supplement rather than override the judgment of the physician. Factors other than the predictors included in the rule may be important when making an admission decision for patients with CAP. In a study of patients evaluated in emergency departments with CAP who were found to be low risk (PSI classes I to III, no arterial oxygen desaturation, or psychosocial contraindications to outpatient therapy), outcomes were compared for the 944 who received outpatient treatment and the 549 who were hospitalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/30\">",
"     30",
"    </a>",
"    ]. Mortality at 30 days was higher for inpatients (2.6 versus 1.0 percent), suggesting physician judgment regarding hospitalization was an appropriate adjunct to the risk stratification score. After matching for potential confounding factors contributing to site of treatment, mortality was the same for outpatients and inpatients, but outpatients had earlier return to work and activity.",
"   </p>",
"   <p>",
"    Low risk patients may have medical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psychosocial contraindications to outpatient therapy. Patient preference, ability to maintain oral intake, history of substance abuse, cognitive impairment, and patient functional status are other factors that may alter decision-making. The presence of certain conditions (eg, non-stroke severe neuromuscular disease) may necessitate more intensive therapy than recommended by the PSI rule. Finally, the rule is applicable to adult patients with CAP, and specifically excludes children, pregnant women, immunocompromised patients with pneumonia, or those with nosocomial or aspiration pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Effectiveness and safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies, including three randomized clinical trials, have examined the effectiveness and safety of using the PSI in hospital emergency departments for patients presenting with CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/25-29,31-33\">",
"     25-29,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings in the randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CAPITAL trial randomized 19 Canadian hospital emergency departments to PSI implementation or usual care study arms. Among the 1743 patients enrolled with CAP, there was an absolute 18 percent decrease in the admission of low risk (risk class I, II, or III) patients in hospitals that implemented the PSI compared to hospitals in the control arm (49 versus 31 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/26\">",
"       26",
"      </a>",
"      ]. In addition, implementation of the PSI had no negative effects on patient quality of life or the occurrence of adverse medical outcomes (ICU admission, mortality, hospital readmission, or complications).",
"     </li>",
"     <li>",
"      A prospective assessment of the safety of using the PSI rule to guide the initial site of treatment was performed in a randomized efficacy trial that compared outpatient care with hospitalization for CAP in 224 adults in risk class II or III (PSI scores &le;90 points) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/28\">",
"       28",
"      </a>",
"      ]. Patients were randomly assigned to outpatient care with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      or hospitalization with intravenous levofloxacin. Exclusion criteria included: respiratory failure (PaO2 &lt;60 mmHg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      saturation of &le;90 percent), complicated pleural effusion, unstable comorbid illness, severe social, cognitive, or psychiatric impairment, or inability to maintain oral intake.",
"      <br/>",
"      <br/>",
"      The majority of patients in both groups had successful outcomes without complications (84 compared to 81 percent of hospitalized patients). Treatment length, frequency of adverse drug events, and subsequent hospital admissions were similar in the groups. However, outpatients reported significantly greater satisfaction with care than did inpatients (91 versus 79 percent). Thus, outpatient treatment appears as safe as traditional inpatient therapy for patients with CAP identified as low risk by the PSI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Emergency Department Community-Acquired Pneumonia (EDCAP) Trial, conducted at 32 emergency departments in the United States, demonstrated that implementation of an admission guideline based upon the PSI safely increased the proportion of low risk patients with CAP treated in the outpatient setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/27\">",
"       27",
"      </a>",
"      ]. In this trial, a practice guideline recommending outpatient treatment for 1901 low-risk patients (PSI risk classes I-III) without evidence of arterial oxygen desaturation, was implemented using randomly allocated low (eight sites), moderate (12 sites), and high-intensity (12 sites) guideline implementation strategies. More low-risk patients treated at the moderate (61 percent) and high-intensity implementation sites were treated as outpatients than at the low-intensity (62 versus 38 percent) sites. No statistically significant difference in safety outcomes (eg, mortality, medical complications, ICU admissions) was observed across the three interventions.",
"      <br/>",
"      <br/>",
"      In this trial, factors independently associated with the hospitalization of low-risk patients were PSI risk classes II or III, the presence of predefined medical or psychosocial contraindication to outpatient treatment, comorbid conditions not contained in the PSI, multilobar chest radiographic infiltrates, and home therapy with oxygen, corticosteroids, or antibiotics before presentation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/31\">",
"       31",
"      </a>",
"      ]. Up to 20 percent of patients had no identified risk factor for hospitalization other than membership in risk class II or III, suggesting that physicians could safely discharge an even greater proportion of low-risk patients than observed in the moderate or high intensity arms of this trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings have been noted in observational studies in the community [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/25,29,32,33\">",
"     25,29,32,33",
"    </a>",
"    ]. In a prospective observational study from France of patients with CAP seen in the emergency department (ED), eight EDs used the PSI to determine site of treatment and eight did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/33\">",
"     33",
"    </a>",
"    ]. The rate of outpatient treatment in eligible patients at low risk was significantly higher in the EDs that used the PSI (43 versus 24 percent).",
"   </p>",
"   <p>",
"    Another prospective observational study assessed both the frequency of admission and outcomes in patients with CAP who were at low risk (PSI risk class I or II) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/29\">",
"     29",
"    </a>",
"    ]. Overall, 19 percent were admitted. Among these patients, almost one-half were hospitalized for more than five days and one-fifth had one or more complications. Thus, as also noted in the clinical trials cited above, the PSI cannot be used as the sole determinant of hospitalization in patients with CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Other applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PSI prediction rule may have uses other than in the choice of site for treatment. As an example, while traditional outpatient therapy with oral antibiotics may be appropriate for most low risk patients with CAP, outpatient parenteral antibiotic therapy may be suitable for low risk patients with intractable nausea or vomiting, poor gastrointestinal absorption, or for those with psychosocial problems or substance abuse who are unlikely to comply with oral therapy. In-home nursing services may be an option for risk class II and III patients who are older or have serious comorbid illnesses, several abnormal vital signs, or borderline arterial oxygenation levels. On the other hand, low risk patients who initially require parenteral antibiotics and are at high risk for disease progression may benefit from the close monitoring and therapeutic options available during a brief observational stay in the hospital followed by discharge when they are stable or improving. Each of these treatment alternatives would presumably be more cost-effective than traditional inpatient therapy.",
"   </p>",
"   <p>",
"    The prediction rule could also be used to adjust for illness severity among patients with CAP, compare patient cohorts, or match clinical sites. Comparisons between predicted and observed 30-day mortality within risk classes for patients presenting with CAP also could be a valuable continuous quality improvement tool for tracking hospital admissions, mortality, physician performance, or practice patterns (",
"    <a class=\"graphic graphic_table graphicRef59537 \" href=\"mobipreview.htm?13/7/13435\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     CURB-65 score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the PSI has been validated and its use is widely endorsed, it requires computation of a patient risk score based on up to 20 variables. As a result, simpler models have been developed.",
"   </p>",
"   <p>",
"    The CURB-65 score is based upon five easily measurable factors from which its name is derived (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?40/62/41952?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       C",
"      </strong>",
"      onfusion (based upon a specific mental test or new disorientation to person, place, or time)",
"     </li>",
"     <li>",
"      <strong>",
"       U",
"      </strong>",
"      rea (blood urea nitrogen in the United States) &gt;7",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       R",
"      </strong>",
"      espiratory rate &ge;30",
"      <span class=\"nowrap\">",
"       breaths/minute",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       B",
"      </strong>",
"      lood pressure [BP] (systolic &lt;90 mmHg or diastolic &le;60 mmHg)",
"     </li>",
"     <li>",
"      Age &ge;",
"      <strong>",
"       65",
"      </strong>",
"      years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the 718 patients (mean age 64) in the derivation cohort of CURB-65, 30-day mortality was 0.7, 2.1, 9.2, 14.5, and 40 percent for 0, 1, 2, 3, or 4 factors; only a small number of patients had five factors. Similar findings were noted in the separate validation cohort. When the two cohorts were combined, the mortality rate was 0.6 percent with 0 factors (1 of 173 patients) and 1.7 percent with one factor (4 of 241 patients). The authors suggested that patients with a CURB-65 score of 0 to 1 could probably be treated as outpatients, those with a score of 2 should be admitted to the hospital, and those with a score of 3 or more should be assessed for ICU care, particularly if the score was 4 or 5 (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?40/62/41952?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A simplified version (CRB-65), which does not require testing for blood urea nitrogen, may be appropriate for decision-making in primary care practitioner's offices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/36\">",
"     36",
"    </a>",
"    ]. In this version, admission to the hospital is recommended if one or more points are present. A study of 670 patients from Germany found good utility from the CRB-65 score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Comparison to PSI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The performance of the Pneumonia Severity Index (PSI) described above, CURB-65, and CURB in predicting 30-day mortality was compared in a prospective study of 3181 adults with CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/37\">",
"     37",
"    </a>",
"    ]. Overall, the PSI classified 68 percent of the patients as low risk, significantly more than the CURB (51 percent) or the CURB-65 (61 percent). Aggregate 30-day mortality rates were slightly lower for low-risk patients identified by the PSI but the performance of the system was not statistically different from the other two systems. The clinical relevance of the slightly better performance of the PSI is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Severe community-acquired pneumonia score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severe community-acquired pneumonia (SCAP) score was developed as a simplified method for predicting in-hospital mortality, need for mechanical ventilation, and risk for septic shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/23\">",
"     23",
"    </a>",
"    ]. In a multivariate analysis from the derivation cohort, the following criteria were correlated with severe CAP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Arterial pH &lt;7.30 &mdash; 13 points",
"     </li>",
"     <li>",
"      Systolic blood pressure &lt;90 mmHg &mdash; 11 points",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minor criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Respiratory rate &gt;30",
"      <span class=\"nowrap\">",
"       breaths/min",
"      </span>",
"      &mdash; 9 points",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       PaO2/FIO2",
"      </span>",
"      &lt;250 mmHg &mdash; 6 points",
"     </li>",
"     <li>",
"      Blood urea nitrogen &gt;30",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (10.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      &mdash; 5 points",
"     </li>",
"     <li>",
"      Altered mental status &mdash; 5 points",
"     </li>",
"     <li>",
"      Age &ge;80 years &mdash; 5 points",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Multilobar/bilateral",
"      </span>",
"      infiltrates on x-ray &mdash; 5 points",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the original validation study, a SCAP score &ge;10 (which represents at least one major criterion or at least two minor criteria) was superior to the PSI and CURB-65 scores for predicting evolution toward severe CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/23\">",
"     23",
"    </a>",
"    ]. In a subsequent validation study, the SCAP score was at least as accurate as the other scoring systems for predicting intensive care unit admission, need for mechanical ventilation, progression to severe sepsis, and treatment failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further studies are needed before the SCAP score should be used to inform site of treatment (home versus hospital) or ICU admission decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PRACTICE GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practice guidelines and prediction rules exist for the management of patients with CAP in order to assist clinicians in the assessment of patient prognosis and selection of an appropriate site of care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Site of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probably the most widely recognized medical practice guidelines are those published by the British Thoracic Society (BTS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/39\">",
"     39",
"    </a>",
"    ], Canadian Infectious Disease Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/40\">",
"     40",
"    </a>",
"    ], and the 2007 consensus guidelines from the Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/41\">",
"     41",
"    </a>",
"    ]. All three guidelines identified risk factors associated with a poor prognosis and provided admission and treatment guidelines for patients with CAP. However, the BTS guidelines were originally designed to identify patients at high risk of mortality thus, limiting utility in identifying low-risk patients in emergency department and ambulatory care clinics and offices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2007 consensus guidelines from the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) recommend using either the CURB-65 or Pneumonia Severity Index (PSI) as a decision aid to guide the initial site of treatment for adults with CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/42\">",
"     42",
"    </a>",
"    ]. The guideline explicitly states that objective criteria should be applied as an adjunct to, rather than replacement for, physician decision making.",
"   </p>",
"   <p>",
"    The CURB-65 criteria (confusion, uremia, respiratory rate, low blood pressure, age 65 years or greater) lead to a severity-of-illness score; patients with scores &ge;2 require more intensive treatment. The PSI is a prognostic model that stratifies patients into low and higher risk of short-term mortality and links this quantification of illness severity to an appropriate level of outpatient treatment, brief inpatient observation, or more traditional inpatient therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/41\">",
"     41",
"    </a>",
"    ]. The PSI relies exclusively on variables readily available at the time of admission decisions though, includes 20 different variables and requires completing a scoring sheet. The CURB-65 is more readily administered, but has not been as well validated as the PSI for multiple populations.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     IDSA/ATS",
"    </span>",
"    consensus committee preferred the CURB-65 criteria for their ease of use and because they were designed to measure illness severity, whereas the PSI was developed to predict the likelihood of mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who do not meet scoring criteria for hospitalization may still require hospital admission. These patients generally fall into one of four categories: pneumonia complications, exacerbation of underlying disease, inability to take oral medication reliably or other issues affecting outpatient care, or multiple risk factors falling just outside of scoring thresholds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Admission to intensive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007",
"    <span class=\"nowrap\">",
"     IDSA/ATS",
"    </span>",
"    consensus guidelines identified two major criteria for direct admission to an intensive care unit (ICU): septic shock requiring vasopressor support and requirement for mechanical ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/43\">",
"     43",
"    </a>",
"    ]. The presence of either criterion requires ICU care.",
"   </p>",
"   <p>",
"    The guidelines also noted that the need for ICU care is suggested by the presence of at least three minor criteria: respiratory rate &ge;30",
"    <span class=\"nowrap\">",
"     breaths/minute,",
"    </span>",
"    <span class=\"nowrap\">",
"     PaO2/FiO2",
"    </span>",
"    ratio &le;250, multilobar infiltrates, confusion, blood urea nitrogen &ge;20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (blood urea 7",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    leukopenia, thrombocytopenia, hypothermia, or hypotension requiring fluid support. A validation study of over 2000 patients with CAP was performed, but only confirmed the validity of the major criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/39,44\">",
"     39,44",
"    </a>",
"    ]. In a subsequent validation study of 1062 patients with CAP who did not have the major criteria or a contraindication to ICU admission, the minor criteria were superior to other scoring systems (including the PSI, CURB-65 score, and severe community-acquired pneumonia score) for predicting the need for mechanical ventilation, vasopressor support, and ICU admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/45\">",
"     45",
"    </a>",
"    ]. The minor criteria were equivalent to the SMART-COP scoring system for predicting these outcomes; the SMART-COP system is described below.",
"   </p>",
"   <p>",
"    The use of another set of clinical criteria to predict which patients require intensive care was investigated prospectively in a study of 882 episodes of CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/40\">",
"     40",
"    </a>",
"    ]. More than 75 percent of patients were over 50 years old. The following factors were significantly associated with the need for intensive respiratory or vasopressor support: low systolic blood pressure (less than 90 mmHg), poor oxygenation, low arterial pH, multilobar pneumonia, hypoalbuminemia, high respiratory rate, tachycardia, and confusion.",
"   </p>",
"   <p>",
"    A scoring system (SMART-COP) was designed in which each factor led to the accrual of one point, except for low systolic blood pressure, poor oxygenation, and low arterial pH, each of which counted as two points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/40\">",
"     40",
"    </a>",
"    ]. A score of &ge;3 points identified 92 percent of patients who received intensive respiratory or vasopressor support. The accuracy of this system was also high in five validation databases.",
"   </p>",
"   <p>",
"    In a separate study of CAP in 335 young adults (&lt;50 years of age), SMART-COP was superior than CURB-65 and PSI for predicting the need for mechanical ventilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inotropic support, but still failed to identify 15 percent of patients who required these measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/41\">",
"     41",
"    </a>",
"    ]. Thus, the sensitivity of SMART-COP appears to be substantially reduced in individuals younger than age 50 and should be interpreted with caution in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1148992221\">",
"    <span class=\"h1\">",
"     OXYGEN SATURATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with blood oxygen saturations &lt;90 percent are usually hospitalized, and this criterion was considered a trigger for hospital admission in the original study of the Pneumonia Severity Index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/9\">",
"     9",
"    </a>",
"    ]. However, a subsequent population-based cohort study showed that oxygen saturations &lt;92 percent are associated with major adverse events in outpatients with pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/46\">",
"     46",
"    </a>",
"    ]. Among 2923 patients with pneumonia who presented to the emergency department but who were discharged to be treated as outpatients, those with oxygen saturations &lt;90 percent had significantly higher rates of 30-day mortality (6 versus 1 percent), hospitalization (18 versus 7 percent), and the composite endpoint of either 30-day mortality or hospitalization (21 versus 8 percent) compared with patients with oxygen saturations &gt;90 percent. Blood oxygen saturation &lt;90 percent was independently associated with 30-day mortality or hospitalization (adjusted odds ratio 1.7, 95% CI 1.1-2.8). If the oxygen saturation threshold was increased to 92 percent, there was no association with adverse events; such a change in threshold would have entailed one additional hospitalization for every 14 patients discharged. These findings suggest that using a blood oxygen saturation of &lt;92 percent would be a safer threshold for hospital admission than a threshold of &lt;90 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     NURSING HOME RESIDENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower respiratory tract infections are common among residents of nursing homes and one of the most frequent reasons for transferring residents to a hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/42,47\">",
"     42,47",
"    </a>",
"    ]. However, hospitalization may be associated with a reduction in quality of life and decline in functional status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/48\">",
"     48",
"    </a>",
"    ]. For these reasons, investigators in Canada designed and evaluated a clinical pathway strategy for treating residents with respiratory tract infections, including pneumonia in the nursing home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38473/abstract/49\">",
"     49",
"    </a>",
"    ]. Twenty-two nursing homes were randomly assigned to use of a clinical pathway or usual care in treatment of lower respiratory infections and a total of 680 nursing home residents &ge;65 years were enrolled in the study.",
"   </p>",
"   <p>",
"    Pneumonia was defined by the presence of two or more symptoms or signs of lower respiratory tract infection (eg, new or increased cough, new or increased sputum production, temperature &gt;38&ordm;C, pleuritic chest pain, or new or increased abnormal findings on chest examination) and a new or increased infiltrate on chest radiograph. Residents were assessed clinically by study nurses and care was provided in the nursing home if residents met all of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Able to eat and drink",
"     </li>",
"     <li>",
"      Pulse &le;100 beats per min",
"     </li>",
"     <li>",
"      Respiratory rate &le;30 per min",
"     </li>",
"     <li>",
"      Systolic blood pressure &ge;90 mmHg or a decrease of &le;20 mmHg from baseline if &lt;100 mmHg",
"     </li>",
"     <li>",
"      Oxygen saturation &ge;92 percent or if the resident had COPD &ge;90 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Residents treated by the clinical pathway were significantly less likely to be hospitalized (10 versus 22 percent hospitalized in the usual care group)",
"     </li>",
"     <li>",
"      There was no significant difference in mortality rate (8 versus 9 percent), health-related quality life, or functional status between the clinical pathway versus usual care groups, respectively.",
"     </li>",
"     <li>",
"      The clinical pathway resulted in an overall cost savings of United States $1016 per resident treated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study suggests that treating residents of nursing homes with pneumonia with a clinical pathway can result in comparable clinical outcomes, while reducing hospitalizations and health care costs. Limitations of the study are that this approach, although successful in a single payer healthcare system (eg, Canada), may be difficult to implement in a multiple payer system (eg, United States), that the study was limited to enrollment by nursing homes with &ge;100 beds and may not be generalizable to smaller nursing homes, and that only 36 percent of the study population had radiographically confirmed pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/38/30308?source=see_link\">",
"       \"Patient information: Pneumonia in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4063445\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospital admission rates in the United States for adults with CAP vary by a factor of three and are often not directly related to local disease severity, suggesting that clinicians use inconsistent criteria when making the initial decision about the appropriate site of care. In addition, clinicians often overestimate patient risk of short-term mortality, even among low-risk patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Practice guidelines and prediction rules exist for the management of patients with CAP in order to assist clinicians in the assessment of patient prognosis and selection of an appropriate site of care. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical prediction rules for severity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Practice guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many studies have been conducted to identify independent predictors of adverse medical outcomes for the purpose of objectively assessing the severity of illness for patients presenting with CAP. Each of these prediction rules for prognosis should satisfy rigorous quality standards for validity before widespread application to clinical decision making. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical prediction rules for severity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The 2007 consensus guidelines from the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) recommend using either the Pneumonia Severity Index (PSI) (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?43/42/44705?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) CURB-65 (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?40/62/41952?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) or as a decision aid to guide the initial site of treatment for adults with CAP. The guideline explicitly states that objective criteria should be applied as an adjunct to, rather than replacement for, physician decision making. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Practice guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Pneumonia Severity Index (PSI) clinical prediction rule meets the highest quality standards for both prediction rules and decision aids. The PSI rule was derived and validated as part of the Pneumonia Patient Outcomes Research Team (PORT) prospective cohort study for the purpose of identifying patients with CAP at low risk for mortality (",
"      <a class=\"graphic graphic_table graphicRef59537 \" href=\"mobipreview.htm?13/7/13435\">",
"       table 2",
"      </a>",
"      ). The PSI is the only decision aid for risk stratification of patients with CAP that has had its effectiveness and safety for guiding the initial site of treatment demonstrated in randomized trials and other interventional studies. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pneumonia Severity Index'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the PSI has been validated and its use is widely endorsed, it requires computation of a patient risk score based on 20 variables (",
"      <a class=\"graphic graphic_table graphicRef81747 \" href=\"mobipreview.htm?37/13/38108\">",
"       table 1",
"      </a>",
"      ). As a result, simpler models have been developed. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Limitations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The CURB-65 score is based upon five easily measurable factors from which its name is derived:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Confusion (based upon a specific mental test or new disorientation to person, place, or time)",
"     </li>",
"     <li>",
"      Urea (blood urea nitrogen in the United States) &gt;7",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      Respiratory rate &gt;30",
"      <span class=\"nowrap\">",
"       breaths/minute",
"      </span>",
"     </li>",
"     <li>",
"      Blood pressure (systolic &lt;90 mmHg or diastolic &lt;60 mmHg)",
"     </li>",
"     <li>",
"      Age &gt;65 years (See",
"      <a class=\"local\" href=\"#H10\">",
"       'CURB-65 score'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the patients in the derivation cohort of CURB-65, 30-day mortality was 0.7, 2.1, 9.2, 14.5, and 40 percent for 0, 1, 2, 3, or 4 factors. Similar findings were noted in the separate validation cohort. The authors suggested that patients with a CURB-65 score of 0 to 1 could probably be treated as outpatients, those with a score of 2 should be admitted to the hospital, and those with a score of 3 or more should be assessed for ICU care, particularly if the score was 4 or 5 (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?40/62/41952?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'CURB-65 score'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with blood oxygen saturations &lt;90 percent are usually hospitalized, although one study showed that using a blood oxygen saturation of &lt;92 percent would be a safer threshold for hospital admission since oxygen saturations &lt;92 percent are associated with major adverse events in outpatients with pneumonia. (See",
"      <a class=\"local\" href=\"#H1148992221\">",
"       'Oxygen saturation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Adams, PF, Marano, MA. Current estimates from the National Health Interview Survey, 1994, National Center Health Statistics. Vital Health Statistics, 1995; 10.",
"    </li>",
"    <li>",
"     Anonymous. Proceedings, 25th Public Health Conference on Records and Statistics and the National Committee on Vital and Health Statistics 45th Anniversary Symposium, July 17-19, 1995, Mayflower Hotel, Washington, D.C. Hyattsville, MD: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statistics, 1995.",
"    </li>",
"    <li>",
"     Maryland Department of Health Mental Hygiene, Office of Policy Analysis and Program Evaluation, Division of Medical Practice Patterns Analysis: Variations in the use of medical and surgical services by the Maryland population. Rockville, Maryland Department of Health Mental Hygiene, 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/4\">",
"      McMahon LF Jr, Wolfe RA, Tedeschi PJ. Variation in hospital admissions among small areas. A comparison of Maine and Michigan. Med Care 1989; 27:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/5\">",
"      Roos NP, Wennberg JE, McPherson K. Using diagnosis-related groups for studying variations in hospital admissions. Health Care Financ Rev 1988; 9:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/6\">",
"      Wennberg JE, Freeman JL, Culp WJ. Are hospital services rationed in New Haven or over-utilised in Boston? Lancet 1987; 1:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/7\">",
"      Fine MJ, Hough LJ, Medsger AR, et al. The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 1997; 157:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/8\">",
"      Fine MJ, Hanusa BH, Lave JR, et al. Comparison of a disease-specific and a generic severity of illness measure for patients with community-acquired pneumonia. J Gen Intern Med 1995; 10:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/9\">",
"      Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/10\">",
"      Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. The British Thoracic Society and the Public Health Laboratory Service. Q J Med 1987; 62:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/11\">",
"      Black ER, Mushlin AI, Griner PF, et al. Predicting the need for hospitalization of ambulatory patients with pneumonia. J Gen Intern Med 1991; 6:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/12\">",
"      Daley J, Jencks S, Draper D, et al. Predicting hospital-associated mortality for Medicare patients. A method for patients with stroke, pneumonia, acute myocardial infarction, and congestive heart failure. JAMA 1988; 260:3617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/13\">",
"      Fine MJ, Orloff JJ, Arisumi D, et al. Prognosis of patients hospitalized with community-acquired pneumonia. Am J Med 1990; 88:1N.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/14\">",
"      Fine MJ, Smith DN, Singer DE. Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study. Am J Med 1990; 89:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/15\">",
"      Keeler EB, Kahn KL, Draper D, et al. Changes in sickness at admission following the introduction of the prospective payment system. JAMA 1990; 264:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/16\">",
"      Kurashi NY, al-Hamdan A, Ibrahim EM, et al. Community acquired acute bacterial and atypical pneumonia in Saudi Arabia. Thorax 1992; 47:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/17\">",
"      Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989; 11:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/18\">",
"      Ortqvist A, Hedlund J, Grillner L, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respir J 1990; 3:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/19\">",
"      Porath A, Schlaeffer F, Lieberman D. Appropriateness of hospitalization of patients with community-acquired pneumonia. Ann Emerg Med 1996; 27:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/20\">",
"      Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/21\">",
"      Conte HA, Chen YT, Mehal W, et al. A prognostic rule for elderly patients admitted with community-acquired pneumonia. Am J Med 1999; 106:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/22\">",
"      Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/23\">",
"      Espa&ntilde;a PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006; 174:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/24\">",
"      Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and methodological standards. N Engl J Med 1985; 313:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/25\">",
"      Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med 1998; 158:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/26\">",
"      Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/27\">",
"      Yealy DM, Auble TE, Stone RA, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med 2005; 143:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/28\">",
"      Carratal&agrave; J, Fern&aacute;ndez-Sab&eacute; N, Ortega L, et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med 2005; 142:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/29\">",
"      Marrie TJ, Huang JQ. Low-risk patients admitted with community-acquired pneumonia. Am J Med 2005; 118:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/30\">",
"      Labarere J, Stone RA, Obrosky DS, et al. Comparison of outcomes for low-risk outpatients and inpatients with pneumonia: A propensity-adjusted analysis. Chest 2007; 131:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/31\">",
"      Labarere J, Stone RA, Scott Obrosky D, et al. Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-randomized trial. J Gen Intern Med 2006; 21:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/32\">",
"      Metlay JP, Atlas SJ, Borowsky LH, Singer DE. Time course of symptom resolution in patients with community-acquired pneumonia. Respir Med 1998; 92:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/33\">",
"      Renaud B, Coma E, Labarere J, et al. Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study. Clin Infect Dis 2007; 44:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/34\">",
"      Mandell L. Decisions about treating community-acquired pneumonia. Ann Intern Med 2005; 142:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/35\">",
"      Marrie TJ. The Pneumonia Severity Index score: time to move to a prospective study of patients with community-acquired pneumonia who are discharged from emergency departments to be managed on an ambulatory basis. Clin Infect Dis 2007; 44:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/36\">",
"      Bauer TT, Ewig S, Marre R, et al. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006; 260:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/37\">",
"      Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005; 118:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/38\">",
"      Yandiola PP, Capelastegui A, Quintana J, et al. Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest 2009; 135:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/39\">",
"      Mandell LA. Severe community-acquired pneumonia (CAP) and the Infectious Diseases Society of America/American Thoracic Society CAP guidelines prediction rule: validated or not. Clin Infect Dis 2009; 48:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/40\">",
"      Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/41\">",
"      Chalmers JD, Singanayagam A, Hill AT. Predicting the need for mechanical ventilation and/or inotropic support for young adults admitted to the hospital with community-acquired pneumonia. Clin Infect Dis 2008; 47:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/42\">",
"      Marrie TJ. Pneumonia in the long-term-care facility. Infect Control Hosp Epidemiol 2002; 23:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/43\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/44\">",
"      Liapikou A, Ferrer M, Polverino E, et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis 2009; 48:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/45\">",
"      Chalmers JD, Taylor JK, Mandal P, et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis 2011; 53:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/46\">",
"      Majumdar SR, Eurich DT, Gamble JM, et al. Oxygen saturations less than 92% are associated with major adverse events in outpatients with pneumonia: a population-based cohort study. Clin Infect Dis 2011; 52:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/47\">",
"      Loeb M, McGeer A, McArthur M, et al. Risk factors for pneumonia and other lower respiratory tract infections in elderly residents of long-term care facilities. Arch Intern Med 1999; 159:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/48\">",
"      Gill TM, Allore HG, Holford TR, Guo Z. Hospitalization, restricted activity, and the development of disability among older persons. JAMA 2004; 292:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38473/abstract/49\">",
"      Loeb M, Carusone SC, Goeree R, et al. Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: a randomized controlled trial. JAMA 2006; 295:2503.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7022 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38473=[""].join("\n");
var outline_f37_36_38473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4063445\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PREDICTION RULES FOR SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pneumonia Severity Index",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Potential admission strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Effectiveness and safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Other applications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CURB-65 score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Comparison to PSI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Severe community-acquired pneumonia score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PRACTICE GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Site of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Admission to intensive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1148992221\">",
"      OXYGEN SATURATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      NURSING HOME RESIDENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4063445\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7022\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7022|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/13/38108\" title=\"table 1\">",
"      PSI Step 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/7/13435\" title=\"table 2\">",
"      PSI and mortality",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?43/42/44705?source=related_link\" title=\"calculator 1\">",
"      Calculator: Community-acquired pneumonia severity index (PSI) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?40/62/41952?source=related_link\" title=\"calculator 2\">",
"      Calculator: CURB-65 pneumonia severity score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=related_link\">",
"      Antibiotic studies for the treatment of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/38/30308?source=related_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1801?source=related_link\">",
"      Prognosis of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_36_38474="Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients";
var content_f37_36_38474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/36/38474/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/36/38474/contributors\">",
"     L Darryl Quarles, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/36/38474/contributors\">",
"     Robert E Cronin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/36/38474/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/36/38474/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/36/38474/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/36/38474/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/36/38474/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of secondary hyperparathyroidism in chronic renal failure has evolved based upon new insights into the pathogenesis and clinical features of this disorder, the recognition that abnormal calcium and phosphate homeostasis may impact upon morbidity and mortality as well as mineral homeostasis, and the development of new therapeutic agents that can suppress parathyroid hormone (PTH) without exacerbating hyperphosphatemia and causing hypercalcemia.",
"   </p>",
"   <p>",
"    Because of the interdependence of calcium, phosphate, vitamin D and PTH and FGF23, it is difficult to elucidate the primary and proximate causes of parathyroid gland dysfunction in patients with chronic kidney disease (CKD). In addition, no single pharmacological intervention is sufficient to completely restore disordered calcium and phosphate homeostasis.",
"   </p>",
"   <p>",
"    From a molecular standpoint, there are three major possible targets that regulate parathyroid gland function. These are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      G-protein-coupled calcium-sensing receptor (CaSR)",
"     </li>",
"     <li>",
"      Vitamin D receptor (VDR)",
"     </li>",
"     <li>",
"      Putative extracellular phosphate sensor",
"     </li>",
"     <li>",
"      Fibroblast growth factor receptor",
"      <span class=\"nowrap\">",
"       (FGFR)/Klotho",
"      </span>",
"      complexes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The medical management of secondary hyperparathyroidism in patients with CKD principally involves the use of the combination of phosphate binders, active vitamin D analogs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcimimetics (which increase the sensitivity of the CaSR to calcium), with differences in management based in part upon the degree of renal dysfunction and whether the patient is on dialysis.",
"   </p>",
"   <p>",
"    The treatment of secondary hyperparathyroidism in dialysis patients will be reviewed here. The management of secondary hyperparathyroidism in the predialysis patient with CKD and indications for parathyroidectomy in end-stage renal disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9273?source=see_link\">",
"     \"Indications for parathyroidectomy in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF SECONDARY HYPERPARATHYROIDISM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major factors responsible for stimulating parathyroid gland function in renal failure are hypocalcemia, diminished 1,25-dihydroxyvitamin D levels, and hyperphosphatemia. To help understand the rationale underlying the use of phosphate binders (some of which contain calcium), active vitamin D analogs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcimimetics to control hyperparathyroidism in chronic kidney disease, it is worthwhile to review the effects upon the parathyroid gland of progressive dysfunction of the kidney, decreased vitamin D and calcium levels, hyperphosphatemia, and activation of the calcium-sensing receptor (CaSR).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kidney failure &mdash; Kidney failure disrupts systemic calcium and phosphate homeostasis and affects the bone, gut, and parathyroid glands. This occurs because of decreased renal excretion of phosphate and diminished renal hydroxylation of 25-hydroxyvitamin D to calcitriol (1,25-dihydroxyvitamin D).",
"      <br/>",
"      <br/>",
"      Circulating calcitriol levels begin to fall when the glomerular filtration rate is less than 40",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      (occasionally even less than 80",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/1\">",
"       1",
"      </a>",
"      ]) and are typically markedly reduced in subjects with end-stage renal failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/2\">",
"       2",
"      </a>",
"      ]. The loss of functioning renal tissue, physiologic suppression by hyperphosphatemia (a relatively late phenomenon in CKD), and rise in serum FGF23 levels all participate in the decline in calcitriol synthesis.",
"      <br/>",
"      <br/>",
"      Thus, progressive kidney dysfunction results in hyperphosphatemia and calcitriol deficiency. These ultimately result in hypocalcemia. These abnormalities directly increase PTH levels via different mechanisms. The details of how this occurs are discussed in the next sections.",
"     </li>",
"     <li>",
"      Hypocalcemia and the calcium-sensing receptor &mdash; The CaSR, which is highly expressed in the parathyroid glands, permits variations in the serum calcium concentration to be sensed by the parathyroid gland, leading to the desired changes in PTH secretion. The fall in serum calcium concentration with renal failure, as sensed by the CaSR, is a potent stimulus to the release of PTH.",
"      <br/>",
"      <br/>",
"      Extracellular calcium acting through the CaSR plays the predominant role in regulating parathyroid function, resulting in this receptor being the major therapeutic target for suppressing parathyroid gland function. This is best shown in mouse and human genetic studies in which extracellular calcium acting through CaSR was the major regulator of PTH transcription, secretion, and parathyroid gland hyperplasia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. A review of the function of the calcium-sensing receptor can be found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19258?source=see_link\">",
"       \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decreased vitamin D levels &mdash; Since vitamin D stimulates intestinal phosphate absorption, the decrease in active vitamin D production may be viewed as an adaptive response to minimize hyperphosphatemia in the setting of reduced renal phosphate excretion in patients with kidney failure.",
"      <br/>",
"      <br/>",
"      Calcitriol deficiency also affects a variety of factors regulating calcium homeostasis, thereby altering PTH levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. As an example, there are reductions in calcitriol-regulated calcium absorption in the gut and calcium release from bone, both of which promote the development of hypocalcemia; this is a potent stimulus to the release of parathyroid hormone (PTH), as previously mentioned.",
"      <br/>",
"      <br/>",
"      Calcitriol acts on the vitamin D receptor (VDR) in the parathyroid gland to suppress PTH transcription, but not PTH secretion. The absence of vitamin D also decreases calcium and phosphorus absorption in the gastrointestinal tract. The net effect of low vitamin D levels is to directly increase PTH production due to removal of the normal suppressive effect of calcitriol on the parathyroid glands, and indirectly increase secretion through the gastrointestinal mediated hypocalcemic stimulus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/8\">",
"       8",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A decrease in calcitriol levels also lowers the number of vitamin D receptors in the parathyroid cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/9\">",
"       9",
"      </a>",
"      ]. The lack of calcitriol and the decreased number of receptors may both directly promote parathyroid chief cell hyperplasia and nodule formation through potential non-genomic effects.",
"      <br/>",
"      <br/>",
"      However, the VDR appears to have a lesser physiological role in regulating parathyroid gland function than the CaSR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/2,9-11\">",
"       2,9-11",
"      </a>",
"      ]. As an example, VDR knockout mice, which are fed diets rich in calcium, phosphate, and lactose so as to avoid hypocalcemic secondary hyperparathyroidism, do not develop excess PTH secretion or parathyroid gland hyperplasia, despite the absence of vitamin D effects on the parathyroid gland [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/3\">",
"       3",
"      </a>",
"      ]. As a result, the central role of the VDR has been questioned in the pathogenesis of secondary hyperparathyroidism.",
"     </li>",
"     <li>",
"      Hyperphosphatemia &mdash; Hyperphosphatemia is also an important factor underlying hyperparathyroidism. Although the identity of the extracellular phosphate sensor is unknown and may not exist, a novel phosphaturic factor, FGF23, may be regulated by phosphate and vitamin D [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/12\">",
"       12",
"      </a>",
"      ]. This may have a role in regulating parathyroid gland function in end stage renal disease (ESRD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/13\">",
"       13",
"      </a>",
"      ]. Hyperphosphatemia also lowers the levels of ionized calcium and interferes with the production of 1,25-dihydroxyvitamin D, thereby resulting in increased PTH levels.",
"     </li>",
"     <li>",
"      FGF23 &mdash; The relationship between FGF23 and PTH is not completely understood. As an example, although FGF23 suppresses PTH via the activation of",
"      <span class=\"nowrap\">",
"       FGFR/Klotho",
"      </span>",
"      complexes, elevated FGF23 concentrations do not prevent the development of hyperparathyroidism in patients with CKD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/14\">",
"       14",
"      </a>",
"      ]. Rather FGF23 and PTH concentrations are directly correlated. Downregulation of FGFR and Klotho expression may cause parathyroid gland resistance to the suppressive effects of FGF23. Further data are needed regarding the relationship between PTH and FGF23.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the physiologic abnormalities delineated in the previous section are not corrected, renal bone disease, referred to as renal osteodystrophy, will develop. Although frequently asymptomatic, this disorder can result in weakness, fractures, bone and muscle pain, and avascular necrosis. These symptoms and signs do not generally occur until the patient is undergoing maintenance dialysis. Severe bone pain and myopathy more likely represents osteomalacia than osteitis fibrosa cystica [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several forms of renal osteodystrophy, including osteitis fibrosa cystica, adynamic bone disease, and osteomalacia. In some patients, there is evidence of more than one type, which is called mixed osteodystrophy. Osteitis fibrosa cystica and mixed osteodystrophy are largely the direct result of increased PTH levels, while adynamic bone disease is a consequence of excessive suppression of the parathyroid gland with current therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone biopsies of affected patients with osteitis fibrosa cystica demonstrate increased bone turnover activity and defective mineralization. This disorder is generally asymptomatic, but is associated with bone pain in a minority of patients. There is an increased risk of fractures. Severe symptomatic disease is currently uncommon with modern therapy.",
"     </li>",
"     <li>",
"      Adynamic bone disease, which is characterized by low osteoclastic and osteoblastic activity and bone formation rates, is due to excess suppression of the parathyroid gland with current therapies, particularly calcium-containing phosphate binders and vitamin D analogues. These patients typically maintain a low serum intact PTH concentration, which is frequently accompanied by an elevated serum calcium level. Adynamic bone disease increases the risk for fractures and metastatic calcification.",
"     </li>",
"     <li>",
"      There may be racial differences in the type of bone disease in patients with ESRD. Blacks appear to have greater cortical porosity and are more likely to have high turnover bone disease, whereas whites have a tendency to have lower rates of bone turnover [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Along with these forms of renal osteodystrophy, secondary hyperparathyroidism is associated with disorders of mineral metabolism, principally abnormalities in serum phosphate and calcium levels. A number of reports have delineated an increased risk of all-cause and cardiovascular mortality in patients with disorders of mineral metabolism. Although not found in all studies, the association with decreased survival primarily involves increased phosphate, calcium,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parathyroid hormone levels. These in turn may be associated with accelerated atherosclerosis, arterial calcification, and an increased risk of adverse cardiovascular outcomes and death.",
"   </p>",
"   <p>",
"    Although controversial, the increased presence of vascular calcification in the dialysis population may correlate in part with a therapeutic approach to secondary hyperparathyroidism that relies principally upon calcium-based phosphate binders and high doses of vitamin D analogues. These in turn may result in increased calcium intake, hypercalcemia, and combined elevations in the calcium and phosphate levels, thereby promoting vascular calcification.",
"   </p>",
"   <p>",
"    This and other features of secondary hyperparathyroidism are also discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OVERVIEW OF K/DOQI AND KDIGO TARGET LEVELS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     K/DOQI guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2003",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    practice guidelines were formulated to help optimally manage secondary hyperparathyroidism and mineral metabolism abnormalities in patients with CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/17\">",
"     17",
"    </a>",
"    ]. Given the increasing recognition of possible cardiovascular toxicity associated with current therapies, and the potential role of hyperphosphatemia and increased calcium intake in the pathogenesis of vascular calcifications, the guidelines also focused upon strategies and target goals thought to minimize the risk of vascular calcification and mortality. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for bone metabolism and disease in CKD, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Serum levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;To achieve adequate control of secondary hyperparathyroidism, the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    practice guidelines suggested that target plasma levels of",
"    <strong>",
"     intact",
"    </strong>",
"    PTH (second generation PTH assay) should be between 150 to 300",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    for patients on dialysis or with an estimated GFR of less than 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 (stage 5 chronic kidney disease) (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the management of chronic kidney disease in adults\", section on 'Definition and classification'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Third generation immunoradiometric two-site sandwich assays seem to exclusively detect the biologically active PTH 1-84 (bi-PTH). Although these PTH assays may be the optimal tests for assessing abnormal parathyroid hormone dynamics, practically all of the clinical data related to normal and abnormal conditions of parathyroid hormone secretion, including renal osteodystrophy, are based upon levels derived from the \"intact PTH\" or second generation assay. As a result, these guidelines as well as the KDIGO guidelines have concluded that it is premature to rely clinically on the newer assays. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'KDIGO guidelines'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/58/21416?source=see_link\">",
"     \"Parathyroid hormone assays and their clinical use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to guidelines for PTH levels, the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines also recommend more stringent control of calcium and phosphate in the attempt to lower the risk of vascular calcification. For those with stage 5 CKD, the following are recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum levels of phosphate should be maintained between 3.5 and 5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.13 to 1.78",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Serum levels of corrected total calcium should be maintained between 8.4 and 9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.10 to 2.37",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      The serum calcium-phosphate product should be maintained at less than 55",
"      <span class=\"nowrap\">",
"       mg2/dL2",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     KDIGO guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009 KDIGO practice guidelines were developed to provide recommendations for the evaluation and management of chronic kidney disease-mineral and bone disorder (CKD-MBD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/18\">",
"     18",
"    </a>",
"    ]. The term CKD-MBD was created to describe the syndrome associated with mineral, bone, and calcific cardiovascular abnormalities. The guidelines were formulated in an attempt to minimize the morbidity and mortality associated with abnormal mineral metabolism, abnormal bone processes, and extraskeletal calcification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Laboratory values",
"    </span>",
"    &nbsp;&mdash;&nbsp;In agreement with the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, the KDIGO guidelines recommend using intact PTH levels to evaluate and manage bone abnormalities. This is principally because most of the literature has correlated intact PTH levels with the diagnosis and management of bone disease rather than other assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines were based somewhat on findings derived from a second generation assay that is no longer available. In addition, there are data suggesting significant variability with PTH results among the different available assays as well marked differences based on sample collection and storage.",
"   </p>",
"   <p>",
"    These observations led the KDIGO working group to recommend against targets based upon absolute PTH levels found in one assay. Instead, they suggest maintaining intact PTH levels between approximately two to nine times the upper normal limit for the assay that is being used for patients undergoing dialysis. This requires the clinician to be aware of the particular assay and normal values associated with its use.",
"   </p>",
"   <p>",
"    With respect to calcium and phosphate levels, the KDIGO working group suggests the following for dialysis patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintaining serum calcium in the normal range",
"     </li>",
"     <li>",
"      Lowering elevated phosphorus levels toward the normal range",
"     </li>",
"     <li>",
"      Individual values of serum calcium and phosphorus should be evaluated together, rather than the calcium-phosphorus product.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the work group recommended that decisions regarding treatment should be based upon trends rather than single laboratory values. This is largely based upon the observation that these values can be widely variable due to assay and biological variation issues. These issues include assay validity, variations with dialysis time and meals, and coefficient of variation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TARGET GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our target goals for PTH, calcium, and phosphorus values have been chosen to help manage secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/17\">",
"     17",
"    </a>",
"    ]. Although not proven, these target goals and strategies may also minimize the risk of vascular calcification and mortality given the increasing recognition of possible cardiovascular toxicity associated with current therapies, and the potential role of hyperphosphatemia and hypercalcemia in the pathogenesis of vascular calcifications.",
"   </p>",
"   <p>",
"    For dialysis patients, we suggest the following target goals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intact PTH (second generation PTH assay) should be maintained between 150 to 300",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (and 80 to 160",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      using the Bi-PTH assay)",
"     </li>",
"     <li>",
"      Serum levels of phosphate should be maintained between 3.5 and 5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.13 to 1.78",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Serum levels of corrected total calcium should be maintained between 8.4 and 9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.10 to 2.37",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We also recommend that therapeutic measures be instituted in response to abnormal single values rather than only trends to abnormal levels. This is because definitive treatment is required in response to the identification of highly abnormal levels (rather than only trends), including severe hypercalcemia, hyperphosphatemia, and markedly elevated PTH levels.",
"   </p>",
"   <p>",
"    Despite these goal values, the optimal plasma intact PTH level in advanced kidney disease is not known. Since PTH levels correlate with bone histology, most clinical studies use intact PTH to indicate the state of bone turnover, particularly given that bone biopsies are not commonly and easily obtained. Although not absolute, numerous studies have demonstrated that the higher turnover bone disorders, osteitis fibrosa (and mixed uremic osteodystrophy), are associated with serum levels of intact PTH greater than 400",
"    <span class=\"nowrap\">",
"     pg/mL.",
"    </span>",
"    Suppression of PTH to normal values is also not desirable (below 150",
"    <span class=\"nowrap\">",
"     pg/mL),",
"    </span>",
"    since it is associated with a higher prevalence of adynamic bone disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. African Americans on hemodialysis may be a population that needs special consideration and possibly permitted a higher upper limit for acceptable PTH levels, as suppressing PTH to the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines of 150-300",
"    <span class=\"nowrap\">",
"     pg/ml",
"    </span>",
"    was associated with more adynamic bone disease than the non-African Americans in one cohort study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not clearly proven, it is therefore assumed that avoidance of very high or very low intact PTH levels prevents the development of osteitis fibrosa cystica or adynamic bone disorder, respectively. In addition, among patients with established bone disease, some older studies have found that therapies that lower PTH levels (principally vitamin D therapy) are associated with healing of bone and may benefit those with symptomatic disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Implicit in these target levels is the avoidance of vitamin D if the calcium and phosphate level exceed these upper limits. If followed, these recommendations would result in an overall lowering of the dose of vitamin D analogues (since higher doses are associated with increased calcium and phosphate levels).",
"   </p>",
"   <p>",
"    These target levels are most consistent with",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    target goals, rather than the KDIGO guidelines. With PTH target levels, for example, the KDIGO guidelines recommend to maintain levels in the range of two to nine times the upper normal limit of the assay. In addition, they suggest that therapeutic measures should be instituted only if there is a trend rather than in response to single values.",
"   </p>",
"   <p>",
"    However, there are concerns with these KDIGO goal levels. It is likely that allowing PTH elevations to increase to nine times the upper limit of normal will result in progressive hyperparathyroidism over time since elevated PTH levels reflect abnormal parathyroid gland function. Until there are data to the contrary, we therefore recommend continued use of the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines for PTH target values; we also follow other parameters that may provide insights into bone health (eg, tendency to develop hypercalcemia, and other features).",
"   </p>",
"   <p>",
"    In addition, the KDIGO guidelines suggest that, among dialysis patients, elevated phosphorus levels should be lowered toward the normal range rather than specifically targeting certain maintenance levels. Given the difficulty in treating hyperphosphatemia, the KDIGO guidelines may not be practical and therefore are less clinically useful than the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    target goals given that \"lowering toward the normal range\" provides much less clear guidance in obtaining actual target levels, and a phosphate level of 5.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is a reasonable inflection point at which increased mortality has been observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Assessment and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;To attain goal levels, serum levels of PTH, phosphate, and calcium must be measured frequently. As recommended by the KDIGO guidelines, phosphate and calcium levels should be measured approximately every 1 to 3 months and every 3 to 6 months for PTH levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/18\">",
"     18",
"    </a>",
"    ]. 25(OH) vitamin D levels should also be measured. All of these levels should be assessed more frequently in response to changes in therapeutic measures that affect these levels.",
"   </p>",
"   <p>",
"    The gold standard for the diagnosis of bone disease in patients with chronic kidney disease is a bone biopsy. Because the technique is invasive, it is not easily performed and is not done in most patients. However, we suggest that bone biopsy be performed in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unexplained fractures, unexplained hypercalcemia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unexplained hypophosphatemia",
"     </li>",
"     <li>",
"      Persistent bone pain",
"     </li>",
"     <li>",
"      Possible aluminum toxicity",
"     </li>",
"     <li>",
"      Before therapy with bisphosphonates",
"     </li>",
"     <li>",
"      Before parathyroidectomy to rule out the presence of adynamic bone disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of bone biopsy in the diagnosis of bone disease in patients with chronic kidney disease is discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The presence of vascular calcification increases the overall risk of cardiovascular disease in dialysis patients. In dialysis patients with such vascular disease, the overall calcium load should be minimized in the attempt to manage mineral metabolism abnormalities, although the benefits with this approach are unproven. As noted in the KDIGO guidelines, options to detect vascular calcification include a lateral abdominal radiograph, echocardiogram, or CT scanning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/18\">",
"     18",
"    </a>",
"    ]. As noted elsewhere, an echocardiogram is recommended at the initiation of dialysis to help diagnosis heart disease in patients beginning dialysis therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/49/33559?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     THERAPEUTIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current management of secondary hyperparathyroidism in dialysis patients principally involves the administration of some combination of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Phosphate binders (either calcium or non-calcium containing binders)",
"     </li>",
"     <li>",
"      Vitamin D analogues",
"     </li>",
"     <li>",
"      Calcimimetic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As discussed elsewhere within this topic review and in detail separately in UpToDate, there is increasing evidence that a therapeutic approach that relies principally upon calcium-based phosphate binders and high doses of vitamin D analogues may be associated with adverse clinical outcomes, particularly a high rate of excess vascular calcification (particularly in the form of extensive coronary artery calcification) and increased cardiovascular mortality. Although unproven, an approach that relies more upon calcimimetics and non calcium-based phosphate binders may therefore provide substantial clinical benefits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following sections provide an overview of the different agents, including efficacy, that are currently available to treat secondary hyperparathyroidism in dialysis patients as well as in predialysis patients with CKD.",
"   </p>",
"   <p>",
"    Our detailed approach to treatment that integrates the use of these agents with calcium, phosphate and PTH levels in dialysis patients is discussed below (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Overview of treatment approach'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Phosphate binders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Background",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our initial focus in preventing and managing secondary hyperparathyroidism in the dialysis patient is the prevention and treatment of hyperphosphatemia. For dialysis patients, we suggest that serum levels of phosphate should be maintained between 3.5 and 5.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.13 to 1.78",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    principal rationale for this is based upon the consistent observation that hyperphosphatemia is associated with increased mortality in ESRD and the unequivocal animal and in vitro studies demonstrating that phosphate is the principal factor leading to calcification of extracellular matrix.",
"   </p>",
"   <p>",
"    By comparison, the clinical evidence that improved outcomes are associated with measures that help obtain these exact parameters is somewhat limited. There are no prospective studies that have evaluated whether benefits are derived from the targeting of specific phosphate levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/18\">",
"     18",
"    </a>",
"    ]. A detailed discussion of the management of hyperphosphatemia in chronic kidney disease is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Restricting dietary phosphate intake can first be attempted (adjusted to dietary protein needs) with about 800 to 1000 mg per day being a level that at least some patients will find acceptable. Limiting phosphate intake, however, can be accomplished only by limiting protein intake. Although this may be desirable in many patients with chronic renal failure prior to the onset of end-stage renal disease, different considerations are present in maintenance dialysis. A large fraction of dialyzed patients have either overt or borderline malnutrition.",
"   </p>",
"   <p>",
"    Thus, protein supplementation rather than protein restriction is the goal. In this setting, the patient should be encouraged to avoid unnecessary dietary phosphate (as in dairy products, certain vegetables, many processed foods, and colas) while increasing the intake of high biologic value sources of protein (such as meat and eggs). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most dialysis patients therefore require the administration of oral phosphate binders to limit the absorption of dietary phosphate. Among dialysis patients with hyperphosphatemia, we therefore suggest the administration of an oral phosphate binder.",
"   </p>",
"   <p>",
"    The major modalities that are currently available are calcium salts, and the non-calcium containing phosphate binders",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/37/28244?source=see_link\">",
"     lanthanum carbonate",
"    </a>",
"    . At present, there are no data evaluating clinically important outcomes that clearly favor non-calcium containing phosphate binders rather than calcium-containing binders or favor sevelamer rather than lanthanum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adequate evidence with regard to mortality does not exist at present to favor non-calcium- over calcium-based phosphate binders. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=see_link\">",
"       \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some data suggest that vascular calcification is attenuated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      compared with calcium containing binders; however, there is no evidence that this translates into clinically important outcomes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"       \"Vascular calcification in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Studies evaluating bone histology have found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      and lanthanum are largely similar. However, calcium containing phosphate binders are associated with increased calcium levels and decreased serum PTH levels compared with non-calcium containing phosphate binders. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Calcium-based phosphate binders'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At present, the optimal choice of phosphate binder therefore depends upon the serum calcium level and PTH level, presence of adynamic bone disease on bone biopsy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vascular calcification, and side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Calcium-based phosphate binders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data suggest that high dose calcium administration in the absence of vitamin D therapy can suppress plasma PTH levels while leading to an optimal calcium and phosphate product in patients with mild hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/23\">",
"     23",
"    </a>",
"    ]. Calcium-based binders when administered with meals can serve both as a phosphate binder and a source of calcium.",
"   </p>",
"   <p>",
"    Most patients are administered the calcium-containing phosphate binders,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/48/39685?source=see_link\">",
"     calcium acetate",
"    </a>",
"    (PhosLo). Calcium carbonate has 500 mg of elemental calcium in a 1250 mg tablet; calcium acetate has 169 mg of elemental calcium in one 667 mg tablet. Calcium-based phosphate binders should be taken with meals. Calcium acetate has a greater binding capacity for phosphate than calcium carbonate, thereby allowing a lower dose to be used. However, the incidence of hypercalcemia is similar with these two forms of therapy, possibly due to the greater bioavailability of calcium in the acetate preparation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A strategy that relies upon calcium-containing phosphate binders increases the risk of positive calcium balance, particularly in the setting of concomitant vitamin D therapy. Compared with the use of non-calcium-containing phosphate binders, this may increase the risk of vascular calcification and arterial disease and is associated with decreased serum PTH levels and increased serum calcium levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although we favor an overall strategy that limits excessive intake of calcium, the level of tolerated calcium intake has not been established, and is influenced by concomitant treatment with vitamin D analogues, use of calcimimetics and the bone buffering capacity that is greater in high turnover bone diseases. The future use of larger doses of calcium as a primary treatment of secondary hyperparathyroidism will likely undergo a reevaluation in the context of vitamin D analogue sparing therapies, analysis showing the lack of an association between calcium binders and adverse outcomes in large databases, the use of hypocalcemic causing calcimimetics, and economic pressures to identify the most cost-effective therapies.",
"   </p>",
"   <p>",
"    In patients receiving active vitamin D therapy, consistent with both the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    and KDIGO guidelines, we keep daily elemental calcium intake from binders to less than 1500 mg, and total elemental calcium from diet and binders to less than 2000 mg; however, we may give higher calcium doses in hypocalcemic patients and patients with elevated PTH and high bone turnover.",
"   </p>",
"   <p>",
"    On the other hand, calcium-based phosphate binders increase serum calcium levels, enhance arterial calcification, and lower PTH levels. We suggest that the dose of calcium-based phosphate binders should therefore be restricted in the setting of hypercalcemia, arterial calcification, decreased PTH levels (less than 150",
"    <span class=\"nowrap\">",
"     pg/dL)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adynamic bone disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Non-calcium containing phosphate binders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The problems with phosphate binders containing calcium has led to the search for different compounds that can bind phosphate. One such compound is the nonabsorbable agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    , which does not contain calcium and is a cationic polymer that binds phosphate through ion exchange. As with other phosphate binders, several randomized prospective studies have found that sevelamer is effective in lowering phosphate and PTH levels. The other principal non-calcium containing phosphate binder is lanthanum (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The general recommendation to limit the intake of calcium has resulted in the increasing use of non-calcium containing phosphate binders, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/37/28244?source=see_link\">",
"     lanthanum carbonate",
"    </a>",
"    , to treat hyperphosphatemia. However, this recommendation may change as new data emerge regarding the importance of controlling phosphate may be more important than the binder used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ergocalciferol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D largely represents both vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). The prevalence of nutritional vitamin D deficiency, as defined by 25 hydroxyvitamin D levels less than 30",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    is high in this population of chronically ill patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38184?source=see_link\">",
"     \"Causes of vitamin D deficiency and resistance\"",
"    </a>",
"    .) If 25-OH D levels are less than 30",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    the clinician must decide whether to administer ergocalciferol to replete nutritional stores and provide substrate for the extrarenal production of 1,25(OH)D2 in tissues expressing 1-alpha-hydroxylase.",
"   </p>",
"   <p>",
"    Some administer ergocalciferol (along with active vitamin D analogues if indicated, see next section) in this setting, due largely to data in animals that 25 hydroxyvitamin D has bone effects separate from 1,25-dihydroxyvitamin D and 24,25-dihydroxyvitamin D (which are the kidney active and inactive metabolites, respectively). Limited evidence from a nested-case control study also suggests that low vitamin D levels among incident dialysis patients are associated with increased early mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a paucity of evidence concerning the effect of nutritional vitamin D replacement in dialysis patients. One six-month study of 199 dialysis patients found that ergocalciferol oral supplementation (50,000 IU monthly) significantly increased 25-OH D levels (17 to 54",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    with no increase in serum calcium, phosphate, and Ca x P product levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is an ongoing debate regarding the role of concurrent 25(OH)D repletion in CKD patients already treated with calcitriol or its analogues. Studies have found that 25(OH)D repletion with oral cholecalciferol 50,000 units twice weekly for eight weeks in dialysis patients resulted in a threefold increase in vitamin D receptor (VDR) expression from baseline, along with a 36 percent decrease in the 1 alpha-hydroxylase to 24-hydroxylase ratio in monocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/29\">",
"     29",
"    </a>",
"    ]. Although a similar effect occurred with paricalcitol, the administration of ergocalciferol may therefore provide local production of 1,25(OH)2D without the systemic effects to increase serum calcium and phosphate that accompanies therapy with active vitamin D analogues.",
"   </p>",
"   <p>",
"    However, other than nutritional repletion, there is NO clinical evidence to support a salutary effect of nutritional vitamin D replacement in dialysis patients. Until further data becomes available, the administration of ergocalciferol cannot be strongly endorsed in dialysis patients. Nevertheless, there is no significant toxicity associated with its use in this setting, although long-term studies have not been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Vitamin D derivatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;In dialysis patients with increased PTH levels, we suggest the use of calcitriol or vitamin D analogs or calcimimetics, or some combination to lower PTH levels. We also favor a strategy that limits the dose of active vitamin D analogues because of the known ability of all current vitamin D analogues to induce hyperphosphatemia and hypercalcemia and the unequivocal experimental data in animals that vitamin D therapy promotes vascular calcification in high doses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Background",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contribution of calcitriol deficiency to the development of secondary hyperparathyroidism constitutes the biologic rationale for the use of active vitamin D analogue in patients with CKD. In addition, most dialysis patients with increased plasma intact PTH levels (&gt;300",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    require treatment with calcitriol or other vitamin D analogues.",
"   </p>",
"   <p>",
"    The principal reason for intervention at this degree of hyperparathyroidism is based upon two assumptions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These agents are superior to calcium supplementation alone in suppressing plasma PTH concentrations in most dialysis patients (provided hyperphosphatemia can be prevented)",
"     </li>",
"     <li>",
"      Prevention of hyperparathyroidism is more readily accomplished than treatment of established disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, such therapy also enhances the gastrointestinal absorption of calcium and phosphate, thereby possibly resulting in an increased Ca X P product and overall mortality rate. There is also some evidence that 1,25 dihydroxy vitamin D itself is able to modulate growth of vascular smooth muscle cells and influence vascular calcification; this may be important in plaque formation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20185?source=see_link\">",
"     \"Biology of vascular calcification in renal failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To minimize the potential of calcitriol to increase gastrointestinal absorption of calcium and phosphate, more selective vitamin D analogues have been developed that may reduce the risk of hypercalcemia and hyperphosphatemia. The factors responsible for the seemingly more selective actions of these analogs are incompletely understood.",
"   </p>",
"   <p>",
"    However, clinical trials demonstrate the potential to raise serum calcium and phosphate at high doses with all current vitamin D analogues. The coadministration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    (an effective phosphate binder) with calcitriol may limit the likelihood of vitamin-D induced hyperphosphatemia. Development of tissue specific VDR ligand drugs may ultimately reduce the potential of vitamin D toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the putative association with increased mortality with vitamin D due to",
"    <span class=\"nowrap\">",
"     calcium/phosphate",
"    </span>",
"    abnormalities, some evidence suggests that active vitamin D analogues may have important health benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of several databases found that the use of active vitamin D analogues in incident hemodialysis patients is associated with a survival advantage compared with placebo and that the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32774?source=see_link\">",
"       paricalcitol",
"      </a>",
"      is associated with better survival than calcitriol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study of dialysis patients also found that users of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/14/37093?source=see_link\">",
"       alfacalcidol",
"      </a>",
"      versus non-users had a lower risk of death from cardiovascular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A nested-case control study of incident hemodialysis patients reported a significantly lower risk of all-cause death and cardiovascular mortality among patients with the highest 25 vitamin D and 1,25 vitamin D levels who received active vitamin D therapy, versus untreated patients with the lowest levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether these observations represent a true protective effect of vitamin D or are confounded by indication remains to be determined.",
"   </p>",
"   <p>",
"    To assess the benefits of vitamin D compounds, a 2007 meta-analysis evaluated 76 trials that included 3667 participants (most of whom were dialysis-dependent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/34\">",
"     34",
"    </a>",
"    ]. Established vitamin D steroids increased the risk of hypercalcemia and hyperphosphatemia, but did not consistently lower PTH levels; by comparison, the newer analogues increased calcium levels and lowered PTH levels, and did not increase phosphate levels. The effects on death, hospitalization, cardiovascular events, or fractures were unclear given the small number of studied patients. Limitations with this analysis include the inclusion of many small studies with short duration of follow-up and marked study heterogeneity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/35\">",
"     35",
"    </a>",
"    ]. However, as noted in an accompanying editorial, this meta-analysis has shown that the effects of vitamin D supplementation have only been proven to improve non-clinically relevant outcomes. As a result, further study is required to assess its effects on clinical outcomes, such as fractures and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Indications in dialysis patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the strong association between hyperphosphatemia and mortality, it seems unwise currently to use high doses of active vitamin D analogues in the setting of hyperphosphatemia and increased calcium levels, in spite of the potential survival advantage associated with vitamin D usage that have been identified in primarily retrospective studies.",
"   </p>",
"   <p>",
"    We therefore suggest administering active vitamin D analogue therapy in dialysis patients when the serum iPTH is above the target range (eg, &gt;300",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    for the \"intact assay\"), corrected serum calcium is &lt;9.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;2.375",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and serum phosphate is &lt;5.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;1.78",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    A detailed description of our approach to integration of vitamin D therapy with other components of the treatment regimen can be found below (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Overview of treatment approach'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are six active (1-hydroxylated) vitamin D derivatives currently available:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32774?source=see_link\">",
"     paricalcitol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/12/44229?source=see_link\">",
"     doxercalciferol",
"    </a>",
"    , calcitriol,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/14/37093?source=see_link\">",
"     alfacalcidol",
"    </a>",
"    (not available in the United States), falecalcitriol (not available in the United States), and 22-oxacalcitriol (not available in the United States). Paricalcitol and doxercalciferol are predominantly used in the United States, whereas calcitriol and alfacalcidol are more frequently used in other countries.",
"   </p>",
"   <p>",
"    There are a number of experimental studies and uncontrolled and placebo-controlled trials that have examined the efficacy of calcitriol and other agents in controlling PTH levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/19,23,36-51\">",
"     19,23,36-51",
"    </a>",
"    ]. Based on these studies, some of these vitamin D derivatives may have less calcemic and phosphatemic effects than calcitriol while retaining the ability to suppress PTH secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/36-41\">",
"     36-41",
"    </a>",
"    ]. However, these clinical trials also show that all analogues have the potential of increasing serum calcium and phosphate when administered in high doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/19,23,43-51\">",
"     19,23,43-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is only one large prospective randomized trial that has directly compared the efficacy of one agent versus another (calcitriol versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32774?source=see_link\">",
"     paricalcitol",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/52\">",
"     52",
"    </a>",
"    ]. In this trial, no significant difference was observed in the primary endpoint (lowering of PTH values) and secondary endpoints (the single incidence of hypercalcemia or elevated calcium x phosphate product).",
"   </p>",
"   <p>",
"    As a result, there is no convincing evidence, including the result from the one large prospective randomized comparative trial, supporting the use of a specific derivative over another. Thus, any of the six analogs currently available are considered acceptable treatment until further prospective randomized trials comparing them have been performed. It will be particularly important to see if the survival benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32774?source=see_link\">",
"     paricalcitol",
"    </a>",
"    over calcitriol is reproducible in a prospective randomized trial.",
"   </p>",
"   <p>",
"    The following is a review of the different agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Calcitriol",
"      </strong>",
"      &mdash; 1,25 dihydroxyvitamin D3 (calcitriol) is the natural form of active vitamin D produced by the human body, and was the first option for treatment with an active vitamin D derivative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. Calcitriol is available in both oral (Rocaltrol) and intravenous (Calcijex) preparations. The relative efficacy and adverse effects associated with calcitriol are discussed in subsequent sections.",
"      <br/>",
"      <br/>",
"      Controversies exist regarding the route (oral versus intravenous), the dose and frequency (intermittent higher \"pulse\" therapy versus lower daily therapy), and the timing of calcitriol initiation in patients with chronic renal disease. Optimal therapy has not been determined by evidence from clinical trials. Instead, reimbursement issues in the United States and patient compliance issues have encouraged the intravenous route of administration. With new reimbursement guidelines, this practice may change.",
"      <br/>",
"      <br/>",
"      Initial uncontrolled trials suggested that intermittent intravenous pulse calcitriol was both more effective and better tolerated than oral calcitriol (",
"      <a class=\"graphic graphic_figure graphicRef54922 \" href=\"mobipreview.htm?25/59/26557\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/19,43-45\">",
"       19,43-45",
"      </a>",
"      ]. Subsequent studies suggested that intermittent oral and intravenous bolus therapy were equally effective, but all of these reports lack sufficient power to reach a definitive conclusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/23,46-48,53\">",
"       23,46-48,53",
"      </a>",
"      ]. As an example, a double-blind, placebo controlled clinical trial in chronic maintenance hemodialysis patients compared intermittent oral calcitriol three times weekly at the end of dialysis, (which leads to more physiologic plasma calcitriol levels) and intravenous bolus calcitriol (which leads to transient pharmacologic calcitriol levels) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/46\">",
"       46",
"      </a>",
"      ]. The oral and intravenous routes of administration were equivalent with regard to PTH suppression and side effects.",
"      <br/>",
"      <br/>",
"      In patients treated with chronic peritoneal dialysis in whom intravenous therapy is not practical, pulse oral and daily oral therapy are equally effective in suppressing plasma PTH levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/49,54\">",
"       49,54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32774?source=see_link\">",
"       Paricalcitol",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash; There has been much interest in the \"second generation\" vitamin D analog paricalcitol (19-nor-1-alpha,25-dihydroxyvitamin D2; Zemplar). This is because of the potential survival advantage and ability to suppress PTH levels with less severe increments in serum calcium and phosphate with this agent.",
"      <br/>",
"      <br/>",
"      However, data from the only prospective comparative study suggest no significant differences between paricalcitol and calcitriol. In this phase III, double-blind, multicenter, randomized open labeled trial, paricalcitol was directly compared with calcitriol among 263 hemodialysis patients with plasma PTH levels above 300",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      and a serum Ca x P product less than 75 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/52\">",
"       52",
"      </a>",
"      ]. The primary end point was the ability to reduce plasma PTH to 50 percent of baseline values. Secondary end points were the incidence of hypercalcemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      of elevated Ca x P product (75). Dosing of paricalcitol and calcitriol was adjusted based upon plasma PTH, calcium, and Ca x P product levels.",
"      <br/>",
"      <br/>",
"      There was no difference between paricalcitol and calcitriol in the rate of occurrence of the primary end point; roughly 60 percent of patients in each group achieved a 50 percent PTH reduction (no significant difference between groups). Moreover, serum Ca x P product values were not significantly different between the groups and both treatments resulted in increments in this product.",
"      <br/>",
"      <br/>",
"      In an attempt to assess the relative effect on mortality of paricalcitol and calcitriol, the survival of hemodialysis patients administered paricalcitol (29,021 patients) or calcitriol (38,378 patients) was evaluated in a historic cohort study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/32\">",
"       32",
"      </a>",
"      ]. The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At three year follow-up, mortality was significantly lower in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32774?source=see_link\">",
"       paricalcitol",
"      </a>",
"      group (crude mortality of 18 versus 22.3 percent per person-year for paricalcitol and calcitriol, respectively). These differences were noted by 12 months and were observed across multiple strata.",
"     </li>",
"     <li>",
"      By ICD-9-CM classification, cardiovascular disease accounted for 59 and 57 percent of deaths in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32774?source=see_link\">",
"       paricalcitol",
"      </a>",
"      and calcitriol groups, respectively.",
"     </li>",
"     <li>",
"      At two years, patients who switched from calcitriol to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32774?source=see_link\">",
"       paricalcitol",
"      </a>",
"      (14,862 patients) had a significantly higher survival than patients who switched from paricalcitol to calcitriol (1621 patients) (73 versus 64 percent). Unfortunately, this cross-over design doesn't allow a conclusion as to whether calcitriol or paricalcitol was the source of the difference.",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32774?source=see_link\">",
"       paricalcitol",
"      </a>",
"      group also developed significantly less elevation in serum calcium and phosphate levels and greater degrees of PTH suppression at all time points measured. Information regarding calcium and non-calcium phosphate binders in the two groups was not available.",
"      <br/>",
"      <br/>",
"      This study was not randomized and there were significant differences in baseline characteristics such as age, race, and duration of dialysis between the two groups. Although multivariable analysis was done, a prospective randomized trial is needed to clarify this important issue. At present, this trial is",
"      <strong>",
"       not",
"      </strong>",
"      considered a reason to prefer paricalcitol to other vitamin D analogs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/12/44229?source=see_link\">",
"       Doxercalciferol",
"      </a>",
"      &mdash; Trials suggest that doxercalciferol given orally [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/42\">",
"       42",
"      </a>",
"      ] or intravenously [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/53\">",
"       53",
"      </a>",
"      ] thrice weekly at the time of hemodialysis is both well tolerated and lowers plasma PTH. An oral formulation, Hectorol, has been approved for use in the United States. One small retrospective trial that compared calcitriol with doxercalciferol and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32774?source=see_link\">",
"       paricalcitol",
"      </a>",
"      found that, in adjusted models, there was no significant difference in mortality between doxercalciferol and paricalcitol versus calcitriol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/14/37093?source=see_link\">",
"       Alfacalcidol",
"      </a>",
"      &mdash; Alfacalcidol (1-hydroxyvitamin D which is then 25-hydroxylated to calcitriol in the liver) has been shown to suppress PTH levels in open-label trials compared with placebo treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/56-58\">",
"       56-58",
"      </a>",
"      ]. Trials comparing alfacalcidol to calcitriol have not been performed.",
"     </li>",
"     <li>",
"      <strong>",
"       22-oxacalcitriol",
"      </strong>",
"      &mdash; In open-label trials, 22-oxacalcitriol clearly suppresses plasma PTH levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. The efficacy of 22-oxacalcitriol has also been directly compared with calcitriol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. In one study, for example, 46 hemodialysis patients with secondary hyperparathyroidism were randomly assigned to receive either intravenous 22-oxacalcitriol or oral calcitriol pulse therapies in a 24-week study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/61\">",
"       61",
"      </a>",
"      ]. Although both treatment groups reduced PTH, calcitriol achieved slightly lower PTH values but also slightly higher serum calcium levels. Serum phosphate levels were similar for both groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose of active vitamin D therapy, namely maximum efficacy with least toxicity has not been established and depends upon the concurrent use of calcimimetics, the dose of concomitant calcium-based phosphate binders, and the",
"    <span class=\"nowrap\">",
"     potency/selectivity",
"    </span>",
"    of the vitamin D analog. The current approach has been empiric, with the goal of administering increasing doses of vitamin D analogs along with phosphate binders to achieve a plasma intact PTH level between 150 and 300",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    while limiting the total dose of calcium binders to 1.5 g of elemental calcium per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The continued up-titration with active vitamin D to supra-physiologic levels if necessary to suppress PTH is often successful in lowering PTH, but frequently achieves this one goal at the expense of hypercalcemia and hyperphosphatemia which becomes treatment limiting and requires dose reduction. This \"high dose\" vitamin D strategy has been challenged with the advent of calcimimetics.",
"   </p>",
"   <p>",
"    Physiologic or low dose active vitamin D derivatives combined with calcimimetics can achieve goals for PTH levels, but with less frequent hypercalcemia and hyperphosphatemia than observed with high doses of vitamin D analogues. In an open label trial, for example, chronic hemodialysis patients being treated with a high dose vitamin D derivative were switched to a physiologic dose active vitamin D derivative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/63\">",
"     63",
"    </a>",
"    ]. The calcimimetic, cinacalcet, was then initiated and uptitrated. The percentage of patients achieving goal bio-intact PTH, Ca X P product, and both bio-intact PTH and Ca X P product was then compared between the baseline high dose vitamin D protocol and the physiologic dose active vitamin D protocol. Both high dose and physiologic dose active vitamin D similarly controlled bio-intact PTH (91 and 85 percent, respectively). However, percent at goal was significantly higher with the physiologic active vitamin D protocol for the Ca X P product (72 versus 21 percent) and for both biPTH and Ca X P product (47 versus 17 percent, respectively).",
"   </p>",
"   <p>",
"    Use of supraphysiologic dose active vitamin D is also not supported by existing animal studies. In vivo and in vitro animal studies have shown near maximal effects of calcitriol on PTH gene transcription at physiologic calcitriol levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comparative \"physiologic\" doses for active vitamin D derivatives in the setting of calcimimetic use are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Calcitriol 0.5",
"      <span class=\"nowrap\">",
"       mcg/dialysis",
"      </span>",
"      session",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32774?source=see_link\">",
"       Paricalcitol",
"      </a>",
"      2",
"      <span class=\"nowrap\">",
"       mcg/dialysis",
"      </span>",
"      session",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/12/44229?source=see_link\">",
"       Doxercalciferol",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mcg/dialysis",
"      </span>",
"      session",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With treatment algorithms that titrate vitamin D analogues to reduce PTH results in higher doses of these agents, typical doses of currently used active vitamin D analogues are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Calcitriol 1.5",
"      <span class=\"nowrap\">",
"       mcg/dialysis",
"      </span>",
"      session",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32774?source=see_link\">",
"       Paricalcitol",
"      </a>",
"      6",
"      <span class=\"nowrap\">",
"       mcg/dialysis",
"      </span>",
"      session",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/12/44229?source=see_link\">",
"       Doxercalciferol",
"      </a>",
"      3",
"      <span class=\"nowrap\">",
"       mcg/dialysis",
"      </span>",
"      session",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The maximal tolerated dose of intermittent calcitriol is usually about 7 to 8",
"    <span class=\"nowrap\">",
"     mcg/week",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. With the availability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    HCl to suppress PTH, it is advisable to not exceed the physiological replacement doses of active vitamin D analogues.",
"   </p>",
"   <p>",
"    Active vitamin D analogue requirements are generally greatest during initial therapy, when the osseous manifestations of excess PTH are most prominent. Subsequent healing of the bone disease and reduction in PTH levels reduces the requirement for calcitriol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dose adjustments typically occur at four to eight week intervals as the plasma calcium concentration rises. Patients who are responsive to calcitriol supplementation typically show significant reductions in plasma PTH concentrations during the first three to six months of therapy. In general, the dose of active vitamin D derivatives should be reduced by 50 percent or stopped with plasma calcium levels at the upper normal range and trending upward, or with mild hypercalcemia (between 9.5 and 10.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.37 to 2.55",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    Calcitriol should be discontinued for frank hypercalcemia (&gt;10.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&gt;2.55",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/17\">",
"     17",
"    </a>",
"    ]. After resolution of hypercalcemia, calcitriol can be restarted at one-half the original dose, or cinacalcet therapy initiated or up-titrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D derivatives should not be given until the serum phosphate concentration has been controlled (&lt;5.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&lt;1.78",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and the serum calcium is less than 9.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;2.37",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/17\">",
"     17",
"    </a>",
"    ]. Raising the serum calcium concentration before correcting hyperphosphatemia can promote metastatic calcification and, as previously mentioned, increase the risk of vascular calcification.",
"   </p>",
"   <p>",
"    Another relative contraindication to the use of vitamin D derivatives is a low plasma PTH concentration, possibly below 150",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    because of the association with adynamic bone disease. In patients with PTH levels between 120 and 300",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    noninvasive markers (such as bone specific alkaline phosphatase and osteocalcin) have been used to estimate bone turnover, although the reliability of these markers has not been unequivocally established in chronic kidney disease. Empiric observations suggest that somewhat higher than normal PTH levels are required for normal bone formation rates, presumably due to the end-organ resistance to PTH observed in uremia.",
"   </p>",
"   <p>",
"    However, some patients treated with intermittent calcitriol develop adynamic bone disease despite persistent hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/66\">",
"     66",
"    </a>",
"    ]. This observation suggests that calcitriol itself may directly suppress bone formation via effects on osteoblastic activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis of renal osteodystrophy\", section on 'Adynamic bone disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to one-half of patients with severe hyperparathyroidism show little or no decline in plasma PTH levels with calcitriol therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/46,67\">",
"     46,67",
"    </a>",
"    ]. Limiting factors include large functioning gland mass, altered calcium sensitivity of parathyroid cells, and failure of high dose vitamin D derivatives because of hypercalcemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperphosphatemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/46,67,68\">",
"     46,67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although initial studies suggested that calcitriol causes involution of the parathyroid glands, subsequent prospective trials have been unable to demonstrate a reduction in parathyroid gland size or parathyroidectomy rate. Larger glands are more likely to have areas of nodular hyperplasia, with nodules generally showing a marked reduction in calcitriol receptors that could contribute to the calcitriol resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/10\">",
"     10",
"    </a>",
"    ]. Monoclonal expansion of autonomous parathyroid secreting cells is also possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/69\">",
"     69",
"    </a>",
"    ]. Whether earlier treatment, before transformation occurs would be more effective is uncertain. Patients with severe disease may require parathyroidectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/17\">",
"     17",
"    </a>",
"    ]. Calcimimetics that increases the sensitivity of the parathyroid calcium-sensing receptor may be additional options for such resistant patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9273?source=see_link\">",
"     \"Indications for parathyroidectomy in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Calcimimetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcimimetics are agents that allosterically increase the sensitivity of the CaSR in the parathyroid gland to calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/70\">",
"     70",
"    </a>",
"    ]. The CaSR is the principal factor regulating parathyroid gland PTH secretion and hyperplasia. The separate target offers the potential to suppress PTH by mechanisms complementary and potentially synergistic with vitamin D analogues that target the VDR.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     Cinacalcet",
"    </a>",
"    (Sensipar) is currently the only available calcimimetic. Studies have found that the addition of cinacalcet to current treatment regimens increases the percentage of patients who are able to attain",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    end-points related to PTH, calcium, and phosphate levels. Further secondary analysis of these studies and a phase two study also found that, compared with placebo, cinacalcet reduced the risk of parathyroidectomy, fracture, and cardiovascular hospitalizations.",
"   </p>",
"   <p>",
"    In addition, whereas active vitamin D analogues increase circulating FGF23 concentrations,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    used with lower doses of active vitamin D reduces FGF23 concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in the only randomized trial thus far (Evaluation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     Cinacalcet",
"    </a>",
"    Hydrochloride Therapy to lower Cardiovascular Events [EVOLVE]), cinacalcet did not decrease the risk of death or major cardiovascular events among hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Efficacy studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Efficacy studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous prospective randomized studies in patients on maintenance hemodialysis with mild to severe hyperparathyroidism have found that the administration of the calcimimetics produces a dose-dependent reduction in the plasma PTH concentration and a decrease in the levels of calcium and phosphate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/72-86\">",
"     72-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one large trial (which was the combination of three phase 3 studies), 1136 dialysis patients with intact PTH (iPTH) levels of greater than 300",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    were randomly assigned to traditional therapy plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    HCl or placebo for 26 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/79\">",
"     79",
"    </a>",
"    ]. To achieve the target iPTH levels of between 100 to 250",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    the dose was adjusted from 30 to 180",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    More specifically, after receiving an initial dose of 30",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    cinacalcet HL was increased every 3 to 4 weeks if the previous iPTH level was &gt;200",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    and the serum calcium concentration was &gt;7.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;1.95",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    This continued until 180",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of cinacalcet HCl was reached or the iPTH level was &lt;200",
"    <span class=\"nowrap\">",
"     pg/mL.",
"    </span>",
"    The study drug was stopped or reduced if symptoms attributed to hypocalcemia occurred, an adverse event thought related to the study drug was noted, or if iPTH concentrations were less than 100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    on two or more consecutive visits.",
"   </p>",
"   <p>",
"    Compared with placebo, the following benefits with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    in terms of achieving",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    target levels were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant increase in the likelihood of achieving a mean iPTH level of less than 300",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (56 versus 10 percent).",
"     </li>",
"     <li>",
"      Significantly more likely to achieve serum calcium levels between 8.4 to 9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.10 to 2.37",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      (42 versus 24 percent), serum phosphorus levels between 3.5 to 5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.13 to 1.78",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      (46 versus 33 percent), and a Ca x P product less than 55",
"      <span class=\"nowrap\">",
"       mg2/dL2",
"      </span>",
"      (4.44",
"      <span class=\"nowrap\">",
"       mmol2/L2)",
"      </span>",
"      (65 versus 36 percent).",
"     </li>",
"     <li>",
"      Concurrent achievement of both a iPTH level of less than 300",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      and the Ca x P product of less than 55",
"      <span class=\"nowrap\">",
"       m2/dL2",
"      </span>",
"      (4.44",
"      <span class=\"nowrap\">",
"       mmol2/L2)",
"      </span>",
"      (41 versus 6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A combined analysis of the three phase 3 trials (which are also analyzed in the previously cited study) and one phase two trial also found that, compared with placebo,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    lowered the risk of parathyroidectomy, fracture, and cardiovascular hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/87\">",
"     87",
"    </a>",
"    ]. Compared with placebo, randomization to cinacalcet resulted in significant reductions in the risk of parathyroidectomy (RR 0.07, 95% CI 0.01-0.55), fracture (RR 0.46, 95% CI 0.22-0.95), and cardiovascular hospitalization (RR 0.61, 95% CI 0.43-0.86).",
"   </p>",
"   <p>",
"    Benefits with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    in terms of achieving target levels have also been observed in several studies of patients with elevated PTH levels who were unable to take adequate doses of vitamin D because of elevated calcium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    phosphate levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/83,85,86,88\">",
"     83,85,86,88",
"    </a>",
"    ]. While cinacalcet has been used in combination with vitamin D treatment, phosphate binders and calcium supplementation, cinacalcet's ability to lower PTH does not appear to require vitamin D therapy.",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    on mortality and cardiovascular outcomes is not clear. Although a prospective observational study found that the use of cinacalcet was associated with improved survival among hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/89\">",
"     89",
"    </a>",
"    ], in the EVOLVE randomized trial, cinacalcet did not decrease the risk of death or major cardiovascular events among hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/71\">",
"     71",
"    </a>",
"    ]. In this trial, 3883 patients were randomly assigned to receive cinacalcet or placebo in addition to conventional therapy including phosphate binders",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin D. At a median followup of less than two years, there was no difference between groups in the primary composite end point that included time until death or the first nonfatal cardiovascular event, (myocardial infarction, hospitalization for unstable angina, heart failure or a peripheral vascular event) (relative hazard 0.93, 95% CI 0.85-1.02). Cinacalcet reduced the rate of parathyroidectomy by approximately half.",
"   </p>",
"   <p>",
"    Hypocalcemia and gastrointestinal side effects were more common in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    group. Although the rate of serious side effects was similar between groups, there was a nonsignificant trend toward more neoplastic events in the cinacalcet group (exposure-adjusted rates of 2.9 versus 2.5 events per 100 patient-years, respectively).",
"   </p>",
"   <p>",
"    The interpretation of this trial is limited by both a high drop-out rate in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    group (62 percent), and a high rate of crossover in the placebo group: nearly 20 percent of patients in the placebo group ended up taking commercially available cinacalcet. The high rate of crossover may have diminished between group differences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     Cinacalcet",
"    </a>",
"    may be indicated in dialysis patients with PTH levels &gt;300",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    who have serum calcium levels &gt;8.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;2.1",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Hyperphosphatemia is not a contraindication for starting cinacalcet, unlike vitamin D analogues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     Cinacalcet",
"    </a>",
"    is initiated at a dose of 30",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    with stepwise increments to 60, 90, and 180",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The dose can be increased every four weeks until goals are achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     Cinacalcet",
"    </a>",
"    should not be started if serum calcium is below 8.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;2.1",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Low serum calcium levels have been observed, which are typically asymptomatic and managed by adjustments in calcium-based phosphate binders, vitamin D sterols, or reductions in cinacalcet dose. However, caution should be used in patients with seizure disorders and frequent monitoring of plasma calcium and PTH levels is needed, since hypocalcemia may lead to seizures and QT prolongation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/36/38474/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nausea and vomiting is the most frequently reported side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    . This symptom may be lessened with food and often resolves with continued use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific target goals that we recommend are discussed above. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Target goals'",
"    </a>",
"    above.) To attain these goals, we use a strategy that places an emphasis on the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Attempt to reduce serum phosphate levels to the normal range.",
"     </li>",
"     <li>",
"      Limit excessive calcium loading",
"     </li>",
"     <li>",
"      Use a calcimimetic in patients with elevated PTH levels",
"     </li>",
"     <li>",
"      Avoid high dose active vitamin D analog administration and reduce vitamin D analog dose in patients with suppressed PTH levels",
"     </li>",
"     <li>",
"      Prevent progression of parathyroid disease",
"     </li>",
"     <li>",
"      Maintain bone health, prevent fractures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unlike other strategies, our approach emphasizes the possibility of decreased morbidity and mortality with a regimen that limits calcium loading and high dose active vitamin D analogue administration, while normalizing phosphate levels and lowering PTH levels. This relies in part upon the observations that calcimimetic agents suppress parathyroid hormone (PTH) without exacerbating hyperphosphatemia and causing hypercalcemia. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Calcimimetics'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Vitamin D derivatives'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We realize that the optimal combinations of the various therapies are based upon opinions and knowledge of the efficacy and toxicity profiles of the various agents alone and in combination. Prospective clinical trials comparing various treatment regimens have",
"    <strong>",
"     not",
"    </strong>",
"    been performed that have examined this strategy. Until prospective data are available, we also disagree with the clinical trend to administer vitamin D analogues to patients with increased calcium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    phosphate levels, which is based upon retrospective survival data with active vitamin D therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Stepped approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among dialysis patients with elevated PTH levels, we suggest the following stepped approach to the management of hyperparathyroidism and bone mineral abnormalities in dialysis patients:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Steps 1 and 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum calcium, albumin, phosphate, 25(OH) vitamin D and intact PTH levels are measured initially and then on an ongoing basis. The initial focus in managing secondary hyperparathyroidism should be the prevention and management of hyperphosphatemia.",
"   </p>",
"   <p>",
"    As a first step, a dietary restriction of 900",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of phosphorus is appropriate. There should be an emphasis on high biologic sources of phosphorus (meats, eggs) and avoidance of lower nutritional sources (certain vegetables, colas).",
"   </p>",
"   <p>",
"    Serum phosphate and calcium levels are next optimized, which involves treating hyperphosphatemia without causing hypercalcemia. This is difficult to achieve with thrice weekly hemodialysis.",
"   </p>",
"   <p>",
"    We suggest the following interventions based upon serum phosphate and calcium levels.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phosphate &lt;5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;1.78",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and calcium &lt;9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;2.37",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      &mdash; Calcium-based phosphate binders should be administered. We suggest keeping daily elemental calcium intake from binders to less than 1,500 mg, and total elemental calcium from diet and binders to less than 2,000 mg (in the presence of concurrent therapy with active vitamin D analogues). Either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/48/39685?source=see_link\">",
"       calcium acetate",
"      </a>",
"      can be administered.",
"     </li>",
"     <li>",
"      Phosphate &lt;5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;1.78",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and calcium &gt;9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;2.37",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      &mdash; No phosphate binder is necessary in most patients. Among those with vascular calcifications, we suggest treatment with a non-calcium containing phosphate binder. Either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      or lanthanum can be given.",
"     </li>",
"     <li>",
"      Phosphate &gt;5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;1.78",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and calcium &gt;9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;2.37",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      &mdash; We recommend the administration of a non-calcium containing phosphate binder rather than calcium containing binders. Either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      or lanthanum can be given.",
"     </li>",
"     <li>",
"      Phosphate &gt;5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;1.78",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and calcium &lt;9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;2.37",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      &mdash; We suggest first titrating a calcium-based phosphate binder (up to 1,500 mg of elemental calcium from binders alone if there is concurrent use of active vitamin D analogues). If phosphate remains above 5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;1.78",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we then add a non-calcium containing phosphate binder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Step 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next step is to decide whether phosphate binder therapy is sufficient or whether a calcimimetic or vitamin D analogue should be added. This is based upon calcium, phosphate, and PTH levels that are measured when administering",
"    <strong>",
"     optimal",
"    </strong>",
"    phosphate binder therapy (as defined in step 2).",
"   </p>",
"   <p>",
"    If calcium supplementation and phosphate binders are effective in controlling PTH (ie, level between 150 and 300",
"    <span class=\"nowrap\">",
"     pg/mL),",
"    </span>",
"    no additional therapy may be needed. Serial follow up of PTH levels should be performed at three month intervals to assess the continued control of disease.",
"   </p>",
"   <p>",
"    If PTH levels remain greater than 300",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    with optimal binder therapy, the choice is either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    or vitamin D analogues. The decision to use vitamin D or cinacalcet as the next step, without additional data on outcomes, should be based upon the calcium and phosphate levels that are measured when administering optimal phosphate binders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the calcium and phosphate levels are both toward the upper limit of target levels, we suggest administering",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"       cinacalcet",
"      </a>",
"      . This is because cinacalcet lowers both these parameters, while vitamin D therapy has the potential to further increase calcium and phosphorus levels.",
"     </li>",
"     <li>",
"      If the calcium level is near or below the lower limit of normal and the phosphate is well within the normal range, we suggest the administration of vitamin D, given that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"       cinacalcet",
"      </a>",
"      would further lower the serum calcium. There are no compelling data to use intravenous versus oral therapy or one form of vitamin D analogue over the other. Cost and patient compliance would be two considerations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon this rationale, we initiate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    in patients with PTH &gt;300",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    and the following measured levels of phosphate and calcium when administering optimal phosphate binder therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Phosphate &gt;5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;1.78",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and Calcium &gt;8.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;2.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Phosphate &lt;5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;1.78",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and Calcium &gt;9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;2.37",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    lowers serum calcium levels, it should not be initiated if the serum calcium level is less than 8.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (less than 2.1",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    We suggest that a vitamin D analogue would be the initial choice in patients with PTH &gt;300",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    and the following measured levels of phosphate and calcium when administering optimal phosphate binder therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phosphate &lt;5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;1.78",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and Calcium &lt;9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;2.37",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since vitamin D analogues raise serum calcium and phosphate levels, we recommend NOT initiating these agents if the serum calcium level is greater than 9.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;2.37",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    serum phosphate is greater than 5.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;1.78",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    or the Ca X P product is greater than 55",
"    <span class=\"nowrap\">",
"     mg2/dL2.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Step 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final step is to adjust the doses of phosphate binders, active vitamin D, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    to attempt to attain target values:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with inadequate reduction of PTH with initial therapies, serum phosphate &lt;5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;1.78",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and serum calcium &lt;9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;2.37",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we suggest adding active vitamin D among those already receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"       cinacalcet",
"      </a>",
"     </li>",
"     <li>",
"      Among patients with inadequate reduction of PTH with initial therapies and serum calcium &gt;8.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;2.1",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we suggest adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"       cinacalcet",
"      </a>",
"      among those already receiving a vitamin D analogue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following these guidelines is a complex balancing of four medications, namely calcium-containing binders, non-calcium containing binders, calcimimetics, and vitamin D analogues. Computer algorithms are being developed to assist clinicians, nurses, and dieticians in implementing these guidelines. One of these is available online at",
"    <a class=\"external\" href=\"file://www.asremed.com/\">",
"     www.asremed.com",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment failures are dialysis patients with tertiary hyperparathyroidism, which is defined as elevated PTH levels and spontaneous hypercalcemia (ie, not due to treatment with calcium and vitamin D analogues) or patients with persistent and progressive elevations of serum PTH that cannot be lowered to levels less than 300",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    despite treatment with vitamin D analogues and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    (180",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Indications for surgery in the dialysis patient with secondary hyperparathyroidism are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9273?source=see_link\">",
"     \"Indications for parathyroidectomy in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major factors responsible for stimulating parathyroid gland function in renal failure are hypocalcemia, diminished 1,25-dihydroxyvitamin D levels, and hyperphosphatemia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If physiologic abnormalities are uncorrected, renal bone disease will develop. This disorder can result in weakness, fractures, bone and muscle pain, and avascular necrosis, which most commonly occur in those undergoing dialysis. Along with renal osteodystrophy, secondary hyperparathyroidism is associated with disorders of mineral metabolism, principally abnormalities in serum phosphate and calcium levels. There appears to be an increased risk of all-cause and cardiovascular mortality in patients with disorders of mineral metabolism. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For dialysis patients, we suggest maintaining intact PTH (second generation PTH assay) levels between 150 to 300",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (and 80 to 160",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      using the Bi-PTH assay), serum phosphate levels between 3.5 and 5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.13 to 1.78",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and serum levels of corrected total calcium between 8.4 and 9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.10 to 2.37",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Target goals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The current management of secondary hyperparathyroidism in dialysis patients principally involves the administration of some combination of phosphate binders (either calcium or non-calcium containing binders), vitamin D analogues, and a calcimimetic. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Therapeutic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among dialysis patients with elevated intact PTH levels, our general strategy is to reduce serum phosphate levels to the normal range, limit excessive calcium loading, avoid high dose active vitamin D analog administration, reduce vitamin D analog dose in patients with suppressed PTH levels, use a calcimimetic to help lower PTH levels, prevent progression of parathyroid disease, maintain bone health and prevent fractures. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Overview of treatment approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among dialysis patients with elevated PTH levels, we suggest a stepped approach to the management of hyperparathyroidism and bone mineral abnormalities (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This approach requires a complex balance of four medications, namely calcium-containing binders, non-calcium containing binders, calcimimetics, and vitamin D analogues. Details of this approach are discussed in the section. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Stepped approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aspects of our approach include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that the initial focus in managing secondary hyperparathyroidism is the management of hyperphosphatemia with diet",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      phosphate binders (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Specific interventions are based upon serum phosphate and calcium levels. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Steps 1 and 2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The next step is to decide whether phosphate binder therapy is sufficient or whether a calcimimetic or vitamin D analogue should be added. This is based upon calcium, phosphate, and PTH levels that are measured when administering optimal phosphate binder therapy. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Step 3'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The final step is to adjust the doses of phosphate binders, active vitamin D, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"       cinacalcet",
"      </a>",
"      to attempt to attain target values. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Step 4'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/1\">",
"      Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/2\">",
"      Pitts TO, Piraino BH, Mitro R, et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 1988; 67:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/3\">",
"      Li YC, Amling M, Pirro AE, et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998; 139:4391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/4\">",
"      Panda DK, Miao D, Bolivar I, et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004; 279:16754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/5\">",
"      Hsu CH, Patel SR, Young EW, Vanholder R. The biological action of calcitriol in renal failure. Kidney Int 1994; 46:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/6\">",
"      Silver J, Naveh-Many T, Mayer H, et al. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986; 78:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/7\">",
"      Malluche HH, Mawad H, Koszewski NJ. Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney Int 2002; 62:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/8\">",
"      Brumbaugh PF, Hughes MR, Haussler MR. Cytoplasmic and nuclear binding components for 1alpha25-dihydroxyvitamin D3 in chick parathyroid glands. Proc Natl Acad Sci U S A 1975; 72:4871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/9\">",
"      Denda M, Finch J, Brown AJ, et al. 1,25-dihydroxyvitamin D3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats. Kidney Int 1996; 50:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/10\">",
"      Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/11\">",
"      Szabo A, Merke J, Beier E, et al. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/12\">",
"      Wetmore JB, Liu S, Krebill R, et al. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010; 5:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/13\">",
"      Saito H, Maeda A, Ohtomo S, et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005; 280:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/14\">",
"      Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012; 92:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/15\">",
"      Alvarez-Ude F, Feest TG, Ward MK, et al. Hemodialysis bone disease: correlation between clinical, histologic, and other findings. Kidney Int 1978; 14:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/16\">",
"      Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 2011; 26:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/17\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/18\">",
"      KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76(Suppl 113):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/19\">",
"      Gallieni M, Brancaccio D, Padovese P, et al. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int 1992; 42:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/20\">",
"      Moore C, Yee J, Malluche H, et al. Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/21\">",
"      Wetmore JB, Quarles LD. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clin Pract Nephrol 2009; 5:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/22\">",
"      Navaneethan SD, Palmer SC, Craig JC, et al. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 54:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/23\">",
"      Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 2000; 57:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/24\">",
"      Fournier A, Morini&egrave;re P, Ben Hamida F, et al. Use of alkaline calcium salts as phosphate binder in uremic patients. Kidney Int Suppl 1992; 38:S50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/25\">",
"      Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/26\">",
"      Goldsmith D, Ritz E, Covic A. Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int 2004; 66:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/27\">",
"      Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/28\">",
"      Saab G, Young DO, Gincherman Y, et al. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105:c132.",
"     </a>",
"    </li>",
"    <li>",
"     Stubbs et al. CJASN 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/30\">",
"      Ma Y, Khalifa B, Yee YK, et al. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J Clin Invest 2006; 116:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/31\">",
"      Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/32\">",
"      Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/33\">",
"      Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/34\">",
"      Palmer SC, McGregor DO, Macaskill P, et al. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007; 147:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/35\">",
"      Tonelli M. Vitamin D in patients with chronic kidney disease: nothing new under the sun. Ann Intern Med 2007; 147:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/36\">",
"      Slatopolsky E, Berkoben M, Kelber J, et al. Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism. Kidney Int Suppl 1992; 38:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/37\">",
"      Finch JL, Brown AJ, Kubodera N, et al. Differential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism. Kidney Int 1993; 43:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/38\">",
"      Tan AU Jr, Levine BS, Mazess RB, et al. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997; 51:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/39\">",
"      Monier-Faugere MC, Geng Z, Friedler RM, et al. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 1999; 55:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/40\">",
"      Slatopolsky E, Cozzolino M, Finch JL. Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int 2002; 62:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/41\">",
"      Slatopolsky E, Finch J, Brown A. New vitamin D analogs. Kidney Int Suppl 2003; :S83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/42\">",
"      Fraz&atilde;o JM, Elangovan L, Maung HM, et al. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000; 36:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/43\">",
"      Slatopolsky E, Weerts C, Thielan J, et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984; 74:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/44\">",
"      Delmez JA, Tindira C, Grooms P, et al. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest 1989; 83:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/45\">",
"      Andress DL, Norris KC, Coburn JW, et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/46\">",
"      Quarles LD, Yohay DA, Carroll BA, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994; 45:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/47\">",
"      Levine BS, Song M. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 1996; 7:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/48\">",
"      Mazess RB, Elangovan L. A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients. Clin Nephrol 2003; 59:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/49\">",
"      Moe SM, Kraus MA, Gassensmith CM, et al. Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. Nephrol Dial Transplant 1998; 13:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/50\">",
"      Martin KJ, Gonz&aacute;lez EA, Gellens M, et al. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/51\">",
"      Coburn JW, Maung HM, Elangovan L, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004; 43:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/52\">",
"      Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/53\">",
"      Maung HM, Elangovan L, Fraz&atilde;o JM, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001; 37:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/54\">",
"      Gadallah MF, Arora N, Torres C, et al. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients. Adv Perit Dial 2000; 16:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/55\">",
"      Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/56\">",
"      Ljunghall S, Althoff P, Fellstr&ouml;m B, et al. Effects on serum parathyroid hormone of intravenous treatment with alphacalcidol in patients on chronic hemodialysis. Nephron 1990; 55:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/57\">",
"      Matuszkiewicz-Rowiska J, Niemczyk S, Pacocha E, et al. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure]. Pol Arch Med Wewn 1996; 96:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/58\">",
"      Ritzerfeld M, Klasser M, Mann H. Alfacalcidol in the therapy of renal bone disease. Int J Clin Pharmacol Ther 2001; 39:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/59\">",
"      Kurokawa K, Akizawa T, Suzuki M, et al. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study. Nephrol Dial Transplant 1996; 11 Suppl 3:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/60\">",
"      Tsukamoto Y, Hanaoka M, Matsuo T, et al. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2000; 35:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/61\">",
"      Tamura S, Ueki K, Mashimo K, et al. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients. Clin Exp Nephrol 2005; 9:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/62\">",
"      Mochizuki T, Naganuma S, Tanaka Y, et al. Prospective comparison of the effects of maxacalcitol and calcitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter, randomized crossover study. Clin Nephrol 2007; 67:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/63\">",
"      Chertow GM, Blumenthal S, Turner S, et al. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol 2006; 1:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/64\">",
"      Quarles LD, Davidai GA, Schwab SJ, et al. Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism. Kidney Int 1988; 34:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/65\">",
"      Sheikh MS, Maguire JA, Emmett M, et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 1989; 83:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/66\">",
"      Goodman WG, Ramirez JA, Belin TR, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/67\">",
"      Malberti F, Corradi B, Cosci P, et al. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism. Am J Kidney Dis 1996; 28:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/68\">",
"      Katoh N, Nakayama M, Shigematsu T, et al. Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism. Am J Kidney Dis 2000; 35:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/69\">",
"      Arnold A, Brown MF, Ure&ntilde;a P, et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995; 95:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/70\">",
"      Nemeth EF, Bennett SA. Tricking the parathyroid gland with novel calcimimetic agents. Nephrol Dial Transplant 1998; 13:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/71\">",
"      EVOLVE Trial Investigators, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/72\">",
"      Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int 1998; 53:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/73\">",
"      Goodman WG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/74\">",
"      Goodman WG, Hladik GA, Turner SA, et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/75\">",
"      Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/76\">",
"      Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/77\">",
"      Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/78\">",
"      Harris RZ, Padhi D, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 2004; 44:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/79\">",
"      Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/80\">",
"      Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/81\">",
"      Szczech LA. The impact of calcimimetic agents on the use of different classes of phosphate binders: results of recent clinical trials. Kidney Int Suppl 2004; :S46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/82\">",
"      Sterrett JR, Strom J, Stummvoll HK, et al. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 2007; 68:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/83\">",
"      Messa P, Mac&aacute;rio F, Yaqoob M, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/84\">",
"      Sprague SM, Evenepoel P, Curzi MP, et al. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol 2009; 4:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/85\">",
"      Arenas MD, Alvarez-Ude F, Gil MT, et al. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 2007; 22:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/86\">",
"      Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008; 3:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/87\">",
"      Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/88\">",
"      Amgen Sensipar clears FDA: Phosphate binders are a competitive target. FDC Rep Drugs Cosmet 2004; 66:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/89\">",
"      Block GA, Zaun D, Smits G, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010; 78:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/36/38474/abstract/90\">",
"      Amgen Sensipar label prepares for off-label use in pre-dialysis population. Pharmaceutical Approvals Monthly 2004; 9:28.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1918 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38474=[""].join("\n");
var outline_f37_36_38474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF SECONDARY HYPERPARATHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OVERVIEW OF K/DOQI AND KDIGO TARGET LEVELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      K/DOQI guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Serum levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      KDIGO guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Laboratory values",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TARGET GOALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Assessment and monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      THERAPEUTIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Phosphate binders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Background",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Calcium-based phosphate binders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Non-calcium containing phosphate binders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ergocalciferol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Vitamin D derivatives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Background",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Indications in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Calcimimetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Efficacy studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      OVERVIEW OF TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Stepped approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Steps 1 and 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Step 3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Step 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1918\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1918|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/59/26557\" title=\"figure 1\">",
"      IV vs PO calcitriol in ESRD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20185?source=related_link\">",
"      Biology of vascular calcification in renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38184?source=related_link\">",
"      Causes of vitamin D deficiency and resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/49/33559?source=related_link\">",
"      Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9273?source=related_link\">",
"      Indications for parathyroidectomy in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/58/21416?source=related_link\">",
"      Parathyroid hormone assays and their clinical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=related_link\">",
"      Vascular calcification in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_36_38475="Preop evaluation questions";
var content_f37_36_38475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Preoperative medical evaluation questions for a healthy patient",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Questions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Do you usually get chest pain or breathlessness when you climb up two flights of stairs at normal speed?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Do you have kidney disease?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Has anyone in your family (blood relatives) had a problem following an anaesthetic?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Have you ever had a heart attack?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Have you ever been diagnosed with an irregular heartbeat?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Have you ever had a stroke?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. If you have been put to sleep for an operation were there any anaesthetic problems?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Do you suffer from epilepsy or seizures?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Do you have any problems with pain, stiffness or arthritis in your neck or jaw?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Do you have thyroid disease?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11. Do you suffer from angina?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12. Do you have liver disease?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13. Have you ever been diagnosed with heart failure?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14. Do you suffer from asthma?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15. Do you have diabetes that requires insulin?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16. Do you have diabetes that requires tablets only?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17. Do you suffer from bronchitis?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hilditch, WG, Asbury, AJ, Jack, E, McGrane, S. Validation of a pre-anaesthetic screening questionnaire. Anaesthesia 2003; 58:874.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38475=[""].join("\n");
var outline_f37_36_38475=null;
var title_f37_36_38476="HCC surveillance recommendations";
var content_f37_36_38476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Groups for whom HCC surveillance is recommended or in whom the risk of HCC is increased, but in whom efficacy of surveillance has not been demonstrated",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Population group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Annual incidence (percent per year) for which surveillance is considered to be cost-effective",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incidence of HCC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Surveillance recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asian male hepatitis B carriers over age 40",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        0.4-0.6 percent per year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asian female hepatitis B carriers over age 50",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        0.3-0.6 percent per year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis B carrier with family history of HCC",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        Incidence higher than without family history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        African/North American blacks with hepatitis B",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        HCC occurs at a younger age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cirrhotic hepatitis B carriers",
"       </td>",
"       <td>",
"        0.2-1.5",
"       </td>",
"       <td>",
"        3-8 percent per year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis C cirrhosis",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        3-5 percent per year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stage 4 primary biliary cirrhosis",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        3-5 percent per year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genetic hemachromatosis and cirrhosis",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        Unknown, but probably &gt;1.5 percent per year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alpha 1-antitrypsin deficiency and cirrhosis",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        Unknown, but probably &gt;1.5 percent per year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other cirrhosis",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Surveillance benefit uncertain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis B carriers younger than 40 (males) or 50 (females)",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        &lt;0.2 percent per year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis C and stage 3 fibrosis",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        &lt;1.5 percent per year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-cirrhotic NAFLD",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        &lt;1.5 percent per year",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HCC: hepatocellular carcinoma; NAFLD: nonalcoholic fatty liver disease.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An Update. Hepatology 2010. Copyright &copy; 2010 John Wiley &amp; Sons.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38476=[""].join("\n");
var outline_f37_36_38476=null;
var title_f37_36_38477="Disorders of glycogen - glucose metabolism";
var content_f37_36_38477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders of glycogen/glucose metabolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Classification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Key clinical findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD 0a (MIM #240600, glycogen synthase-2 deficiency in liver)",
"       </td>",
"       <td>",
"        Ketotic hypoglycemia, no hepatomegaly",
"       </td>",
"       <td>",
"        Liver biopsy and enzyme testing; DNA testing",
"       </td>",
"       <td>",
"        Uncooked cornstarch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD 0b (MIM #611556, muscle glycogen synthase deficiency)",
"       </td>",
"       <td>",
"        Cardiomyopathy, exercise intolerance, weakness",
"       </td>",
"       <td>",
"        Muscle biopsy (glycogen depletion), enzyme assay, DNA testing",
"       </td>",
"       <td>",
"        No specific treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD I (MIM #232200; GSD Ia, von Gierke disease, glucose-6-phosphatase deficiency; GSD Ib, c, and d due to transport defects)",
"       </td>",
"       <td>",
"        Ketotic hypoglycemia, hepatomegaly",
"       </td>",
"       <td>",
"        DNA testing, liver biopsy and enzyme assay",
"       </td>",
"       <td>",
"        Cornstarch, allopurinol, granulocyte-colony stimulating factor (G-CSF)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD II (MIM #232300, Pompe disease, lysosomal acid maltase deficiency)",
"       </td>",
"       <td>",
"        Hypotonia, muscle weakness, hypertrophic cardiomyopathy",
"       </td>",
"       <td>",
"        Fibroblast, leukocyte, muscle or liver enzyme assay; DNA testing",
"       </td>",
"       <td>",
"        Enzyme replacement, high protein/ low carbohydrate diet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Danon disease (MIM #300257, lysosome-associated membrane protein 2 [LAMP2] deficiency, formerly GSD IIb)",
"       </td>",
"       <td>",
"        Hypotonia, hypertrophic cardiomyopathy",
"       </td>",
"       <td>",
"        Muscle biopsy, DNA testing",
"       </td>",
"       <td>",
"        No specific treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD III (MIM #232400, glycogen debrancher deficiency)",
"       </td>",
"       <td>",
"        Ketotic hypoglycemia, hepatomegaly",
"       </td>",
"       <td>",
"        Fibroblast or liver enzyme assay; DNA testing",
"       </td>",
"       <td>",
"        Uncooked cornstarch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD IV (MIM #232500, glycogen branching enzyme deficiency)",
"       </td>",
"       <td>",
"        Hepatomegaly",
"       </td>",
"       <td>",
"        Fibroblast, muscle, or liver biopsy; DNA testing",
"       </td>",
"       <td>",
"        Liver transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD V (MIM #232600, McArdle disease, muscle phosphorylase deficiency)",
"       </td>",
"       <td>",
"        Fatigability, myoglobinuria",
"       </td>",
"       <td>",
"        Muscle enzyme assay, DNA testing",
"       </td>",
"       <td>",
"        Sucrose prior to exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD VI (MIM #232700, Hers disease, liver phosphorylase deficiency)",
"       </td>",
"       <td>",
"        Hepatomegaly, mild hypoglycemia",
"       </td>",
"       <td>",
"        Liver biopsy and enzyme assay; DNA testing",
"       </td>",
"       <td>",
"        No specific treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD VII (MIM #232800, Tarui disease, phosphofructokinase deficiency in muscle)",
"       </td>",
"       <td>",
"        Fatigability, myoglobinuria",
"       </td>",
"       <td>",
"        Muscle enzyme assay, DNA testing",
"       </td>",
"       <td>",
"        No specific treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phosphoglycerate kinase deficiency (MIM #311800)",
"       </td>",
"       <td>",
"        Hemolysis, fatigability, myoglobinuria, CNS dysfunction",
"       </td>",
"       <td>",
"        Muscle/RBC enzyme assay; DNA testing",
"       </td>",
"       <td>",
"        Bone marrow transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD IX (phosphorylase kinase deficiency; IX a1, MIM #306000, formerly GSD VIII, alpha-2 subunit defect in liver; IXb, MIM #261750, beta subunit defect in liver; IXc, MIM #613027, gamma subunit defect in liver and muscle; IXd, MIM #300559, alpha subunit defect in muscle)",
"       </td>",
"       <td>",
"        Hepatomegaly, mild hypoglycemia, fatigability, exercise intolerance",
"       </td>",
"       <td>",
"        Liver/muscle biopsy; enzyme assay; DNA testing",
"       </td>",
"       <td>",
"        No specific treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD X (MIM #261670, Phosphoglycerate mutase deficiency)",
"       </td>",
"       <td>",
"        Fatigability, myoglobinuria, exercise intolerance",
"       </td>",
"       <td>",
"        Muscle biopsy and enzyme assay; DNA testing",
"       </td>",
"       <td>",
"        No specific treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD XI (MIM #612933; lactate dehydrogenase a [LDHA, MIM #150000] deficiency and lactate dehydrogenase b deficiency [LDHB, MIM #150100])",
"       </td>",
"       <td>",
"        Fatigability, myoglobinuria",
"       </td>",
"       <td>",
"        Muscle or RBC enzyme assay; DNA testing",
"       </td>",
"       <td>",
"        No specific treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GLUT2 deficiency (MIM #138160; Fanconi-Bickel syndrome)",
"       </td>",
"       <td>",
"        Growth retardation, renal Fanconi syndrome, galactosemia",
"       </td>",
"       <td>",
"        Clinical features, DNA testing",
"       </td>",
"       <td>",
"        Small meals, cornstarch, electrolytes as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD XII (MIM #611881, aldolase A deficiency)",
"       </td>",
"       <td>",
"        Hemolysis, jaundice, myoglobinuria, muscle weakness, fatigability",
"       </td>",
"       <td>",
"        Muscle or RBC enzyme assay; DNA testing",
"       </td>",
"       <td>",
"        No specific treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD XIII (MIM #612932, beta-enolase deficiency in muscle)",
"       </td>",
"       <td>",
"        Exercise intolerance, increased CPK",
"       </td>",
"       <td>",
"        Muscle biopsy, enzyme assay, DNA testing",
"       </td>",
"       <td>",
"        No specific treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD XIV (MIM #612934, phosphoglucomutase-1 deficiency in muscle)",
"       </td>",
"       <td>",
"        Exercise intolerance, myoglobinuria, increased CPK",
"       </td>",
"       <td>",
"        Muscle biopsy, enzyme assay, DNA testing",
"       </td>",
"       <td>",
"        No specific treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GSD XV (MIM #613507, glycogenin-1 deficiency in muscle)",
"       </td>",
"       <td>",
"        Muscle weakness, arrhythmias",
"       </td>",
"       <td>",
"        Muscle biopsy (glycogen depletion), DNA testing",
"       </td>",
"       <td>",
"        No specific treatment",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system; CPK: creatinine phosphokinase; GSD: glycogen storage disease; RBC: red blood cell.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38477=[""].join("\n");
var outline_f37_36_38477=null;
var title_f37_36_38478="Timeline of Campylobacter enteritis";
var content_f37_36_38478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Timeline of a typical attack of Campylobacter enteritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 169px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After a mean incubation period of three days, a febrile prodromal period may be observed for a day prior to the onset of gastrointestinal symptoms.&nbsp;Diarrhea lasts a mean of seven days; abdominal pain may persist slightly longer. Organisms may be shed from the stool for several weeks following symptom resolution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38478=[""].join("\n");
var outline_f37_36_38478=null;
var title_f37_36_38479="Diffuse metastatic pheo MIBG";
var content_f37_36_38479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F73899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F73899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse metastatic pheochromocytoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    123-I-meta-iodobenzylguanidine scan from a 41-year-old woman shows diffuse metastatic pheochromocytoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William F Young, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_36_38479=[""].join("\n");
var outline_f37_36_38479=null;
